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The metabolic syndrome has increased considerably worldwide and so have its 
associated conditions including non-alcoholic fatty liver disease (NAFLD). In most cases 
NAFLD manifests as relatively benign hepatic steatosis, but around 10% of the patients 
develop the more severe non-alcoholic steatohepatitis (NASH), which is associated with a 
higher risk for end stage liver disease and hepatocellular carcinoma. The exact 
pathomechanism that leads to progression of hepatic steatosis towards NASH is incompletely 
understood. Dendritic cells (DC) have been implicated to play a protective role in the 
progression of NASH. DCs are specialized antigen-presenting cells that play an important role 
in the regulation of immune responses. They are a heterogenous group of cells and consist of 
several subtypes, such as plasmacytoid DCs (pDC), CD103+ classical DCs type 1 (cDC 1) and 
CD11b+ classical DCs type 2 (cDC 2) as well as a monocyte derived DCs. This study aims to 
characterize the changes of individual DC subtypes during development and progression of 
NAFLD and focuses on the specific role of the CD103+ cDC 1 population using the batf3-
knockout model (batf3-KO). Steatosis and steatohepatitis was induced in wildtype (WT) and 
batf3-KO mice through feeding of high sucrose diet (HSD) and methionine-choline-deficient 
diet (MCD) respectively and changes of hepatic immune cells were mapped using multicolor 
flow cytometric analysis. Together with HE-staining, cytokine arrays and serum analysis, flow 
cytometry was further used to investigate the effect of CD103+ cDCs 1 on the composition of 
hepatic immune cells and disease progression. 
All DC subtypes increase in the steatohepatitis model, suggesting their involvement in the 
pathogenesis of NASH. Lack of CD103+ cDCs 1 during HSD feeding results in progression 
towards steatohepatitis with increased presence of inflammatory cells types including 
inflammatory monocytes, monocyte derived DCs and other myeloid cells as well as elevated 
production of pro-inflammatory cytokines. Importantly disease progression in batf3-KO animals 
is not associated with aggravated adipose tissue inflammation or increased insulin resistance, 
indicating a local mechanism rather than a systemic effect of batf3-KO cells 
This study shows, that murine CD103+ cDCs 1 hold an important protective role in the 
progression of steatosis towards steatohepatitis, by regulating the composition of hepatic 
immune cells, the influx of inflammatory cells and the intrahepatic production of cytokines. 
Furthermore, it implies a role of the remaining DC subsets in the pathogenesis of NASH, which 




Die nicht-alkoholische Fettlebererkrankung (NAFLD), welche als hepatische Konsequenz 
des metabolischen Syndroms betrachtet wird, trat in den letzten Jahrzehnten weltweit 
vermehrt auf. In den meisten Fällen der NAFLD handelt es sich um die relativ benigne 
Steatosis Hepatis (Fettleber), allerdings kommt es bei etwa 10% der Fälle zu der Genese einer 
nicht-alkoholischer Steatohepatitis (NASH), die durch entzündliche Infiltrate und 
Hepatozytenschäden charakterisiert ist und mit einem erhöhten Risiko für die Entwicklung von 
terminaler Leberinsuffizienz oder eines hepatozellulären Karzinoms einhergeht. Der genaue 
Pathomechanismus für die Progression der Steatosis Hepatis zur Steatohepatitis ist noch nicht 
vollständig geklärt. Den dendritischen Zellen (DC) wird eine protektive Funktion im Rahmen 
der Pathogenese einer NASH zugeschrieben. DCs sind spezialisierte, antigen-präsentierende 
Zellen, welche eine wichtige Rolle bei der Regulation von Immunantworten spielen. Sie werden 
meist als CD11c+MHC-II+ Zellen identifiziert. Allerdings handelt es sich bei DCs um eine sehr 
heterogene Gruppe, welche unter anderem aus plasmazytoiden DCs (pDCs), CD103+ 
klassischen DCs Typ 1 (cDCs 1), CD11b+ klassischen DCs Typ 2 (cDCs 2) sowie DCs der 
monozytären Linie (moDCs) besteht. Um ein besseres Verständnis der Funktion dieser Zellen 
zu erhalten wurden in der vorliegenden Studie die Veränderungen dieser individuellen 
Subtypen während der Genese und Progression der NAFLD untersucht.  
Zudem wurde an batf3-knockout (batf3-KO) Mäusen, welchen der CD103+ cDCs 1 Subtyp 
fehlt, die Rolle dieses Zelltyps in der Entwicklung einer NASH genauer betrachtet. Hierzu 
wurden anhand unterschiedlicher Ernährungsregime 3 Gruppen gebildet. Um eine Steatosis 
Hepatis beziehungsweise Steatohepatitis zu induzieren erhielt je eine Gruppe eine 
saccharosereiche (high sucrose diet, HSD), respektive eine methionin- und cholindefiziente 
Diät (methionin-choline-deficient diet, MCD). Die dritte Gruppe erhielt ein normales 
Ernährungsregime. Als Kontrolle dienten Wildtyp (WT) Mäuse mit jeweils identischen Diäten. 
Veränderungen der hepatischen Immunzellen wurden mit Hilfe der Multicolor 
Durchflusszytometrie untersucht. Diese wurde zudem in Verbindung mit HE-Färbungen der 
Leberproben, Zytokin Arrays und Serum Analysen genutzt, um den Effekt von cDCs 1 auf die 
anteilige Zusammensetzung der hepatischen Immunzellen und den Progress der Steatosis 
Hepatis zur Steatohepatitis zu untersuchen.  
In dieser Studie wird gezeigt, dass alle DC Subtypen im Rahmen einer NASH vermehrt in 
der Leber auftreten, was auf ihre mögliche Involvierung in der Pathogenese der NASH 
hinweist. Eine HSD führt bei WT Mäusen zu einer benignen Steatosis Hepatis, während sie 
bei cDCs 1-defizienten batf3-KO Mäusen zur Entwicklung einer NASH führt. Bei Letzteren 
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kommt es hierbei zu einer Zunahme von inflammatorischen Monozyten, monozytären DCs und 
anderer Zellen der myeloiden Reihe in der Leber sowie zu einer Verschiebung der 
intrahepatischen Zytokinproduktion in Richtung eines pro-inflammatorischen Milieus. Dabei 
führt die HSD trotz Fortschreiten der Erkrankung in batf3-KO Tieren allerdings nicht zu einer 
verstärkten Entzündung im Fettgewebe oder der Verschlechterung der Insulinresistenz, was 
darauf schließen lässt, dass die Progression der Erkrankung ein lokal begrenzter Effekt von 
cDCs 1 ist und nicht in Folge einer systemischen Verschlechterung beim Fehlen von cDCs 1 
auftritt. 
Zusammenfassend kann in dieser Studie gezeigt werden, dass cDCs 1 eine wichtige 
protektive Rolle in der Entwicklung der Steatohepatitis aus der Steatosis Hepatis innehaben 
indem sie die Zusammensetzung hepatischer Immunzellen, die Einwanderung 
inflammatorischer Zellen und die intrahepatische Zytokinproduktion regulieren. Außerdem 
deuten die Ergebnisse dieser Studie daraufhin, dass die übrigen DC Subtypen ebenfalls eine 
Rolle in der Pathogenese der NASH einnehmen. Diese müssen in weiteren Studien noch 
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1.1 Non-alcoholic fatty liver disease 
1.1.1 Definition 
In 1980 Ludwig et. Al described a hepatic disease of unknown origin characterized by a 
histology similar to alcoholic hepatitis, while the patients’ history lacked typical increased 
alcoholic intake (1). They established the term non-alcoholic steatohepatitis (NASH). NASH 
has since emerged as one of the most common causes for liver disease in developed countries 
(2). It belongs to a group of liver pathologies comprised in the term non-alcoholic fatty liver 
disease (NAFLD) which are characterized by increased lipid accumulation in the absence of 
any other cause of secondary steatosis, such as ethanol consumption >20g ethanol/day, 
drugs, viral hepatitis or genetic conditions (3). According to the Sk2 Guidelines of the German 
Society for Digestive and Metabolic Diseases the spectrum of NAFLD ranges from simple 
steatosis hepatis, also referred to as non-alcoholic fatty liver (NAFL), to more severe NASH 
with inflammatory infiltrate and hepatocellular damage and can ultimately result in end-stage 
liver diseases such as cirrhosis or hepatocellular carcinoma (4,5). NAFL is defined as steatosis 
in >5% of hepatocytes, with a further division in mild (<33%), moderate (33-66%) and severe 
steatosis (>66%), while NASH is characterized by an additional necroinflammatory component 
with or without fibrosis (5). Histologically this corresponds to the presence of inflammatory 
infiltrates, hepatocellular ballooning and necrosis (3,6). Since until now no reliable biomarker 
has been identified to distinguish between NAFL and NASH liver biopsies remain gold standard 
for the diagnosis of NASH (7–9) 
1.1.2 Epidemiology 
The number of patients with NAFLD has increased dramatically within the last few 
decades affecting both adults and children worldwide (2,10). The prevalence of NAFL in the 
western population is 20-30%, but increases further in obese patients and patients with 
diabetes mellitus or hyperlipidemia (2,3). The more severe NASH affects 2-3% of the general 
population, up to 20% of the obese and 50% of the morbidly obese (2,11,12). While bland, 
uncomplicated steatosis does not affect long-term prognosis, the presence of inflammation 




(13,14). In fact NASH has been identified as a major cause of cryptogenic cirrhosis and it has 
been suggested to be the first cause for liver transplant during the next years (2,15,16). 
Therefore, it is crucial to understand the mechanisms that promote the progression of NAFL 
towards NASH. 
1.1.3 Pathophysiology 
NAFLD is considered the hepatic consequence of the metabolic syndrome (17). It is 
closely correlated with obesity, dyslipidemia, insulin resistance (IR) and type-II diabetes 
mellitus (DM-II) (1,18–20). The exact mechanisms involved in the development of NAFLD and 
the progression towards NASH are not yet fully understood. The “two-hit” hypothesis has for a 
long time been widely accepted as a model for the pathogenesis of NASH (21). First published 
in 1998 by Day et al. it suggests that insulin resistance causes steatosis and leads to increased 
hepatic lipid accumulation, considered the “first hit”, which leaves the liver more susceptible to 
injury (21). In consequence mitochondrial dysfunction and oxidative stress in lipid-loaded 
hepatocytes would, as a “second hit”, be more likely to trigger inflammatory reactions that result 
in steatohepatitis (21,22). The extensive research that has been conducted since challenges 
this hypothesis and suggests a pathogenesis of “multiple parallel hits”. It becomes evident that 
the relationship between steatosis and inflammation is not as straight forward as suggested in 
the “two-hit” hypothesis (22). In some cases of NASH hepatic inflammation actually precedes 
steatosis and there is some evidence suggesting that increased intrahepatic triglyceride 
content could actually serve as a protective mechanism to eliminate free fatty acids (FFA) from 
the liver (23–25). FFAs are believed to play a key role in the pathogenesis of NASH through a 
mechanism called lipotoxicity, which describes a variety of toxic effects caused by the 
accumulation of FFA and their metabolites in the liver. Such effects include the formation of 
reactive oxygen species, endoplasmatic reticulum stress, activation of inflammatory pathways 
and cell death (22,26–28). Obesity and the associated IR contribute to this, by enhancing the 
influx of FFA to the liver through inappropriate lipolysis of the large amounts of adipose tissue 
(22). Increased amounts of adipose tissue further contribute to disease progression by 
promoting innate immune responses through the production of inflammatory cytoadipokines 
(29). Besides such alterations of the lipid metabolism, changes of the gut microbiome and 
increased intestinal permeability resulting in endotoxinemia with toll-like receptor (TLR) 
activation have also been described as an additional factor for disease development (30,31). 





So it becomes evident that the pathogenesis of NASH is more complex than originally 
thought and includes a combination of genetic variances, dysregulation of lipid metabolism, 
changes in the gut microbiome and local inflammatory responses (12). It remains to be 
determined how these mechanisms interact with each other, how they influence innate and 
adaptive immunity and what triggers disease progression. 
1.1.4 Mouse models to investigate NAFLD 
Several models are available to study NAFLD in mice. However, none of the available 
models completely replicates the human phenotype (33). 
Methionine-choline deficient diet 
Methionine-choline deficient diet (MCD) is a popular model to investigate NASH in 
mice. Feeding MCD results in mild steatosis and minimal focal inflammation after as early as 
1 week into the diet. A 4 week MCD treatment increases steatosis and causes prominent 
inflammation within the liver, while after 8-10 weeks fibrosis development can be observed 
(34,35). The MCD treatment differs from human NAFLD in several important aspects: animals 
fed MCD diet experience severe weight loss, have low plasma triglyceride (TG) levels and a 
reduced liver weight/body weight ratio. Further they generally do not develop IR or DM-II during 
MCD treatment. Although this stands in contrast to the human NAFLD, the MCD model is still 
the best-established model to study inflammatory and fibrotic elements of the NAFLD spectrum 
(33). 
High sucrose diet 
Feeding of a high sucrose (a disaccharide of glucose and fructose) or high fructose diet is 
another model to investigate NAFLD in mice. Increased consumption of fructose is reported to 
be a risk-factor for NAFLD development in humans (36). Feeding of a diet containing 65% 
sucrose for 8 weeks to C57BL/6 mice causes obesity, IR and macrovesicular steatosis, but 
does not result in histopathological evidence of NASH or fibrosis NASH (37,38). Treatment 
with high sucrose diet (HSD) mimics the human disease better than the MCD model and is a 
useful model to investigate bland liver steatosis in mice. 
1.2 Basics of Immunology 
The immune system is a complex system with the key role to protect the organism from 




consists of a group of specialized, closely connected cells which constantly communicate with 
each other and their surroundings. Cells and functions of the immune system are attributed to 
either innate or adaptive immunity. Innate immunity is characterized by an immediate 
availability of specialized cells or defense mechanisms against a wide range of pathogens, 
regardless of a prior exposure (39). Adaptive immunity on the other hand requires a first-time 
exposure, before being able to initiate an immune response towards an individual pathogen. 
On a second encounter with this antigen it then acts highly specific and with a great efficiency 
(39). Importantly innate and adaptive immunity are not two isolated systems, but are closely 
connected with many regulatory overlaps and feedback mechanisms. For a better 
understanding of dendritic cells (DCs) and their role in immunity the following chapter will briefly 
recapitulate the basics of innate and adaptive immune responses. Described surface markers 
and transcription factors refer to the murine immune system, since this study is based on 
murine models. 
1.2.1 Innate immune responses 
Cells of the innate immune system can recognize molecules that are expressed by 
microbes or released during tissue damage and cell death as danger signals through 
specialized, highly conserved receptors (40). When recognizing such danger signals, cells of 
the innate immune system are activated within seconds and start to initiate and amplify the 
inflammatory response. This includes recruiting more inflammatory cells to the site of danger, 
setting the whole organism in a state of alertness and initiating a systemic response (39).  
One group of innate immune cells are so called polymorphonuclear cells (PMN cells), 
which include neutrophils, basophils, eosinophils and mast cells. PMN cells are in line of first 
defense against intruding microorganisms and are recruited to sites of inflammation within the 
first hour of an immune response (40). Another type of innate immune cells are natural killer 
cells (NK cells). These cells represent the major lymphocyte populations of the innate immune 
response and are crucial for controlling infection and immune surveillance (41). NK cell surface 
receptors (NKR) recognize changes in major histocompatibility complex I (MHC-I) expression 
patterns on cells, which occur for example after infection or tumor transformation, and then kill  
the transformed cells through cell lysis (39). NK cells are also potent producers of cytokines 
(42). A third part of the innate immune system is the mononuclear phagocyte system (MPS), 
which includes macrophages, DCs and monocytes (43). Macrophages and DCs are tissue 
resident phagocytic cells, which ingest exogenous proteins and cellular debris. As professional 
antigen-presenting cells (APCs) they process ingested proteins and present them on MHC-II 




also produce antimicrobial peptides as well as chemokines and cytokines with messenger 
function to mediate inflammatory responses (39). Functionally macrophages specialize in the 
clearance of cellular debris, pathogens and foreign material, whereas DCs are markedly more 
potent in antigen presentation and initiating T cell response (43). Monocytes represent a very 
dynamic cell population within the MPS. Classical monocytes, which are characterized by a 
high expression of Ly6C, circulate the blood from where they migrate into tissues and 
differentiate to replenish the macrophage and DC populations (44,45). This is a process which 
happens mostly during inflammation, whereas in steady state tissue resident macrophages 
are mainly maintained through self-renewal and DCs evolve from circulating precursor DCs 
(pre-DCs) from the bone marrow (43,46,47).  
1.2.2 Adaptive immune responses 
Adaptive immunity is mostly mediated through T- and B lymphocytes, also referred to 
as T- and B cells. B cells are producers of immunoglobulins and play an important part in 
humoral adaptive immune defense. B cell activation is facilitated through cytokine production 
of activated T helper cells (40). T cells are the main cell type of cellular adaptive immune 
responses and they interact closely with DCs. They express a specialized, unique T cell 
receptor (TCR) which recognizes antigens presented on MHC molecules. Due to genetic 
rearrangement the individual TCRs are extremely diverse, with up to 1016 specificities (39). 
Until they are presented with “their” antigen, naïve T cells circulate between blood and 
peripheral lymphoid tissue. When activated, T cells proliferate and differentiate into different 
effector cells (48). Activation of T cells happens mainly in lymph nodes and is accomplished 
through professional APCs especially DCs (39). The two main subsets of T cells are CD8+ 
cells, also called cytotoxic T cells, and CD4+ cells, so called T helper cells (TH cells), which are 
further divided into individual subsets. CD8+ T cells recognize alternated MHC-I molecules on 
virus infected or tumor cells and subsequently kill the target cell (48). The major effector 
function of CD4+ T cells is the production of cytokines, which then influence multiple other cell 
types. The four major subsets of CD4+ cells are TH1, TH2, TH17 and regulatory T cells (Treg): 
TH1 cells produce cytokines which act on macrophages, NK cells and CD8+ T cells and induce 
cell-mediated immunity. TH2 cells promote humoral immunity (49). TH17 cells produce 
cytokines that promote pro-inflammatory responses and seem to be involved in processes of 
autoimmunity (50). Tregs (CD25+FoxP3+) secrete the anti-inflammatory cytokines IL-10 and 





As mentioned above naïve lymphocytes are only activated through antigen presentation 
on MHC molecules. CD8+ T cells recognize antigens on MHC-I molecules and CD4+ T cells 
recognize antigens on MHC-II molecules (51). Full activation requires the binding of 
corresponding co-stimulatory molecules such as CD80/CD86 and CD28, as isolated 
recognition of the TCR with MHC-complexes results in T cell inactivation, a process called 
anergy, which prevents unwanted immune responses against harmless or self-antigens (52). 
In contrast to the innate immune system, which reacts immediately, activation and 
differentiation of lymphocytes is a four to five day process (39). After the first encounter with 
the antigen most effector T cells die, except for a few long-lived memory cells, which continue 
to circulate the organism. Upon a second encounter with the antigen, memory T cells lead to 
a direct proliferation and differentiation of T cells and thus a more rapid and effective response 
(48).  
Lastly a third subpopulation of T cells exists, the so called NKT cells. These are 
characterized by the expression of both an invariant TCR and the NK cell marker NK1.1 (53). 
Importantly, unlike regular T cells, NKT cells recognize antigens through interaction with CD1d, 
a MHC-I like molecule that presents mostly glycolipid antigens (54). This means that NKT cells 
are important for the recognition of lipid antigens as opposite to the other T cells, which are 
primarily presented with peptide fragments of protein antigens (54,55).  Moreover NKT cells 
have a potent capacity of producing both pro- and anti-inflammatory cytokines involved in TH1- 
and TH2-regulation (55). NKT cells are especially abundant in the liver. Here they inhabit a 
regulatory role by patrolling the hepatic sinusoids, interacting with other cell types and 
modulating T cell response (56).  
1.3 Dendritic cells and their role in immunity 
DCs were first described by Steinman et al. in 1973 and have since been in the focus of 
intensive immunological research (57). They were identified as the cellular subset which is 
mainly responsible for T cell activation. This function is reflected in their potent capabilities of 
antigen-presentation, migration and cytokine-production (58). Ubiquitous in the organism, DCs 
especially reside at locations targeted by disease-relevant stimuli such as the skin, mucosal 
surfaces or the respiratory and gastrointestinal system (59). They constantly scan their 
environment for antigens and recognize pathogens and other danger signals (60). Once they 
have sampled an antigen they migrate from their position in the periphery to lymph nodes, 
where they present it to naïve T cells and regulate their response (61). This capability to 
migrate into lymphoid organs is one of the primary functional properties of DCs, since it allows 




are not only responsible for initiating adaptive immune responses, but are also important for 
maintaining homeostasis in the immune system. Through presenting self-antigens to T cells, 
deleting autoreactive T cells and inducing regulatory T cells, DCs also play a crucial role in 
developing immune tolerance (63).  
Until recently it was thought that DCs exist in two distinct functional states: immature and 
mature DCs (58). Immature DCs appear under non-inflammatory conditions and show a 
tolerogenic phenotype, i.e. expressing low levels of co-stimulatory molecules and producing 
low amounts of pro-inflammatory cytokines (64). Mature, immunogenic DCs express high 
levels of co-stimulatory molecules (e.g. CD80/86 and CD40) and produce pro-inflammatory 
cytokines like IL-12 or IL-6 to induce an immunologic response (65). Today a more accurate 
thesis is believed, that when activated, DCs evolve into different effector DCs with distinct 
functional capabilities. Depending on the effector type they will then initiate T helper cell 
differentiation, start cytotoxic T cell responses, or induce T cell tolerance (60,66).  
Generally, when presenting antigens, all cells express MHC-I molecules to present 
endogenous, intracellular produced antigens and specialized antigen-presenting cells also use 
MHC-II molecules to present exogenous antigens (67). In addition to this DCs have developed 
a third mechanism called cross-presentation: they take up antigens from an exogenous source 
and present them on MHC-I molecules (68). Cross-presentation enables DCs to activate naïve 
CD8+ T cells towards an antigen which is not directly expressed by DCs themselves. This is 
especially important for initiating cytotoxic T cell responses against viruses or intracellular 
pathogens (69).  
In addition to their strong role in adaptive immunity several studies in both mice and 
humans have presented evidence for crosstalk between NK cells and DCs. DCs seem to 
promote NK cell survival and proliferation, cytokine production, activation and cytotoxicity 
(41,70–73). Reciprocal, NK cells can on the one hand induce DC activation and enhance their 
ability to stimulate naïve allogeneic CD4+ T cells, but may on the other hand also lyse 
autologous DCs in vitro depending on the NK:DC ratio (41,72,74). This links DCs to innate 
immune responses and further underlines their importance as mediators of immune 
responses.  
1.4 Murine dendritic cell subtypes 
Although often simply defined as CD11c+MHC-II+ cells, DCs are in fact a heterogeneous 
group of different cell subtypes. Since their discovery several nomenclature systems have 
been introduced to distinguish between DC subtypes. The most recent and currently used 




secondarily accordingly to their function and phenotype (43). This classification categorizes 
DCs into three subsets, which all stem from a common DC precursor (CDP) in the bone-
marrow, and one subset, which develops from circulatory monocytes particularly during 
inflammatory conditions (43). Cells that develop from the CDP are named classical DCs Type 
1 (cDC 1), classical DCs Type 2 (cDC 2) and plasmacytoid DCs (pDC), while the fourth subset 
is called monocyte derived DC (moDC) (43). The CDP develops in a FMS-like tyrosine kinase 
3 ligand (Flt3L) dependent fashion from a common macrophage-DC-progenitor cell and from 
this stage on is restricted to producing cDCs and pDCs (47,75). Distinct sets of transcription 
factors determine the further differentiation of the CDP into the DC subsets (46). Pre-DCs enter 
the peripheral circulation from the bone marrow, traveling to lymphoid and non-lymphoid 
organs where they differentiate into the different cDC or pDC subtypes (75,76). Pre-DCs 
express CD11c on their surface, but are not yet MHC-II positive (47). 
The development of cDCs 1 is dependent on several transcription factors such as basic 
leucine zipper transcription factor ATF-like 3 (batf3), inhibitor of DNA binding 2 (Id2), interferon 
regulatory factor 8 (IRF8) and nuclear factor interleukin 3 (NFIL3) (43,77–80). Phenotypically 
cDCs 1 are characterized by the expression of CD11 and MHC-II as well as CD8α in lymphoid 
tissues or CD103 in non-lymphoid tissues (81). This subset is specialized in the cross-
presentation of cell-associated and soluble antigens on MHC-I molecules as well as initiation 
of a cytotoxic CD8+ T cell response (60,69,73). Furthermore, cDCs 1 of the gut and airways 
have shown the ability to induce  CD4+ CD25+ FoxP3+ Tregs indicating that these cells also hold 
an important role in the induction of tolerance and regulation of immune responses (60,82–
84). 
cDCs 2 are DCs whose development is regulated through IRF4 and which express 
CD11b (43). In this context it is important to mention that the classification system based upon 
ontogeny is fairly new and until recently cDCs were classified into the CD8α-/CD103- CD11b+ 
DC subtype and CD103+/CD8α+ CD11b- DC subtype merely based on their surface expression 
pattern (61,85). Here the CD103+/CD8α+ CD11b- DC subtype corresponds to the above 
described batf3-dependent cDC 1 subtype, whereas the  CD8α-/CD103- CD11b+ population is 
heterogeneous with different origins and functions (61). In fact the IRF-4 dependent cDCs 2 
share their expression pattern of CD11c+ MHC-II+ and CD11b+ with moDCs, which means that 
the simple categorization into CD11b expressing DCs is not sufficient to investigate the 
individual cell populations (86). It is possible to distinguish the cDC 2 and moDC subset through 
the surface marker CD64, which is expressed by moDCs but not cDCs 2 (87–89). Because of 
these overlaps in surface markers and the only recent discrimination of cDCs 2 and moDCs it 




been identified as a critical cell type for type 3 immune responses against extracellular bacteria 
and fungi through  IL-23 production and also seem to play a role in the induction of TH2 cells, 
but the exact mechanism involved remains unclear (73,90,91). Additionally, CD11b expressing 
DCs have been described to be more efficient in the induction of a type 2 immune response, 
CD4+ T cell activation and seem to have a potent role in presenting MHC-II molecules (73,92).  
pDCs build the third big subtype of DCs. Although they differ from cDCs in morphology 
and function they share their origin in the bone marrow (47). Their differentiation from the CDP 
is facilitated through the transcription factor E2-2 (93). pDCs express PDCA-1 and are 
specialized in the fast secretion of large amounts of type I interferons during viral infections 
(61,94,95). 
1.5 The liver as a lymphoid organ 
The liver is considered the biggest metabolic organ the body. It is responsible for the 
extraction and storage of nutrients, elimination of toxins and production of vital protein (56). 
Everyday arterial and venous blood mixes within the liver sinusoids, which creates a unique 
microenvironment unseen anywhere else in the organism. Here, circulatory leukocytes from 
the arterial flow encounter gut derived macromolecules like toxins, food antigens and microbial 
products arriving through the portal vein. This renders the liver a central “meeting point” for 
immune cells and antigens, which explains its important role in the induction of immunity, the 
setup of immune memory and maintaining immune tolerance (96). Due to the constant 
exposure towards pro-inflammatory agents, the risk of immune activation in the liver appears 
to be higher than anywhere else in the organism. Still, hepatic immune cells usually do not 
elicit an immune response during steady state. Despite the continuous antigenic challenge 
they are able to maintain immune homeostasis (97).  
Several different cell populations with immunologic function exist within the liver. 
Hepatocytes can present endogenous antigens to naïve CD8+ T cells, which results in 
apoptotic death of the stimulated cells and contributes to the tolerizing phenotype of the liver 
(98). Furthermore, all liver sinusoidal cells, such as Kupffer Cells (KCs), hepatic stellate cells 
(HSC), endothelial cells as well as DCs, are capable of antigen presentation to CD4+ and CD8+ 
T cells. They cross-present hepatocyte-derived antigens as well as present circulating 
antigens. Thus sinusoidal cells influence adaptive immunity towards both local and systemic 
antigens (96). During steady state, this is strongly biased towards the prevention of 
inflammatory responses: Liver APCs inhibit antigen-specific T cell activation and induce 




differentiation into non-TH1 and non-TH17 effector cells, such as a TH2 cells that secrete low 
levels of IL-4 and IL-10 (49,99). 
1.6 DCs in NAFLD – What do we know? 
During NASH the tolerogenic environment of the liver, which normally withstands constant 
immunologic stimuli without an overreactive immune response, switches into an inflammatory 
state. Immune cell activation then causes hepatocellular damage and promotes hepatic 
fibrosis (29). To elucidate the cellular and molecular mechanisms which promote this switch 
will be a major step in understanding the pathogenesis of NASH and thereby identifying 
potential therapeutic targets.   
The liver hosts more DCs than other parenchymal organs, probably as a consequence of 
the high occurrence of antigens in portal blood (100). All previously described DC subsets can 
be found within the liver (101). Several studies have been conducted about liver DCs and their 
role in NAFLD and liver fibrosis, however, most of these studies focused on the role of all 
CD11c expressing cells, which are not exclusively DCs (101,102). 
CD11c+ cells of the healthy liver exhibit a tolerogenic phenotype in accordance to the 
unique microenvironment they inhabit (100,101). They have a lower capability to endocytose 
antigens or stimulate T cells, express low levels of MHC-II and costimulatory molecules and 
have a low intracellular lipid content (i.e. triglycerides, phospholipids), a feature which has also 
been attributed to a tolerogenic phenotype (103–105). Furthermore, they show a higher 
production of the anti-inflammatory cytokines IL-10 and IL-27 (106). 
The role of CD11c+ cells in during liver injury and fibrosis development has been described 
in various disease models: Generally, during fibrosis the level of CD11c+ cells is elevated and 
the majority of these cells display a pro-inflammatory phenotype, which includes the 
upregulation of MHC-II and costimulatory molecules, production of pro-inflammatory cytokines 
and high intracellular lipid content (62,101,105,107–109). In mice with biliary fibrosis 
monocyte-derived CD11c+ cells show a higher capacity to acquire antigens and stimulate T 
cells (108). During thioacetamide (TAA) and recombinant leptin induced fibrosis CD11c+ cells 
produce an increased amount of pro-inflammatory TNFα and IL-6 and show a high capability 
to activate HSC, the key fibrogenic cells in the liver (107). Further, depletion of CD11c+ cells 
reduces the expression of pro-inflammatory cytokines in other non-parenchymal cells (NPCs) 
(107). As opposite to this, other data suggests that CD11c+ cells protect liver integrity. CD11c+ 
cell depletion worsens liver pathology in acetaminophen-induced acute liver injury (110). 




of carbon tetrachloride (CCl4) induced liver fibrosis, where CD11c+ cell depletion delays 
fibrosis regression and clearance of activated HSC (111).  
Thus the role of DCs in hepatic injury is considered to be of a dichotomous character: 
on the one hand liver DCs have been accredited a pro-inflammatory function as they showed 
higher lipid content, elevated cytokine production and increased capacity for T cell stimulation 
(101,105,107,108). On the other hand depletion of DCs exacerbates liver pathology and slows 
fibrosis regression, suggesting a protective role (110,111). 
Concerning the potential role of DCs in the pathogenesis of NASH Hennig et al. 
published a well conducted study in 2012 using the MCD model in mice. They used a 
combination of phenotypical and functional analyses both in vivo and in vitro to clarify the role 
of DCs during disease progression (109): After 6 weeks of MCD treatment the CD11c+ MHC-
II+ population expands 3-4 fold and displays an activated, pro-inflammatory phenotype as 
measured by upregulation of the co-stimulatory molecules CD54, CD80 and CD86.  At the 
same time other leukocyte cell populations like KCs, neutrophils, monocytes and CD8+ T cells 
also increase, whereas NKT cells, B cells and CD4+ T cells diminish. CD11c+ MHC-II+ cells 
isolated from a NASH liver produce increased levels of TNFα, IL-6, MCP-1 and IL-10 and show 
an increased cytokine response to TLR9 ligation. In vitro they also show an increased ability 
to activate CD4+ T cells, but not CD8+ T cells compared to cells from healthy liver. Furthermore, 
CD4+ T cells produce higher levels of TH1, TH2 and TH17 cytokines, while the expression of the 
Treg phenotype is downregulated. Since these results implicate that DCs contribute to disease 
progression, a the authors continued their study under the hypothesis that DC depletion in 
CD11c-DTR mice mitigates hepatic insult (109). Interestingly, contrary to this hypothesis, the 
absence of CD11c+ cells causes an exacerbation of the NASH phenotype. CD11c depleted 
animals experience higher weight loss, develop a higher intrahepatic inflammatory infiltrate, 
show accelerated hepatic fibrosis and increased production of pro-inflammatory cytokines by 
other liver NPCs. The frequency of KCs, neutrophils and inflammatory monocytes increases 
and KCs exhibit an elevated TLR9 and TLR4 expression, which has been linked to the 
pathogenesis and severity of NASH (112,113). The CD8+ T cell population also increases, 
whereas the number of CD4+ T cells and Tregs decreases compared to the control (109). 
Moreover, an increased presence of apoptotic bodies can be observed in CD11c depleted 
animals and expression of apoptotic markers increases. DC depletion also leads to the 
accentuation of sterile inflammation within the liver which has been connected to the 
pathogenesis of NASH (112–114). Additionally, DCs isolated from NASH-liver show a greater 
capacity to clear necrotic debris compared to those from healthy animals. This lead the authors 




cellular debris (109). In a final experiment, the role of DCs in the recovery phase of NASH was 
investigated by switching the diet back to normal chow. Here DC depletion delays the 
resolution of NASH. In summary, this study shows that DCs play a role both during progression 
and regression of NASH: On the one hand DCs expand in NASH and assume an activated 
phenotype, on the other hand depletion of CD11c+ cells worsens the disease and delays its 
resolution. The authors conclude from their study that DCs limit fibroinflammatory injury in 
NASH through limiting sterile inflammation by clearance of cellular debris and by regulating 
the expansion of innate and adaptive immune cell subsets (109). 
When looking at this data it is important to consider two major limitations. First, most of 
our current understanding of liver DCs is based on the study of MHC-II+ or CD11c+ cells. This 
marker combination is not sufficient, however, to distinguish DCs from other cell types, since 
CD11c expressing cells also include macrophages, monocytes or NK cells and MHC-II is 
present on all professional APCs (101,102,115). In addition, investigating CD11c+ MHC-II+ 
cells does not take into account the different functions of previously described individual DC 
subsets. Second, the most widely used animals model for investigating DCs is the CD11c-DTR 
model, which is depleted of all CD11c+ cells (116). Observations made in these animals might 
not mimic the effect of DCs in vivo but are the result of the animal being depleted from all 
CD11c+ cells (101) 
In conclusion, current data suggests a potential role of DCs in both NASH and more severe 
liver injuries with established fibrosis. However, studies conducted so far do not permit a 
differentiation of liver DCs from other cells or between individual DC subsets. Various novel 
animal models have been developed in order to characterize specific cellular subtypes, such 
as the batf3-KO mouse for CD103+/CD8+ DCs or the IRF4-KO mouse for cDCs 2 (73,77). Only 
few of those have been investigated during NASH and fibrosis, they will present a powerful 
tool to gain better understanding of the role of immunologic cells in NASH (117). 
1.7 Relevant surface markers of murine liver immune cells 
The various subsets of immune cells found in the liver can be distinguished through their 
expression of surface molecules. Table 1 details the surface markers used in this study to 







CD45 also known as common leukocyte marker, is a tyrosine kinase expressed on all 
nucleated cells of the hematopoietic lineage. It is often used as a general 
marker for all immune cells (118). 
Antigens to distinguish DC subsets 
CD11b also known as integrin αM, is expressed on a variety of cells such as 
granulocytes, monocytes, macrophages, various DC subsets and NK-cells 
(61,119).  
CD11c also known as integrin αX, is expressed on DCs, but also macrophages, 
monocytes and NK cells. A high expression of CD11c is especially attributed to 
DCs (101). 
MHC-II The major histocompatibility complex type II is present on APCs such as 
macrophages, DCs and B-cells (115). 
CD103 This glycoprotein is expressed on the cDC 1 subtype in non-lymphoid tissue 
and can be used to distinguish this subsets from other DCs (76). 
PDCA-1 also known as CD317 is typically used as a marker for pDCs, but can also be 
upregulated in other cells activated by IFN (94,115). 
CD64 is a cellular receptor for immunoglobulins (Fc-Receptor). It can be used to 
distinguish monocyte-derived DCs from classical DC subtypes (87)  
 Antigens to distinguish monocyte, macrophage and granulocyte populations 
F4-80 F4-80 is typically highly expressed in all macrophages including KCs and on 
lower levels on monocytes (120). 
Ly6C a high expression of Ly6C is typical for classical monocytes, while low 
expression can be observed on the non-classical monocyte subset, KCs and 
restorative macrophages (45,117). 
Ly6G is a marker used for neutrophils (121). 
Antigens to distinguish lymphocyte subsets 
CD19 is a costimulatory receptor and typically used as the hallmark antigen to identify 
the B cell lineage (122). 
CD3ε is a subunit of the CD3 surface molecule on T cells, which is necessary for 
TCR-mediated signal transduction. It is typically used as the hallmark antigen 
to identify the T cell lineage (39,123). 




CD4 is a T cell co-receptor for signal transduction through MHC-II molecules. It is 
also present on monocytes, macrophages and some DC subtypes (39,60) . 
CD8 is a T cell co-receptor for signal transduction through MHC-I molecules, but 
also present on some NK cells and the lymphoid cDC 1 subset (39,65).  
Table 1 Surface markers used for flow cytometry to distinguish of various immune cells in the liver 
1.8 Aims of this project 
The aim of this project was to characterize changes of liver DC subtypes during developing 
and established steatohepatitis and to investigate the influence of batf3-dependent cDCs 1 on 
inflammation and the cellular infiltrate during disease progression.  
As the hepatic consequence of the metabolic syndrome the incidence of NAFLD has 
increased dramatically in the past decade and is now the number one cause of liver disease 
in developed countries. The mechanisms which promote the progression from steatosis to 
steatohepatitis are not yet completely understood. DCs have been described to play a 
protective role in the development of NASH by limiting fibro-inflammation, however the role of 
individual DC subsets remains to be determined. 
In this study, we used different dietary models to investigate animals with various 
severities of NAFLD, that is bland steatosis, initiating NASH and established NASH. The first 
aim of this study was to map changes of individual DC subsets based on their surface markers 
using multicolored flow cytometric analysis during disease development. As a second step, we 
wanted to investigate if and how batf3-dependent cDCs 1 have an impact on disease 
progression and in this context how they influence the composition of the hematopoietic 
infiltrate in the liver. As part of this we also wanted to determine whether the lack of batf3-
dependent cDCs 1 affects the systemic metabolism of the animals.  
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2 Material and Methods 
2.1 Animals 
2.1.1 Housing and maintenance 
All experiments have been approved by the ethics and animal care committees of 
Saarland University Medical Center, Homburg, Germany (Animal protocol number 46/2012). 
Wildtype (WT) or batf3-/- C57Bl/6 mice were purchased at Charles River (Sulzfeld, Germany) 
or Jackson Laboratories (Bar Harbor, USA). They were kept at the Helmholtz Centre for 
Infectious Research in Braunschweig, Germany and were transported at 8-10 weeks of age to 
our institute at University of Saarland, Innere Medizin II (Homburg, Germany). During 
maintenance in an assigned mouse cabinet (Bioscape, Castrop-Rauxel, Germany) the animals 
were kept in special pathogen free conditions and had access to food and water ad libitum. No 
more than 4 mice were kept in a cage. Food, water levels and general condition of the animals 
was controlled daily. Cages and water bottles were changed weekly, weight was monitored 
weekly or every second week. Individual animals were distinguished using the ear punch 
system depicted in Figure 1. 
 
Figure 1 Ear punch system to distinguish individual animals (124) 
2.1.2 Mouse strains 
Batf3 knockout mice 
Batf3-KO mice (Jackson Laboratories, Bar Harbor, USA, JAX stock number: 013755) 
were used to study the function of cDCs 1 in vivo. This knockout-strain lacks the exons 1 and 
2 of the batf3 gene, abolishing gene function. The knock-out of batf3 results in the depletion of 
CD8α+ cDCs 1 in lymphoid organs and the corresponding CD103+ cDCs 1 in non-lymphoid 
organs (77).  




C57Bl/6J mice were used as a wild-type control (WT). This is a widely used inbred 
strain and suggested by Jackson Laboratories as control strain for batf3-KO mice.  
2.1.3 Dietary models  
Normal chow diet 
As an untreated control, C57BL/6J and batf3-KO mice matched in age and gender were 
fed cereal based chow (NC) for 5 weeks. The diet was purchased from Altromin (Lage, 
Germany; diet number 1324). 
Methionine-choline-deficient diet 
For experiments on NASH, mice were fed MCD purchased from Research Diet (New 
Brunswick, NJ, USA; diet number A02082002B). Its detailed composition is depicted in Table 
2. MCD is a well-established model to investigate NASH as it induces severe liver 
inflammation, hepatic steatosis and hepatocellular damage in a short timeframe. For 
experiments to investigate established NASH the MCD treatment was continued over 5 weeks. 
For the pilot experiments investigating the onset of NASH the MCD treatment was continued 
over 2 weeks. 
High sucrose diet 
For experiments on hepatic steatosis mice were fed a HSD over the course of 5 weeks. 
The HSD was purchased from Research Diet (New Brunswick, NJ, USA; diet number 
A02082003B). Its detailed composition is depicted in Table 2. 
 MCD HSD 
Energy source g % kcal % g % kcal % 
Protein 17 16 17 16 
Carbohydrate 66 63 65 62 
Fat 10 21 10 21 
     
Ingredient g kcal g kcal 
L-Alanine 3.5 14 3.5 14 
L-Arginine 12. 48.4 12. 48.4 
L-Asparagine-H2O 16 24 16 24 
L-Aspartate 3.5 14 3.5 14 
L-Cystine 3.5 14 3.5 14 
L-Glutamine 40 160 40 160 
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Glycine 23.3 93.2 23.3 93.2 
L-Histidine-HCl-H2O 4.5 18 4.5 18 
L-Isoleucine 8.2 32.8 8.2 32.8 
L-Leucine 11.1 44.4 11.1 44.4 
L-Lysine-HCl 18 72 18 72 
L-Phenylalanine 7.5 30 7.5 30 
L-Proline 3.5 14 3.5 14 
L-Serine 3.5 14 3.5 14 
L-Threonine 8.2 32.8 8.2 32.8 
L-Tryptophan 1.8 7.2 1.8 7.2 
L-Tyrosine 5 20 5 20 
L-Valine 8.2 32.8 8.2 32.8 
Total L-Amino Acids 171.4 685.6 171.4 685.6 
     
Sucrose 455.3 1821.2 452.3 1809.2 
Corn Starch 150 600 150 600 
Maltodextrin 50 200 50 200 
     
Cellulose 30 0 30 0 
     
Corn Oil 100 900 100 900 
     
Mineral Mix S10001 35 0 35 0 
Sodium Bicarbonate 7.5 0 7.5 0 
     
Vitamin Mix V10001 10 40 10 40 
     
L-Methionine 0 0 3 12 
Choline Bitartrate 0 0 2 0 
     
Total 1009.2 4246.8 1011.2 4246.8 
Table 2 composition of methionine-choline-deficient and high sucrose diet: Mice were fed MCD for 5 weeks to 
induce steatohepatitis and HSD 5 weeks to induce steatosis. For pilot experiments on onset steatohepatitis mice 
were fed with MCD for 2 weeks. The composition is shown as indicated by the supplier, Research Diets (Brunswick, 
NJ, USA). 
2.2 Organ harvest and collection of bodily fluids 
For the organ harvest mice were anesthetised with isopropyl alcohol and killed through 
cervical dislocation. They were then placed on their back on a dissecting board and the belly 
fur was wetted with 70% ethanol. The skin was carefully cut along the midline and removed by 
blunt dissection to expose thorax and abdomen. 
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A thoracotomy was performed using scissors and 2-3ml blood were drawn from the 
heart’s right ventricle using a 26G needle. The blood was left to clot in a 1.5ml tube for a 
minimum of 30 minutes at room temperature. It was then centrifuged at 1500g for 15 minutes 
to separate the serum and corpuscular parts. The serum was stored at -80°C until further 
usage. 
For the organ harvest and fat collection the peritoneum was carefully cut open. To 
harvest the liver large and small intestines were mobilised and moved to the left to expose the 
liver. Liver lobes were cut at the base and carefully removed using a cotton swab. The tissue 
samples were either used to prepare a single cell suspension, further processed for histology, 
or flash frozen in liquid nitrogen and stored at -80°C for future analyzes. For fat tissue analyses 
all intraperitoneal organs were mobilized and all retroperitoneal fat was carefully cut off using 
scissors. The fat tissue was either used to prepare a single cell suspension or flash frozen in 
liquid nitrogen and stored at -80°C for future analyzes. 
2.3 Preparation of a liver single cell suspension 
Fig. 2 shows the liver digest protocol I to create a single cell suspension. This protocol 
was used during the early experiments of this study. Most dot-blots depicted in the results 
section were made with data obtained using the digest protocol Il. In case data from earlier 
experiments with this protocol I is shown, it will be marked in the figure legend. Table 3 details 
the exact composition of used buffers. 
Liver digest protocol I 
To prepare a single cell suspension the median liver lobe or retroperitoneal fat was 
collected as described above and briefly stored in Hanks’ Balanced Salt Solution (HBSS; Life 
technologiesTM, Carlsbad, USA) on ice until the organ harvest was completed. The tissue 
samples were cut into small pieces using a scalpel, transferred into a 15ml falcon tube and 
suspended in digestion buffer (3x800ml). All further mechanical and enzymatic digestion of the 
tissue was made in a 37°C water bath. At 5 and 15 minutes, the tubes were slightly tapped to 
mix the suspension and allow the buffer to thoroughly cover the tissue. After allowing the tissue 
to settle down the supernatant was collected and transferred through a 10µm mesh into a 
second 15ml falcon on ice containing 800ml collection buffer, which contains EDTA and stops 
the enzymatic digestion. The digestion buffer in the falcon was replaced and the tissue 
incubated further to continue the digest. After 15 minutes, the liver pieces were passed through 
a 1000 µl pipetting tip every 7 minutes. This helped to disperse loose cells and created a larger 
surface area for the enzymes. After each mixing step, the tissue was allowed to settle down 
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and the supernatant containing dissociated cells was collected into the second falcon as 
described above. After 50 minutes, the mixing interval was reduced to 5 minutes. In the 
beginning the pipetting tip was cut to allow bigger pieces to pass through, after 3 to 4 mixing 
steps all liver pieces were expected to be small enough to fit through an uncut tip. 
In the second falcon collection buffer was added to the collected supernatant. Every 
second cycle the collected supernatant was centrifuged at 1400rpm for 4 minutes. The 
supernatant was discarded, and the pellet was then resuspended in 1600µl collection buffer 
and transferred for storage into a third falcon on ice until the digest was complete. After a 
maximum of 90 minutes the digest was terminated to avoid damage to already collected cells. 
After the digest was completed the total amount of collected cell suspension was spun 
down and the supernatant discarded. To eliminate red blood cells an ammonium chloride 
potassium lysis (ACK-lysis) was performed: the cell pellet was resuspended in 2ml ACK-lysing 
buffer (Life technologies, Darmstadt, Germany), which was neutralized after one minute using 
5ml collection buffer. It was then spun down as before, the pellet was resuspended in collection 
buffer to have total volume of 2 or 3ml, depending on pellet size, and kept on ice until further 
usage. 
 
Figure 2 Flow chart of the digest protocol I: In this protocol the collected supernatant containing dispersed cells was 
centrifuged every 2 digestion cycles and then transferred into another falcon on ice. In the digest protocol II these 
centrifugation steps were abolished to reduce mechanical stress on cells.  
Liver digest protocol II 
During the course of the study the digest protocol was adjusted. The digest was 
performed as described above in digest protocol I, but the centrifugation steps during the digest 
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were abolished to reduce mechanical stress on cells. Further the collection buffer was 
prepared without EDTA as shown in Table 3. The disruption of enzymatic digestion was solely 
achieved by dilution of enzymes with collection buffer and storing it on ice. At the end of the 
digest all collected supernatant was centrifuged (180g, 8min, acc.4, decc. 2, 4°C) to pellet the 
cells and then ACK lysis was performed as described above. These modifications create less 
debris in the single cell suspension by reducing mechanical stress to the cells. All fat digests 
were made using this protocol as well as most of the liver digest for the representative data 
shown in this thesis. 
Reagent Supplier Concentration 
Digestion Buffer 
RPMI medium Life technologies, Darmstadt, Germany  
Collagenase P Roche, Mannheim, Germany 0.2 mg/ml 
DNase Life technologies, Darmstadt, Germany 0.1 mg/ml 
Dispase Roche, Mannheim, Germany 0.8 mg/ml 
Heat inactivated FBS Life technologies, Darmstadt, Germany 1 % 
Collection Buffer (digest protocol I) 
RPMI medium Life technologies, Darmstadt, Germany  
EDTA Life technologies, Darmstadt Germany 2 mM 
Heat inactivated FBS Life technologies, Darmstadt, Germany 1 % 
Collection Buffer (digest protocol II) 
RPMI medium Life technologies, Darmstadt, Germany  
Heat inactivated FBS Life technologies, Darmstadt, Germany 1% 
Table 3 Composition of buffers used in the preparation of a liver or fat single cell suspension 
2.3.1 Living cell count 
To stain the cells for flow cytometric analysis (FACS-analysis) or to culture them it is 
important to determine the exact concentration of the cell suspension. This was done using 
the MACSQuant Flow Cytometer (Miltenyi, Bergisch-Gladbach, Germany). For this 10µl of cell 
suspension were stained with proprium iodide (PI) as shown in Table 4. PI is a fast and reliable 
method in flowcytometry to identify dead or dying cells. It permeates membranes of dead cells, 
while living cells are not affected, and binds to double stranded DNA (125). To avoid 
falsification of the results it is important to ensure a thorough mixing of the cell suspension prior 
to taking out the sample of the cell suspension. A volume of 15µl was measured on “high” 
setting and after debris exclusion (Figure 3.A) and cell doublets exclusion (Figure 3.B) the 
number of single PI negative cells (Figure 3.C) was used to calculate the living cell 
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concentration within the cell suspension. As the number of cells collected in the fat tissue digest 
is very low, the living cell concentration was not determined, but all cells were used for 
fluorescent staining. 
Cell Count 
Reagent Supplier Volume 
MACSQuant® Running Buffer Miltenyi Biotec, Bergisch Gladbach, Germany 187 µl 
Proprium Iodide Miltenyi Biotec, Bergisch Gladbach, Germany 0.6 µg 
Cell suspension  10 µl 
Table 4 Composition of reagents to count the amount of living cells in the single cell suspension  
 
Figure 3 Gating strategy for living cell count: A) events with low values for size (FSC-A) and internal complexity 
(SSC-A) were excluded to get rid of cell debris B) cell area (FSC-A) was plotted against cell height (FSC-H) to 
exclude cell doublets C) events negative for PI signal were selected to measure only living cells 
2.4 Flow-cytometric analysis 
2.4.1 Basics of flow cytometry 
Flow cytometry is a laser based technique used in immunology to analyze various 
qualitative and quantitative parameters of a cell suspension. Although a quite complicated 
system the flow cytometer can be broken down to 3 major parts: fluidics, optics and electronics. 
Fluidics guide the cells in a single cell stream through a path of light. Optics generate this light 
and can detect small changes caused by passing cells. Electronics convert these optical 
signals to electronic signals and depict them as an “event” on a histogram or dot plot. The 
information we gather is based on the manner how the passing cells scatter the light and if and 
how they emit fluorescence (126). 
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As a cell passes the light it reveals several information on its structural parameters 
without any prior handling: An increase of forward scatter (FSC) signifies a bigger cell size or 
surface area, while changes of sideward scatter (SSC) are proportional to the cells granularity 
(126). 
To gather additional information on the cells such as surface receptors, intracellular 
proteins or viability fluorescent reagents can be used. When using a mixture of different 
fluorochromes-conjugated monoclonal antibodies these will bind to their respective antigen on 
the cell. The flow-cytometric analysis will then show a fluorescent signal proportional to the 
number of antibodies on the cell. The usage of different lasers and optical filters in a flow 
cytometer then enables the analysis of signals from various fluorochromes of different spectra, 
which allows the analysis of cell multiple parameters during a single measurement (126). 
A problem in flow-cytometric analyzes can be unspecific background signals. These 
can be caused by binding of the antibodies to Fc-Receptors (FcR) on the target cell, 
nonspecific antibody interaction and cellular autofluorescence. To minimize background 
signals, it is therefore advisable to block unspecific binding prior to staining the cells using anti-
FcR antibodies. Furthermore, a negative control staining should be performed for each 
fluorochrome.  This can be done either by replacing the primary antibody of interest with an 
isotype control or simply not adding the antibody, which is called fluorescent minus one (FMO). 
The Isotype controls in class and type, but lack the specificity of the target, thus showing the 
level of unspecific binding (127). 
In this study, we used the MACSQuant Analyzer 10 (Miltenyi Biotech, Bergisch 
Gladbach, Germany) for all flow-cytometric measurements. It is equipped with three lasers and 
eight optical filters which enables it to analyze probes with up to eight different fluorochromes 
as well as number, size and granularity of the cells. The optical configuration of the 
MACSQuant® Analyzer is detailed in Table 5. 
Optical specification of MACSQuant Analyzer 
Laser + Excitation Channel Filter Dye 
Violet diode laser (405nm) 
V1 450/50 
VioBlue, AlexaFluor405, Pacific Blue BD, 
Horizon V450 
V2 525/50 VioGreen, AlexaFluor430 
Blue argon laser (488nm) 
B1 525/50 FITC, AlexaFluor488 
B2 585/40 PE 
B3 655 (LP) PE-Cy5 
B4 750 (LP) PE-Cy7 
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Red diode laser (635 nm) 
R1 655 (LP) APC, AlexaFluor647 
R2 759 (LP) APC-Cy7 
Blue argon laser 
FSC 488/10 Size 
SSC 488/10 Granularity 
Table 5 Optical configuration of a MACSQuant ®10 Analyzer 
2.4.2 Monoclonal antibodies 
Various combinations of fluorochromes-conjugated monoclonal antibodies were used 
in this study. A full list of the antibodies with their fluorochromes and isotype controls is depicted 
in Table 6. If no Isotype Control was available FMO was used as a negative control instead. 
Antibodies highlighted by italic print require a secondary antibody conjugated to a 
fluorochrome. 





CD 45 APC-Cy7 1:400 30F11 BioLegend Rat IgG2α,κ 0.2 mg/ml 
CD 11b PE-Cy7 1:2000 M1/70 BioLegend Rat IgG2b, κ 0.2 mg/ml 
CD 11c APC 1:400 N418 BioLegend Armenian 
Hamster IgG 
0.2 mg/ml 
CD 11c VioBlue 1:20 N418 Miltenyi Biotech Hamster IgG 30 µg/ml 
PDCA-1 FITC 1:400 927 BioLegend Rat IgG2b, κ 0.5 mg/ml 
PDCA-1 PE 1:200 129.C1 BioLegend Rat IgG2b, κ 0.2 mg/ml 
MHC-II Alexa Fluor® 488 1:4000 M5/114.15.2 BioLegend Rat IgG2b, κ 0.5 mg/ml 
CD 103 PE 1:200 2.00E+07 BioLegend Hamster IgG 0.2 mg/ml 
Ly6G FITC 1:200 1A8 BioLegend Rat IgG2α, κ 0.5 mg/ml 
CD 19 PE-Cy7 1:100 6D5 BioLegend Rat IgG2α, κ 0.2 mg/ml 
CD 3e Alexa Fluor® 488 1:100 145-2C11 BioLegend Armenian 
Hamster IgG 
0.5 mg/ml 
NK 1.1 Biotin 1:100 PK136 BioLegend Mouse IgG2α, κ 0.5 mg/ml 
CD 4 APC 1:100 GK 1.5 BioLegend Rat IgG2b, κ 0.2 mg/ml 
CD 8α PE 1:200 53-6.7 Biolegend Rat IgG2α, κ 0.2 mg/ml 
F4/80 Alexa Fluor® 488 1:200 BM8 Biolegend Rat IgG2α, κ 0.5 mg/ml 
F4/80 PE 1:200 BM8 BioLegend Rat IgG2α, κ 0.2 mg/ml 




Ly6C APC 1:1000 HK1.4 BioLegend Rat IgG2c, κ 0.2 mg/ml 




1:500 polyclonal Biotechne  1 mg/ml 
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1:500 polyclonal Biotechne  1 mg/ml 
Streptavidin 
(anti biotin) Alexa Fluor® 405 1:400  Life Technology 
 1 mg/ml 
Secondary 
AB Anti-
Goat IgG  
Alexa Fluor® 647 1:800* polyclonal Life Technology Donkey IgG 2mg/ml 
Table 6 Antibodies: Overview of all antibodies used in this study, including supplier, dilution, host and isotype 
control. Suppliers were Miltenyi Biotech (Bergisch Gladbach, Germany), BioLegend (San Diego, CA, USA), Life 
Technologies (Darmstadt, Germany). Antibodies highlighted by italic print are unlabled and required staining with 
a secondary antibody conjugated to a fluorochrome. 
2.4.3 Multicolored fluorescent staining of surface antigens 
Figure 4 shows the staining protocol for the staining of surface antigens. Cells and 
reagents were kept on ice during at all time. 1.25*105 living, single cells were suspended in 
400µl FACS-Buffer and pelleted at 300g for 4 minutes. To block nonspecific binding of 
fluorochromes-conjugated antibodies, cells were incubated for 5-10 minutes with 50µl FACS-
Buffer containing murine Fc-Block and CD64 as detailed in Table 8. Then 50 µl staining mix 
containing various combinations of fluorochromes-conjugated primary antibodies was added 
and cells were incubated for further 20 minutes. To wash the cells 400 µl FACS-Buffer was 
added and the cells were spun down at 300g for 4min. For the analysis, the pellet was 
resuspended in 200 µl FACS-Buffer with 0.6 µg PI and measured using the MACSQuant 
Analyzer (Miltenyi Biotech, Bergisch Gladbach, Germany). Some markers were not available 
directly conjugated to a fluorochrome, which requires an additional staining step. The staining 
was performed as described above with the staining mix containing also the non-fluorescent 
primary antibody. Afterwards cells were incubated for another 20 minutes in 100 µl FACS-
Buffer containing a secondary, fluorescent antibody to bind to the primary antibody. They were 
then washed and analyzed as described above. If the digest was done using digest protocol I 
the number of stained cells was 2.5*105 living, single cells. The number of cells collected from 
a fat tissue digest is very low. Therefore, it was only possible to use one staining mix per animal 
when investigating fat tissue and all recovered cells were used for that stain. When staining 
for CD64 expression the Fc-Block was prepared without purified anti-CD64.  
Table 7 details 5 basic marker combinations that were used in this study to look at 
individual cell populations. Antibodies highlighted by italic print were not used in all 
experiments. 
  




Staining Mix Antibodies 
classical DCs CD45, CD11b, CD11c, CD103, CD64, MHC-II, F4-80 
plasmacytoid DCs CD45, CD11b, CD11c, PDCA-1, MHC-II 
lymphoid cells CD45, CD19, CD3e, NK1.1, F4-80, CD4 
myeloid cells CD45, F4-80, CD11b, Ly6C 
neutrophils CD45, CD11b, PDCA-1, F4-80, Ly6G, Ly6C 
Table 7 surface marker combinations used to identify different cell populations 
Reagent Supplier Volume 
Fc-Block I 
Fc-Block (anti-mouse CD16/32) BioLegend, San Diego, USA 2 µl  (stock 0.5 mg/ml) 
CD64 purified BioLegend, San Diego, USA 1 µl  (stock 0.5 mg/ml) 
MACS-Quant® Running Buffer Miltenyi Biotech, Bergisch Gladbach, Germany 50 µl 
Fc-Block II 
FcR-Blocking reagent Miltenyi Biotech, Bergisch Gladbach, Germany 10 µl 
CD64 purified BioLegend, San Diego, USA 1 µl  (stock 0.5 mg/ml) 
MACS-Quant® Running Buffer Miltenyi Biotech, Bergisch Gladbach, Germany 50 µl 
Table 8 Composition of Fc-Blocking reagents used in multicolored fluorescent staining of surface antigens. The 
CD64 antibody was left out when analyzing CD64 expression. 
 
Figure 4 flow-chart of antigen staining protocol 
2.4.4 Staining of intracellular cytokines 
Staining of intracellular cytokines was performed using the BD Cytofix/CytopermTM 
Fixation/Permeabilization Kit (BD Biosciences, Heidelberg, Germany) according to the 
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manufacturers instructions. 2.5*105 living, single cells were planted for 4h at 37°C in a U-
Bottom 96-well plate as shown in Table 6. BD GolgiStop is a protein transport inhibitor that 
blocks intracellular transport processes which will result in the accumulation of most cytokine 
proteins in the Golgi complex. The cells were either left unstimulated or stimulated using LPS. 
After the incubation period cells were pelleted at 300g, 4°C for 3 minutes and kept on ice during 
all further steps. Staining of surface molecules was performed as described in chapter 1.3.4. 
After washing with 200 µl FACS-Buffer and pelleting the cells as described before, they were 
fixed and permeabilized by incubating them in 200 µl BD Fixation/Permeabilization solution for 
20 min. They were then washed two times using 200 µl BD Perm/WashTM buffer per well. To 
maintain cells in a permeabilized state mixes for intracellular staining were prepared using the 
BD Perm/WashTM buffer rather than the standard FACS-Buffer. Cells were incubated for 20 
minutes in 50 µl of staining mix containing the anti-cytokine antibody of interest. They then 
were washed two times using 200 µl BD Perm/WashTM buffer and ultimately resuspended in 
200 µl FACS-Buffer for flow cytometric analyses. Since the cells die during fixation it was not 
necessary to ad PI prior to measurement. If the digest was done using the original protocol the 
number of cells was 5*105 living, single cells. Table 10 details the combination of antibodies 
used for surface stain and the antibodies used for intracellular staining.  
Cell Culture 
Reagent Supplier Volume or Concentration 
living, single cells  5*105 / well 
RPMI Life technologies, Darmstadt, Germany 200 µl / well 
GolgiStop BD Biosciences, Heidelberg, Germany 4 µl / 6ml culture medium 
+/- LPS 
(E. coli O127:B8) 
Sigma, Taufkirchen, Germany 250 ng / ml 
Table 9: Composition of reagents for planting cell culture for intracellular staining. 
Staining Mix Antibodies 
Surface staining CD45, CD11b, CD11c, CD103, PDCA-1, F4-80 
Intracellular staining TNF or CXCL-1 or CXCL-2 or CCL-5  
Table 10: Staining mix for surface stain during intracellular cytokine staining and the analyzed cytokines. 
2.4.5 Data-analysis 
Data was analysed using FlowJo 10.0.8 software (FlowJo LLC, Ashland USA). Statistical 
analyses were performed with Prism 5 software (Graphad Software). Performed tests were 
unpaired two-tailed T test, T test with Welch’s correction or one-way ANOVA using Bonferroni 
post-test. *p<0.05, ** p<0.005, ***p<0.0001 
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2.5 Cytokine-array analysis 
Cell culture supernatant was created by planting 5*105 living, single cells in a total 
volume of 100 µl. Cells were incubated at 37°C for 18h either unstimulated or stimulated using 
LPS. The detailed composition of reagents is depicted in Table 11. Subsequently cells were 
spun down at 300g, 4°C for 3 minutes and a maximum of 90 µl supernatant was collected to 
avoid taking up any cells or debris. Supernatants of each group were pooled and stored at -
80°C until further usage. The Cytokine Array was performed using the Proteome Profiler 
Mouse Cytokine XL protein array (Biotechne, Minneapolis, USA). This is a nitrocellulose 
membrane spotted with various capture and control antibodies to detect differences in 
cytokines, chemokines and growth factors between samples. The assay was performed 
according to the manufacturers’ guidelines. For each membrane 200 µl supernatant was used. 
Prior to adding it to the membrane it was defrosted at room temperature and subsequently 
spun down (300g, 3min) to eliminate any particles. The membranes were imaged using 
ChemidocMP Imaging System (Biorad, Munich, Germany) and mean grey values were 
calculated using ImageJ 1.50i Software (Wayne Rasband, National Institutes of Health, USA). 
Cell Culture 
Reagent Supplier Volume or Concentration 
Living, single cells  5*105 / well 
RPMI Life technologies, Darmstadt, Germany 100 µl / well 
+/- LPS 
(E. coli O127:B8) 
Sigma, Taufkirchen, Germany 250 ng / ml 
Table 11 Composition of reagents for cell culture to perform cytokine production array 
2.6 Liver triglyceride quantification 
Liver triglyceride content was determined using the abcam Triglyceride Quantification Kit (Cambridge, 
UK) following the manufacturer’s guidelines. Liver tissue samples were harvested and stored at -80°C 
as described in chapter 2.2. 100mg of liver tissue was thawed on ice and then homogenized in a 5% 
NP-40/dH2O solution using a Potter-Elvehjem tissue homogenizer (VWR, Darmstadt, Germany). 
Triglycerides were solubilized at 80-100°C and insoluble material was eliminated through centrifugation. 
In the assay triglycerides a lipase converts triglycerides to free fatty acids and glycerol. The latter is then 
oxidized to a product, which reacts with the probe to generate a colorimetric reaction. The resulting 
signal was measured using Tecan SunriseTM Microplate Reader (Tecan Group Ltd., Männedorf, 
Switzerland) at a wavelength of 570nm. 
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2.7 qPCR of retroperitoneal fat tissue 
Real-time quantitative polymerase chain reaction (qPCR) is a widely used method to 
determine the expression levels of specific genes in a biological sample. PCR is a method to 
exponentially amplify highly specific DNA sections through repeating cycles of denaturation of 
template DNA to produce single stranded molecules, annealing of specific primers to the target 
sequence and the synthesis of the complementary sequence by a DNA polymerase. qPCR 
allows a real-time analysis of the DNA amplification and the starting amount of template DNA 
by using fluorescent dye that binds to double stranded DNA. The expression of specific genes 
in biological samples can be measured by isolating RNA from the samples and producing a 
complementary DNA (cDNA) through reverse transcription, which can then be used for qPCR 
with primers specific for the gene of interest. A housekeeping gene is used as a reference, 
which is a gene that does not vary in expression level in the sample type of interest. 
Retroperitoneal fat tissue was collected as described in chapter 2.2. RNA extraction was 
performed using RNeasy Lipid tissue mini kit (Quiagen, Hilden, Germany) according to the 
manufacturer’s guidelines. Following cDNA was synthesized through reverse transcription 
using the Quantinova RT system (Qiagen, Hilden Germany). qPCR was carried out with 
validated primers detailed in Table 12 using Qantinova SYBR Green qPCR reagen (Quiagen, 
Hilden, Germany) mix as a fluorescent dye. The plates were measured with the Applied 
Biosystems 7500 Fast (Darmstadt, Germany) using the following program: one cycle of DNA 
polymerase activation at 95°C for 2 min and 40 cycles of amplification with denaturation at 
95°C for 5s and annealing and extension at 60°C for 30s. As a housekeeping gene beta-actin 
was used. 
Gene Catalog number Supplier 







Table 12 Primers used for real-time quantitative PCR analysis of retroperitoneal fat tissue: target gene, catalog 
number and supplier are indicated for each primer used in this study 
2.8 Serum analysis 
Serum was prepared as described in chapter 2.2. ALT-Values were determined at the 
diagnostic laboratory center of Saarland University Hospital in Homburg, Germany. Serum 
Material and Methods 
29 
 
samples were diluted 1:2 or 1:5 with Sodium Chloride 0,9% (B. Braun, Melsungen, Germany) 
and the values calculated according to the dilution. Leptin levels were measured using leptin 
DuoSet® ELISA (Biotechne, Minneapolis, USA) according to the manufacturer’s guidelines 
with the serum being diluted 1:10 or 1:5 in Reagent Diluent (0.5% Tween®20 in PBS). Serum 
insulin levels were measured using the murine insulin ELISA kit (Thermo Fischer Scientific, 
Germany) according to the manufacturer’s guidelines. ELISA plates were measured using 
Tecan Sunrise Microplate Reader (Tecan Group Ltd., Männedorf, Switzerland) and values 
were calculated using the software www.elisanalysis.com (www.elisakit.com, Scoresby 
(Melbourne), Australia).  
2.9 Intraperitoneal glucose tolerance test 
For the intraperitoneal glucose tolerance test (IPGTT) animals were fasted for 6 hours. 
The blood for glucose testing was drawn from the tail vein. The mice were briefly warmed up 
under infrared light to dilate the blood vessels and then put in a restraining device. The vein 
was incised using a sterile scalpel and a small blood drop was put on the testing strip for blood 
glucose measurement using the Accu-check Aviva measuring system (Roche Diabetes Care 
GmbH, Mannheim, Germany). After measuring fasting glucose, the animals were injected 
intraperitoneal with 2 mg glucose/g body weight in a total volume of 200µl PBS. Blood glucose 
measurement was repeated at 30, 60, 120 and 180 minutes after the glucose injection. 
2.10 HbA1c measurement 
For HbA1c measurement blood was collected from the mice’ tails as described in chapter 
2.7. To prevent it from clotting blood was kept in PBS (Life technologies, Darmstadt Germany) 
containing 10mM EDTA (Life technologies, Darmstadt Germany). HbA1c was directly analyzed 
at the diagnostic laboratory center of Saarland University Hospital, Homburg, Germany.   
2.11 Histology 
2.11.1 Preparation of paraffin sections 
For paraffin sections one liver lobe was carefully cut at the base and stored in 4% 
paraformaldehyde solution (VWR International GmbH, Darmstadt, Germany). The tissue 
samples were transferred to the Institute of Anatomy and Cell Biology, University of Saarland, 
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where it was embedded in paraffin, cut into 5 µm slices and either stained with hematoxylin-
eosin (HE) or left native for later connective tissue staining. 
2.11.2 Necroinflammatory score 
The HE sections were assessed based on the presence of inflammation, necrosis and 
hepatocyte ballooning graded on a scale from 0 to 4 (Table 13). This was done using the Leica 
DM500B microscope (Leica Microsystems, Wetzlar, Germany). Of each liver lobe two different 




1 mild or focal 
2 noticeable 
3 severe 
Table 13: Score to assess necroinflammation in liver sections: scoring was based on presence of inflammatory 
infiltrate, hepatocellular balooning and necrosis 
2.11.3 Connective tissue staining 
Connective tissue staining of paraffin embedded liver sections was performed using 
the Picro Sirius Red Stain Kit (Abcam, Cambridge, UK) and evaluated using the Leica DM500B 
microscope (Leica Microsystems, Wetzlar, Germany). Sirius Red Stain is a technique for the 
histological visualization of collagen I and III fibers. Staining was performed according to the 
manufacturer’s guidelines. Since paraffin sections were used, deparaffinization by submerging 
the slides in alcohol as following:  
 2 x 3min Xylol 
 3 min  1:1 Xylol: 100% ethanol 
 2 x 3 min 100% ethanol 
 3 min  95% ethanol 
 3 min  70% ethanol 
 3 min  50% ethanol 






3.1 Effects of dietary treatment on WT mice 
Figure 5.A shows representative pictures of HE-stained liver of WT mice treated with 
either 5 weeks NC, HSD or MCD. Animals treated with NC show a regular histologic liver 
structure without any signs of inflammation or steatosis. In HSD livers a mild, mostly 
microvesicular steatosis can be observed with occasional signs of necroinflammation such as 
inflammatory infiltrates or hepatocellular ballooning, but an overall low scoring for NASH at 
either 0 or 1 points. In the 5 weeks MCD treated WT animals the histological assessment 
shows established steatosis, both micro- and macrovesicular and severe signs of 
necroinflammation with frequent inflammatory infiltrates, necrosis and hepatocellular 
ballooning. The histological observations for steatosis are paralleled by the values for 
quantitative liver triglyceride measurement: in WT animals NC livers have a low level of 
triglyceride content (mean NC WT 13.6 µg/mg liver), which increases significantly to an 
average of 59.1 µg/mg liver in HSD treated animals and even further to 117.8 µg/mg liver in 5 
weeks MCD treated animals (Figure 5.E). The inflammatory infiltrate can also be detected in 
flow cytometric analysis based on the influx of CD45+ cells. These have an average percentage 
of 33.5% CD45+ cells within all living cells in the NC treated healthy WT animals. Parallel to 
the histological scoring in WT animals, this ratio does not change significantly in HSD treated 
animals (mean WT HSD 29.2%), but significantly doubles to an average of 68.7% in the 5 
weeks WT MCD treated group (Figure 5.B). Serum ALT values, as a further parameter for liver 
damage, also mirror these tendencies: in NC treated animals the mean ALT values are at 32.4 
U/L and slightly, albeit not significantly, increased to 81.1 U/L in HSD. After MCD feeding the 
values more than triple to an average of 277.7 U/L after 5 weeks (Figure 5.D). 
Summary Chapter 3.1: 
• 5 weeks HSD feeding results in bland liver steatosis with increased liver triglyceride 
content, but without histological signs of inflammation, increased CD45+ cell 
infiltrate or elevated ALT serum values. 
• 5 weeks of MCD feeding results in NASH, which is presented as severe histological 
signs of inflammation, increased CD45+ cell infiltrate, increased liver triglyceride 





Figure 5 parameters of disease progression in WT C57Bl/6 mice after 5 weeks of HSD or MCD treatment or feeding 
of NC A) histological assessment of HE-stained liver sections imaged at 20x objectives. The bar graph shows the 
necroinflammatory scoring based on the presence hepatocellular ballooning, necrosis and inflammation: nHSD = 10, 
nMCD = 8. Data includes samples from 2-4 independently conducted experiments B) infiltrate of CD45+ 
hematopoietic cells in the liver. Left figure shows representative dot-blots gated on living, single cells with signal for 
CD45 (APC-Cy7 1:400) plotted against forwards scatter and selecting leukocytes by gating on CD45+ cells. Right 
figure shows bar-graph with percentage ratio of CD45+ cells within living, single cells of WT mice after NC, HSD or 
MCD treatment: nNC= 5, nHSD = 5, nMCD = 5. Data is representative of multiple, independent experiments for NC, 
HSD and MCD: repetitionsNC = 3 (n=4-5/group), repetitionsHSD = 6 (n=3-5/group), repetitionsMCD = 4 (n=4-5/group). 
Bar-graphs depict mean + SEM. C) bar graph shows comparison of serum ALT values: nNC = 12, nHSD= 13, nMCD = 
18. Data includes samples from 2-4 independently conducted experiments per treatment group D) bar graph shows 
comparison of liver triglyceride levels. Data for liver triglyceride measurement was provided by Anna Maier. Bar-
graphs depict mean + SEM. Data includes samples from 3-4 independently conducted experiments per treatment 
group. Significance is indicated through *p<0.05, ** p<0.005, ***p<0.0001. Underlined asterisks show statistical 
significance compared to the respective NC group of WT animals. 
3.2 Identifying cDC subtypes in the murine liver 
Since the characterization of CD11c+MHC-II+ cells as DCs is not sufficient to map cDC 
subtypes in the murine liver it is necessary to develop a gating strategy, that employs a more 
accurate marker combination. This is depicted in Figure 6: A basic gating strategy is used for 
all flow-cytometric analyses in this study (Section A). It includes gating on living, single cells 
as described in chapter 2.3.1 and subsequently selecting all CD45+ to gate on all immune cells. 
When looking at the CD11c expression of CD45+ leukocytes it is possible to distinguish 
between CD11c negative and positive cells (Figure 6.B). Since cDCs are characterized by a 
high expression of CD11c a gate was drawn that included only events with a high CD11c 
signal, but left out all events with an intermediate or negative signal. As the two cDC subtypes 
are characterized by their expression of either CD11b or CD103 these markers are then plotted 
against each other as depicted (Figure 6.C). This separates the CD11chi cells into three 




positive for CD103 (dark blue gate) and the remaining cells are negative for both markers. A 
CD11b CD103 double positive population is not present. This expression pattern marks the 
CD11chiCD103+CD11b- events as cDCs 1 and the CD11chiCD103-CD11b+ events as both 
cDCs 2 and monocyte derived DCs, while the CD11chiCD11b-CD103- events are a mixture of 
other CD11c expressing cells. To verify that cells of the yellow and dark blue gate are indeed 
DCs the MHC-II expression can be checked (Figure 6.D, Figure 6.E). Indeed, both cell 
populations show a positive signal for MHC-II (pink gate, light blue gate) and do not contain 
MHC-II negative cells. Consequently, all cells in the yellow and dark blue gate of Figure 6.C 
are DCs and adding MHC-II to the staining mix does not further separate the cell populations, 
thus does not provide further information. Therefore, to differentiate between the cDC 
subtypes, it is sufficient to gate on CD11chi cells and subsequently CD103+ or CD11b+ cells 
without the need for MHC-II as an additional marker. 
An alternative gating method for CD11b+ DCs is depicted in Figure 6.G and Figure 6.H, 
with the respective isotype controls in Figure 6.J. Here the CD11c and MHC-II signal of CD45+ 
leukocytes is first plotted against each other and only CD11chiMHC-IIhi expressing cells are 
gated on (red gate). Subsequently CD11b+ expressing cells (orange gate) are selected. This 
is valid, as in Figure 6.C CD11chi cells do not contain a CD11b CD103 double positive cell 
population, therefore all CD11b expressing cells are CD103 negative and vice versa. This is a 
gating strategy that can be useful during the inflammatory state, in which some non-DC cells 
upregulate their CD11c expression and possibly shift into the CD11chi gate. Adding the criterion 
of a high MHC-II expression to the gating strategy preempts that non-DCs are included in the 
analysis. 
Since the CD11b+ DCs can either origin from the monocyte cell-line or develop from 
preDCs. CD64, which is expressed by moDCs, but not cDCs, can be used to separate these 
two cell types. As depicted in Figure 6.I when plotting CD11b+ DCs accordingly to their CD64+ 
expression, they separate into a CD64+ population (red gate), which represent moDCs, and a 
CD64- population (dark green gate) which represent cDCs 2.  
Concluding a reliable way to identify the cDC 1 and CD11b+ DC subpopulation is to use 
a marker combination that includes CD11c and CD11b or CD103 respectively, with the crucial 
step being the selection of only CD11chi signals. As additional markers MHC-II can be used, 
which is especially useful in the inflamed liver, and CD64 to separate the CD11b+ DC 





Figure 6 Gating strategy for cDC subtypes in the murine liver A) basic gating strategy: debris, doublet and dead cell 
exclusion. Gating on leukocytes by selecting all CD45+cells. B) representative dot blots of CD45+ cells showing 
CD11c signal (APC 1:400) plotted against sideward scatter: gating on CD11chi cells C) representative contour blots 




CD103+CD11b- cells (dark blue gate) and CD103-CD11b+ cells (yellow gate) D) representative contour blots of 
CD103-CD11b+ cells showing MHC-II signal (FITC 1:4000) plotted against CD11c signal (APC 1:400) to gate on 
MHC-II+ cells (pink gate) E) representative contour blots of CD103+CD11b- cells showing MHC-II signal (FITC 
1:4000) plotted against CD11c signal (APC 1:400) to gate on MHC-II+ cells (light blue gate) F) isotype controls for 
gating strategy of figures B-F G) representative dot blots of CD45+ cells showing CD11c signal (APC 1:400) plotted 
against MHC-II signal (FITC 1:4000) to gate on CD11chi MHC-IIhi cells (red gate) H) representative contour plot of 
CD11chiMHC-IIhi cells showing CD11b signal (PE-Cy7 1:2000) plotted against forwards scatter to gate on CD11b+ 
cells (orange gate) I) representative contour plot of CD11chiMHC-IIhiCD11bhi cells showing CD64 signal (Brilliant 
Violet 421 1:200) plotted against CD11b (PE-Cy7 1:2000) to gate on CD64+ (dark red gate) and CD64- (dark green 
gate) J) isotype controls for gating strategy of figures G-I  
3.3 Mapping DC subtypes during disease progression 
Liver DCs have been suggested to be involved in the pathogenesis of NASH. The first 
aim of this study was to determine how DC subtypes change during disease progression in 
WT animals. For this purpose, WT animals were fed either HSD or MCD for five weeks to 
induce steatosis or steatohepatitis respectively. NC fed animals served as a control group. The 
DC subtypes were then tracked based on their expression of DC surface antigens using flow 
cytometry. 
3.3.1 cDCs 1 
To track changes of the CD103+ cDC 1 population in different treatment groups the flow 
cytometric data can be analyzed as described in chapter 3.1. Figure 7.B shows an influx of 
CD11chi cells in the MCD diet group, whereas the dot blot of the HSD experiment does not 
change compared to the control NC fed group. When looking at the CD103+ cells among this 
population they show similar changes (Figure 7.C and E). The percentage ratio of 
CD11chiCD103+ cells does not change significantly in the HSD treated animals (means WT: 
NC 1.8%, HSD 2.2%) nor does the total cell amount per gram liver (means WT: NC 36x103 
cells/g liver, HSD 27x103 cells/g liver). After 5 weeks of MCD diet the percentage ratio of cDCs 
1 increases about 2.4-fold to mean 4,4%. These changes are even more distinct in the absolute 
cell count per gram liver, where the numbers increase 8.2-fold to mean 300x103 cells/g liver. 
Thus 5 weeks feeding of HSD does not cause any significant change in the cDC 1 






Figure 7 changes of cDCs 1 in WT C57Bl/6 after 5 weeks of HSD or MCD compared to NC fed animals A) basic 
gating strategy: debris, doublet and dead cell exclusion. Gating on leukocytes by selecting all CD45+cells. B) 
representative dot blots of CD45+ cells showing CD11c signal (APC 1:400) plotted against sideward scatter: gating 
on CD11chi cells C) representative contour blots of CD11chi cells showing CD11b signal (PE-Cy7 1:2000) plotted 
against CD103 signal (NC: PE 1:200; HSD, MCD: A488 1:200) to gate on CD103+ DCs D) bar-graphs show 
comparison of percentage ratio within CD45+ cells (upper graph) and total cell amount per gram digested liver (lower 
graph) of cDCs 1 in different dietary models. nNC= 5, nHSD = 5, nMCD= 5.  
Data (A-D) for NC, HSD and MCD is representative of multiple independent experiments: repetitionsNC= 3 (n= 4-5), 
repetitionsHSD= 5 (n=4-5), repetitionsMCD= 4 (n=4-5). Bar-graphs depict mean + SEM. Significance is indicated 
through *p<0.05, ** p<0.005, ***p<0.0001. Underlined asterisks show statistical significance compared to the 
respective NC group of WT animals. 
3.3.2 CD11b+ DCs 
Changes in the CD11b+ DC population are investigated using a gating strategy as 
described in chapter 3.1: a gate is drawn around cells that show a high expression of CD11c 
and MHC-II and then CD11b positive events are selected. Similar as described for CD11chi 
cells in Figure 7 it is possible to detect an influx of CD11chiMHC-IIhi cells in the MCD treated 
group, whereas the dot blot for HSD animals does not show distinct changes compared to the 
control group (Figure 8.B). And same as cDCs 1, changes of CD11b+ DCs mirror those of the 




significantly compared to the control group (means WT: NC 2.2%, HSD 2.7%), nor are there 
any significant changes in total cell count per gram liver (means WT: NC 34x103 cells/g liver, 
HSD 27x103 cells/g liver). On the other hand, MCD treatment amplifies the percentage ratio 
3.6-fold to an average of 7.8% after 5 weeks feeding. This observation is mirrored in the total 
cell count with a 13-fold increase after 5 weeks MCD treatment (mean WT: MCD 448x103 
cells/g liver).  
 
Figure 8 changes of CD11b+ DCs in WT C57Bl/6 mice after 5 weeks of HSD or MCD compared to NC fed animals. 
A) basic gating strategy: debris, doublet and dead cell exclusion. Gating on leukocytes by selecting all CD45+cells. 
B) representative dot blots of CD45+ cells showing CD11c signal (APC 1:400) plotted against MHC-II signal (FITC 
1:4000): gating on only high expression of CD11c and high MHC-II C) representative contour blots of CD11chiMHC-
IIhi cells showing CD11b signal (PE-Cy7 1:2000) plotted against forwards scatter to gate on CD11b+ DCs D) bar-
graphs show comparison of percentage ratio within CD45+ cells (upper graph) and total cell amount per gram liver 
(lower graph) of CD11b+DCs in different dietary models. nNC= 5, nHSD= 5, nMCD= 5.  
Data (A-D) for NC, HSD and MCD is representative of multiple independent experiments: repetitionsNC= 2 (n=3-5), 
repetitionsHSD= 5 (n=4-5), repetitionsMCD= 3 (n=4-5). Bar-graphs depict mean + SEM. Significance is indicated 
through *p<0.05, ** p<0.005, ***p<0.0001. Underlined asterisks show statistical significance compared to the 





The pDC population can be identified using a staining mix that contains CD11c, CD11b 
and PDCA-1. After gating on living, single cells that express CD45 (Figure 9.A) a gate is drawn 
based on the expression of CD11c. Unlike cDCs, pDCs express intermediate levels of CD11c 
therefore all CD11c positive cells are selected (Figure 9.B). When subsequently plotting the 
CD11b signal against the PDCA-1 signal the pDC population, which is negative for CD11b 
expression and positive for PDCA-1 expression, distinctly separates from remaining events 
(Figure 9.C). Tracking this population in different treatment models reveals that the percentage 
ratio of pDCs is significantly altered only after 5 weeks of MCD diet in the steatohepatitis model 
(means WT: NC 3.0%, MCD 5.2%), but does not change in the HSD treated animals (mean 
WT: HSD 3.3%). The total cell count per 106 living cells mirrors this increase in the MCD group 
(means WT: NC 9x103 cells/106 living cells, MCD 28x103 cells/106 living cells). In the HSD 
model, the total cell count per 106 living cells does not alter significantly (mean WT: HSD 





Figure 9 changes of pDCs in WT C57Bl/6 mice after 5 weeks of HSD or MCD compared to NC fed animals. A) 
basic gating strategy: debris, doublet and dead cell exclusion. Gating on leukocytes by selecting all CD45+cells. B) 
representative dot blots of CD45+ cells showing CD11c signal (APC 1:400) plotted against sideward scatter to gate 
on all CD11c+ cells C) representative contour blots of CD11c+ cells showing CD11b signal (PE-Cy7 1:2000) plotted 
against PDCA-1 signal (PE 1:200) to gate on PDCA-1+ CD11b- cells D) Isotype controls for CD11c (APC 1:400), 
PDCA-1 (PE 1:200) and CD11b (PE-Cy7 1:2000) E) bar-graphs show comparison of percentage ratio within CD45+ 
cells (upper graph) and total cell amount per 106 living cells (lower graph) of pDCs in different dietary models. nNC= 
5, nHSD= 5, nMCD= 5.  
Data (A-E) for HSD and MCD is representative of multiple independent experiments: repetitionsHSD = 4 (n=4-5), 
repetitionsMCD = 3 (n=4-5). NC experiment was performed one time. Data shown for MCD was created using the 
digest protocol I. Bar-graphs depict mean +SEM. Significance is indicated through *p<0.05, ** p<0.005, 




3.3.4 TNFα production by DC subtypes 
To further characterize the role DCs play in the pathogenesis of NASH the subtypes 
can also be analyzed on a functional level. This can be done through intracellular cytokine 
staining with TNFα-antibodies and a surface staining with a combination of cDC markers.  
Since the cells die during the permeabilization step of the cell membrane during the 
staining procedure, gating on PI positive, living cells is not necessary. The basic gating strategy 
is limited to debris exclusion, single cell selection and gating on CD45+ cells (Figure 10.A). DC 
subtypes are gated on as described in chapter 3.2 by selecting CD11chi expressing cells and 
then either CD103+ cells or CD11b+ cells (Figure 10.B middle). Additional gates are drawn to 
analyze the total CD11c expressing population as well as all F4-80+ cells (Figure 10.B right 
and left). When subsequently plotting the TNFα signal against forward scatter the populations 
are split into positive and negative events, where the positive population corresponds to the 
intracellular produced TNFα (Figure 10.C). CD11c+ cells show an average TNFα production of 
5.0% in WT NC fed mice, which does not change significantly in HSD treated WT animals 
(mean WT: HSD 5.6%). In WT MCD treated animals TNFα production of CD11c+ cells 
increases significantly to an average of 12.6%. In the CD11b+ DC population the overall ratio 
of TNFα positive cells is higher at an average of 12.9% in the NC fed group, but it is not affected 
significantly neither in HSD treated animals nor in MCD treated animals (mean WT: HSD 
14.4%, MCD 10.6%). cDCs 1 neither show any significant increase in TNFα positive cells in 
HSD or MCD compared to NC (mean WT: NC 2.9%, HSD 3.1%, MCD 2.4%). Also, the overall 
percentage ratio of TNFα producing cells is markedly lower than that of CD11b+ DCs. The 
average ratio of TNFα producing cells in F4-80+ cells of NC fed mice is at 4.3%. This does not 
change in HSD treated animals, where the average percentage ratio is at 3.6%. Parallel to the 
TNFα production of the CD11c+ population the ratio of TNFα positive cells increases 
significantly to 21.5% in the MCD treated group. Taken together neither cDC subtype 
significantly increases its TNFα production in HSD induced steatosis or MCD diet induced 
NASH, whereas the total of CD11c and F4-80 expressing cells show a significant upregulation 
of TNFα-production in MCD induced NASH. This points towards the fact that the upregulated 
TNFα-production in the CD11c+ population stems from upregulated production of F4-80+ cells 





Figure 10 TNFα production of different cell populations stimulated with 250ng/ml LPS for 5 hours in WT C57Bl/6 
mice after 5 weeks of HSD or MCD treatment compared to NC fed animals. A) basic gating strategy with debris 
and doublet cell exclusion. Gating on leukocytes by selecting all CD45+cells. B) representative dot-blots for pre-
gating on different cell populations within CD45+ cells to be analyzed for TNFα-production. Plotting CD11c signal 




gating on CD11chi cells (black gate) and then plotting CD11b signals (PE-Cy7 1:2000) against CD103 signals (PE 
1:200) to gate on CD11b+ DCs (lime green gate) or cDCs 1 (dark blue gate). Plotting F4-80 signal (A488 1:200) 
against forward scatter to gate on all F4-80+ cells (orange gate) C) representative contour-blots of the TNFα signal 
(APC 1:200) plotted against forward scatter within the cell populations of interest (red, lime green, blue and orange). 
Gated on TNFα+ cells D) Isotype control for TNFα (APC 1:200) E) bar-graph shows comparison of percentage ratio 
of TNFα+ cells within CD11c+ cells, CD11b+ DCs, cDCs 1 or F4-80+ cells. nNC=4, nHSD=4, nMCD=4.  
Data (A-E) shown for CD11c+, CD11b+ DCs, cDCs 1 is representative of multiple independent experiments for HSD 
and MCD: repetitionsHSD= 4 (n=4), repetitionsMCD = 3 (n=4). Experiment for NC was performed one time. Data (A-
E) shown for F4-80+ cells are representative multiple independent experiments of HSD: repetitionsHSD = 3 (n=4). 
Experiments for MCD and NC were performed one time. Bar-graphs depict mean + SEM. Significance is indicated 
through *p<0.05, ** p<0.005, ***p<0.0001. Underlined asterisks show statistical significance compared to the NC 
group of WT animals. 
Summary chapter 3.3: 
• All DC subtypes show an elevated abundance in the NASH model, but not the 
steatosis model 
• CD11b+ DCs show the overall highest fold change, followed by cDCs 1 and pDCs 
• CD11c+ cells show an increased production of TNFα in NASH, which does not stem 
from increased TNFα production by the DC subpopulation, but from F4-80+ cells. 
• Bland steatosis does not lead to increased production of TNFα by either 
investigated cell population 
3.4 The effect of batf3-dependent cDCs 1 on disease progression 
Figure 11 depicts changes of disease progression parameters in WT animals compared 
to batf3-KO animals. After 5 weeks NC diet, batf3-KO animals show no difference to WT 
animals: the histological assessment of HE stained liver section shows no evidence of 
inflammation or steatosis. The CD45+ cell infiltrate of batf3-KO animals is similar to WT animals 
(means NC: WT 33.5%, batf3-KO 34.8%). ALT-values also show no significant difference with 
average 32.4 U/L in WT and 37.3 U/L in the batf3-KO neither does the mean liver triglyceride 
content with a mean 13.6 µg/mg liver in WT and 17.6 µg/mg liver in batf3-KO animals.  
The HSD treated groups on the other hand show distinct differences between WT and 
batf3-KO animals. The histological assessment of liver sections shows an increase in NASH 
scoring in batf3-KO animals with higher prevalence of inflammatory infiltrates, hepatocellular 
ballooning and necrosis. Also, the liver sections show more prominent macrovesicular and 
microvesicular steatosis compared to the WT (Figure 11.A). This is paralleled by a significantly 
higher influx of CD45+ cells in batf3-KO mice, with an average percentage ratio of 45.5% within 
living single cells compared to 29.2% in the WT (Figure 11.B). The microscopically observed 
increased steatosis can also be measured as triglyceride content in the liver. In HSD treated 
batf3-KO animals this almost 2.4-fold increased (Figure 11.E, means HSD: WT 59.1 µg/mg 




in the WT a slight increase of Serum-ALT values compared to the NC group can be detected 
in batf3-KO animals, albeit this remains non-significant. Also, serum ALT-values do not differ 
significantly between HSD treated WT animals and HSD KO animals (Figure 11.D, means 
HSD: WT 81.1 U/l, batf3-KO 108.4 U/l). Connective tissue staining of the liver in HSD treated 
animals does not show any significant fibrosis development, neither in WT nor in batf3-KO 
animals (Figure 11.C).  
In batf3-KO animals treated with MCD for 5 weeks disease progression parameters are 
worse compared to the NC and HSD treated batf3-KO animals. However, differences between 
WT and batf3-KO animals as observed in the HSD treated groups are not present here. In 
NASH scoring of liver sections WT and batf3-KO animals show no significant difference (Figure 
11.A). This is also true for the CD45+ cell infiltrate, where the percentage ratio of both, WT and 
batf3-KO, doubles to mean 68.7% and mean 70.9% respectively (Figure 11.B). The tendency 
of batf3-KO animals towards higher liver triglyceride content as observed in HSD treated 
animals is also present in the MCD treated groups: batf3-KO animals show a significant 
increase of liver triglycerides compared to the NC group. Moreover, this is significantly higher 
than the liver triglyceride content of WT MCD treated animals (means MCD: WT 117.8 µg/mg 
liver, batf3-KO 142.0 µg/mg liver). Interestingly the liver triglyceride content does not change 
significantly between the batf3-KO HSD group and MCD group (Figure 11.E). Serum ALT-
values of MCD treated batf3-KO animals are almost ten times increased compared to the NC 
group (means batf3-KO: NC 37.3 U/l, MCD 33.9 U/l). Like the HSD groups, MCD treated batf3-
KO mice also show a slight tendency towards higher ALT values compared to the WT (mean 
WT: MCD 277.7 U/L), however this remains non-significant (Figure 11.D). In the connective 
tissue stain MCD treated animals show some slight increase of collagenous fibers in the 
parenchyma compared to the HSD group, but there is no evidence of established fibrosis and 






Figure 11 parameters of disease progression in WT C57Bl/6 mice compared to batf3-KO mice after 5 weeks of NC, 
HSD or MCD treatment A) histological assessment of HE-stained liver sections imaged at 20x objectives. Bar graph 
shows the necroinflammatory scoring based on the presence hepatocellular ballooning, necrosis and inflammation: 
nWT HSD = 10, nKO HSD = 13, nWT MCD = 8, nKO MCD = 15. Data (A) includes samples from 2-4 independently conducted 
experiments B) infiltrate of CD45+ hematopoietic cells in the liver. Left figure shows representative dot-blots of living, 
single cells with signal for CD45 (APC-Cy7 1:400) plotted against forward scatter. Selecting leukocytes by gating 
on CD45+ cells. Right figure shows bar-graph with comparison of percentage ratio of CD45+ cells within living, single 
cells of C57Bl/6 WT (white) and batf3-KO (black) mice after NC, HSD and MCD treatment: nNC= 5/group, nHSD = 
5/group, nMCD = 5/group. Data (B) is representative of multiple, independent experiments for NC, HSD and MCD: 
repetitionsNC = 3 (n=4-5/group), repetitionsHSD = 6 (n=3-5/group), repetitionsMCD = 4 (n=4-5/group). Bar-graphs 




were stained with Sirius Red stain and imaged at 5x objectives. n = 3/group D) bar graph shows comparison of 
serum ALT values: nNC WT = 12, nNC KO= 7, nHSD WT= 13, nHSD KO= 16, nMCD WT= 18, nMCD KO= 26. E) bar graph shows 
comparison of liver triglyceride levels. Data for liver triglyceride measurement was provided by Anna Maier. nNC=6, 
nHSD=9, nMCD=9 Bar-graphs depict mean + SEM. Data (C-E) includes samples from 3-4 independently conducted 
experiments per treatment group. 
Bar-graphs depict mean + SEM. Significance is indicated through *p<0.05, ** p<0.005, ***p<0.0001. Asterisks on 
top of the bar show statistical significance compared to the respective NC group of WT or batf3-KO mice, underlined 
asterisks show statistical significance of WT compared to batf3-KO. 
Summary chapter 3.4: 
• The lack of cDCs 1 results in the aggravation of several NASH related parameters 
in HSD treated animals, such as a higher NASH scoring in the histological analysis, 
higher liver triglyceride content in the liver and a higher CD45+ cell infiltrate. It does 
not affect serum ALT levels or liver fibrosis.  
• The lack of cDCs 1 does not affect the liver on a baseline level in NC treated animals 
concerning histological analysis, CD45+ cells influx or liver triglycerides. 
• The lack of cDCs 1 does not aggravate established NASH in MCD treated animals 
regarding NASH scoring, CD45+ cell infiltrate, ALT values or fibrosis progression, 
but increases liver triglyceride content. 
3.5 The effect of batf3-dependent cDCs 1 on the hematopoietic infiltrate in the 
liver 
With the above described differences detected in batf3-KO animals, especially 
concerning the HSD group, the next aim of this study was to investigate how the lack of cDCs 
1 causes the observed progression of bland steatosis towards steatohepatitis. Considering the 
influx of CD45+ cells during NASH and the increase in the batf3-KO HSD group compared to 
the WT, changes of the hematopoietic cell infiltrate were analyzed with regards to different 
cellular subtypes such as DC populations, lymphocyte subsets and myeloid cells. 
3.5.1 DC-Populations 
To investigate how the lack of batf3-dependent cDCs 1 influences the remaining DC 
subtypes, flow cytometric analysis was done on CD11b+ DCs as well as pDCs in the control 
group as well as HSD or MCD treated animals. 
 CD11b+ DCs  
Figure 12 shows the analysis of the CD11b+ DC subtype in WT and batf3-KO animals 




3.2, by first gating on CD11chiMHC-IIhi expressing cells and then on the CD11b+ population. 
The CD11b+ DC population in batf3-KO animals follows similar changes as in WT animals 
(Figure 12.D). Compared to the NC treated control group the percentage ratio of CD11b+ DCs 
is not altered significantly in the HSD group (means batf3-KO: NC 3.9%, HSD 4.9%), but 
increases significantly in MCD treated animals (mean batf3-KO: MCD 11.0%). The average 
cell count in HSD animals is also significantly higher in NC treated animals and increases 
further in the MCD group (means batf3-KO: NC 59x103 cells/g liver, HSD 165x103 cells/g liver, 
MCD 589x103 cells/g liver). Comparison of WT and batf3-KO animals shows a significant 
baseline difference in percentage ratio: While in WT animals it is at 2.2% in NC treated animals, 
it is increased to 3.9% in batf3-KOs. This difference can also be observed in the HSD treated 
animals. With an average of 4.9% percentage values in batf3-KO animals are significantly 
higher than the average 2.7% in the WT. In MCD treated groups the difference is slightly 
lessened, although there is still a tendency towards higher values in batf3-KO mice (means 
MCD: WT 7.9%, batf3-KO 11.0%). When looking at percental ratio it is important to consider 
that these are relative values and not absolute numbers. Since batf3-KO animals are missing 
the cDC 1 population it is important to confirm whether differences detected in the CD11b+ 
subtype are true changes or merely a shift of proportions due to the missing population. For 
this purpose, the absolute cell count per gram liver can be calculated. Batf3-KO animals show 
a significant higher cell count in the HSD group (means HSD: WT 27x103 cells/g liver, batf3-
KO 165x103 cells/g liver), whereas differences on a baseline level in the control group or in 
MCD treated animals cannot be confirmed (means NC: WT 34x103 cells/g liver, batf3-KO 
59x103 cells/g liver; means MCD: WT 448x103 cells/g liver, batf3-KO 589x103 cells/g liver). 
  Figure 13 shows further characterization of CD11b+ DCs in NC and HSD treated 
animals using CD64 as an additional marker. The gating is performed as described in chapter 
3.2. The percentage ratio for CD64-  cDCs 2 does not change significantly in the HSD treated 
WT group compared to the NC control (means WT: NC 1.4%, HSD 2.3%). Likewise, batf3-KO 
animals show no significant difference in percentage ratio between NC and HSD (means batf3-
KO: NC 3.0%, HSD 3.8%). Calculated in absolute numbers per gram liver the cDC 2 population 
shows no significant difference between WT and batf3-KO, neither on a baseline level (means 
NC: WT 28x103 cells/g liver, batf3-KO 46x103 cells/g liver) nor after HSD treatment (means 
HSD: WT 30x103 cells/g liver, batf3-KO 68x103 cells/g liver).  This indicates that the difference 
in percentage ratio is mostly due to a shift in proportions because of the missing DC population 
in the batf3-KO animals (Figure 13.C). Values for CD64+ moDCs are notably lower than those 
of cDC 2s, which indicates that the majority of the CD11b+ DCs are cDCs 2 (Figure 13.D). The 




in WT nor in batf3-KO mice (means WT: NC 0.3%, HSD 0.4%; means batf3-KO: NC 0.3%, 
HSD 1.1%). However, comparing values of WT and batf3-KO, there is a significant difference 
in HSD treated animals. The increase in percentage ratio of HSD treated batf3-KO animals 
compared to the WT also manifests in cell count per gram liver (means HSD: WT 5x103 cells/ 
g liver, batf3-KO 20x103 cell/g liver), thus explaining the increase of CD11b+ DCs in batf3-KO 
mice.  
Concluding, in batf3-KO animals the CD11b+ DC population increases significantly both 
after HSD and MCD diet. The majority of CD11b+ DCs consists of CD64- cDCs 2, but it also 
includes some CD64+ moDCs. On baseline level batf3-KO mice show a higher frequency of 
CD11b+ DCs, which is mostly due to a shift of proportions because of the missing cell 
population. This can also be observed in the MCD treated animals, which show a significant 
difference in percentage ratio between WT and batf3-KO that cannot be confirmed in absolute 
numbers. Under HSD an increase of CD11b+ DCs can be observed in the batf3-KO animals 
compared to their WT counterparts. This can be attributed to a higher influx of moDCs in batf3-





Figure 12 changes of CD11b+ DCs in WT C57Bl/6 mice compared to batf3-KO mice after 5 weeks of HSD, MCD or 
NC treatment A) basic gating strategy: debris, doublet and dead cell exclusion. Gating on leukocytes by selecting 
all CD45+cells. B) representative dot blots of CD45+ cells showing CD11c signal (APC 1:400) plotted against MHC-
II signal (FITC 1:4000) to gate on cells with high expression of CD11c and MHC-II (green gate) C) representative 
contour blots of CD11chiMHC-IIhi cells showing CD11b signal (PE-Cy7 1:2000) plotted against forward scatter to 
gate on CD11b+ DCs (purple gate) D) bar-graphs show comparison of percentage ratio within CD45+ cells (left 
graph) and total cell amount per gram digested liver (right graph) of CD11chi MHC-IIhi CD11b+ DCs. nNC= 5/group, 
nHSD= 5/group, nMCD= 5/group.  
Data (A-D) for NC, HSD and MCD is representative of multiple independent experiments: repetitionsNC= 2 (n=3-
5/group), repetitionsHSD= 5 (n=4-5/group), repetitionsMCD= 3 (n=4-5/group). Data shown for MCD was created using 
digest protocol I. Bar-graphs depict mean + SEM. Significance is indicated through *p<0.05, ** p<0.005, 
***p<0.0001. Asterisks on top of the bar show statistical significance compared to the respective NC group of WT 





Figure 13 changes of CD11b+ DCs based on CD64+ expression in WT C57Bl/6 mice compared to batf3-KO mice 
after 5 weeks of HSD or NC feeding A) basic gating strategy: debris, doublet and dead cell exclusion. Gating on 
leukocytes by selecting all CD45+ cells. Selecting CD11chi MHC-IIhi cells, then CD11b+ cells. B) representative 
contour-blots of CD11chiMHC-IIhiCD11b+ cells showing CD64 signal (Brilliant Violet 421 1:200) plotted against 
CD11b signal (PE-Cy7 1:2000) to gate on CD64+ cells (red gate) or CD64- cells (green gate) C) bar-graphs show 
comparison of percentage ratio within CD45+ cells (upper graph) and total cell amount per gram digested liver (lower 
graph) of CD11chi MHC-IIhi CD11b+ CD64- DCs. nNC= 3/group, nHSD= 5/group D) bar-graphs show comparison of 
percentage ratio within CD45+ cells (upper graph) and total cell amount per gram digested liver (lower graph) of 
CD11chi MHC-IIhi CD11b+ CD64+ DCs. nNC= 3/group, nHSD= 5/group.  
Experiments were performed one time per group. Bar-graphs depict mean + SEM. Significance is indicated through 
*p<0.05, ** p<0.005, ***p<0.0001. Asterisks on top of the bar show statistical significance compared to the 
respective NC group of WT or batf3-KO, underlined asterisks show statistical significance of WT compared to batf3-
KO. 
 pDCs 
Changes of the pDC population as depicted in Figure 14 were analysed using the same 
gating strategy as described in chapter 3.3.3. Like in the WT experiments, significant changes 
of the pDC population can only be detected in the MCD treated batf3-KO animals (Figure 
14.D). Here the percentage ratio increases from 2.8% in the NC group to 5.3% in the MCD 
group and the total cell count from an average 9x103 cells/106 living cells to 35x103 cells/106 
living cells. Although there is a slight tendency towards higher values in HSD treated animals, 
changes in percentage ratio and total cell count are not significant (means HSD batf3-KO 3.7%, 




Between WT and batf3-KO animals the treatment groups show no significant 
difference, neither in percentage ratio nor in total cell count per 106 living cells. 
 
Figure 14 changes of pDCs in WT C57Bl/6 mice compared to batf3-KO mice after 5 weeks of HSD, MCD or NC 
feeding. A) basic gating strategy: debris, doublet and dead cell exclusion. Gating on leukocytes by selecting all 
CD45+cells. B) representative dot blots of CD45+ cells showing CD11c signal (APC 1:400) plotted against sideward 
scatter to gate on all CD11c+ cells (red gate) C) representative contour blots of CD11c+ cells showing CD11b signal 
(PE-Cy7 1:2000) plotted against PDCA-1 signal (PE 1:200) to gate on PDCA-1+ CD11b- cells (green gate) D) bar-
graphs show comparison of percentage ratio within CD45+ cells (left graph) and total cell amount per 106 living cells 
(right graph) of pDCs. nNC= 5/group, nHSD= 5/group, nMCD=5/group.  
Data (A-D) for HSD and MCD is representative of multiple independent experiments: repetitionsHSD = 4 (n=4-
5/group), repetitionsMCD = 3 (n=4-5/ group). NC experiments were performed one time. Data shown for MCD was 
created using digest protocol I. Bar-graphs depict mean + SEM. Significance is indicated through *p<0.05, ** 
p<0.005, ***p<0.0001. Asterisks on top of the bar show statistical significance compared to the respective NC group 
of WT or batf3-KO, underlined asterisks show statistical significance of WT compared to batf3-KO. 
Summary chapter 3.5.1: 
• The CD11b+ DCs population consists mostly of CD64- cDCs 2 and to a smaller 




• The lack of cDCs 1 results in a significant influx of CD11b+ DCs in HSD treated animals, 
which can mainly be accounted to an increase of CD64+ moDCs. 
• The lack of cDCs 1 causes a shift of proportions of CD11b+ DCs within CD45+ cells in 
the NC and MCD treatment group. 
• The lack of cDCs 1 does not affect the pDC population. 
3.5.2 Myeloid cell populations 
Figure 15 shows the flow-cytometric analysis of various myeloid cell subsets with a 
staining mix containing the surface markers CD45, F4-80 and Ly6C. After the basic gating 
strategy on CD45+ cells with debris, doublets and dead cell exclusion (Figure 15.A) the signals 
for F4-80 and Ly6C are plotted against each other. As Figure 15.B shows, it is possible to 
separate four major populations that differ in their expression of these two surface markers. 
The light blue gate contains a population that has a positive signal for Ly6C, but is negative for 
F4-80. This gate, which contains both cells with high and intermediate Ly6C expression, 
represents a mixture of myeloid cells such as neutrophils, eosinophils or myeloid derived 
suppressor cells. Cells within the red gate show both a positive signal for Ly6C as well as for 
F4-80, a marker combination which characterizes inflammatory monocytes. Events in the 
green gate exhibit a positive signal for F4-80, but do not express Ly6C. F4-80 is highly 
expressed in macrophages and thus identifies this population as KCs. Respective isotype 
controls are depicted in Figure 15.C.  
 Figure 15.D depicts changes of percentage ratio and total cell count per gram liver of 
the KC population in 5 weeks NC, HSD or MCD treated mice. In both WT and batf3-KO animals 
the mean percentage ratio is not significantly altered between the NC and HSD treated mice, 
but decreases significantly after MCD treatment (means WT: NC 18.2%, HSD 26.9%, MCD 
10.7%; means batf3-KO: NC 16.7%, HSD 19.5%, 10.5%). The total cell count equally shows 
no significant change between both WT and batf3-KO NC and HSD treated mice. Contrary to 
the percentage ratio however, in MCD treated animals KCs in fact increase significantly 
(means WT: NC 517x103 cells/g liver, HSD 408x103 cells/g liver, MCD 949x103 cells/g liver; 
means batf3-KO: NC 482x103 cells/g liver, HSD 466x103 cells/g liver, MCD 848x103 cells/g 
liver).  
 Figure 15.E depicts changes of percentage ratio and total cell count per gram liver of 
the Ly6Chi/intF4-80- gate in NC, HSD and MCD treated mice. In WT animals fed with HSD the 
percentage ratio increases slightly from 16.9% in NC to 19.2% in the HSD group, while the 
total cell count shows no significant difference between NC and HSD (means WT: NC 385x103 




doubles to an average of 32.5%, which is reflected in a significant increase to 2.6x106 cells/g 
liver in total cell count. Unlike the WT, HSD treatment in batf3-KO mice causes a clear increase 
of the percentage ratio of Ly6Chi/intF4-80- cells from an average 17.2% in NC to 26.5% in HSD, 
which is mirrored by the change of total cell count from a mean of 356x103 cells/g liver in NC 
to 674x103 cells/g liver in HSD. MCD treated animals do not differ significantly from the WT 
and show a similar increase of percentage ratio and cell count per gram liver (means batf3-
KO: MCD 33,4%, 2.6x106 cells/g liver). 
 Figure 15.F depicts changes of percentage ratio and total cell count per gram liver of 
cells in the Ly6Chi/intF4-80low gate in NC, HSD and MCD treated mice. In WT animals HSD 
feeding does not significantly alter the percentage ratio nor the absolute cell count per gram 
liver compared to the NC group (means WT: NC 0,8%, 27x103 cells/g liver, HSD 1,1%, 16x103 
cells/g liver). 5-week treatment with MCD significantly increases the percentage ratio to an 
average of 8.4%, which is also reflected in the massive increase of cell count to an average of 
898x103 cells/g liver. NC fed batf3-KO animals show no significant difference in percentage 
ratio or absolute cell count compared to the WT (mean batf3-KO: NC 0,8%, 33x103 cells/g 
liver). Meanwhile HSD treated batf3-KO mice show a significant increase in percentage and 
absolute cell count compared to the baseline NC treated batf3-KO animals as well as the HSD 
treated WT control (means batf-KO: HSD 5.0%, 130x103 cells/g liver). After MCD treatment 
percentage ratio and absolute cell count in batf3-KO mice increase significantly compared to 
the baseline batf3-KO control, but are not significantly altered compared to the MCD treated 
WT animals (means batf3-KO: MCD 9.7%, 930x103 cells/g liver).   
Figure 16 depicts the analysis of the neutrophil cell population in NC, HSD and MCD 
treated WT and batf3-KO mice using a staining mix containing CD45, Ly6C and Ly6G. Figure 
16.A show the basic gating strategy for leukocytes by gating on CD45+ cells after debris, 
doublet and dead cell exclusion. In Figure 16.B signals for Ly6C and Ly6G are plotted against 
each other and the upper right cell population distinctly separates from the remaining cells 
(black gate). Cells in this population express both Ly6C and Ly6G surface markers (compare 
isotype control in Figure 16.C) and are thus identified as neutrophils. Figure 16.D depicts 
changes in percentage ratio and absolute cell count of neutrophils in WT and batf3-KO mice 
during NC, HSD and MCD treatment. In WT animals, HSD treatment causes a significant 
increase of percentage ratio to 3.2% from an average of 1.8% in NC. The cell count per gram 
liver also is tendentially higher in HSD, although this remains insignificant (means WT: NC 
35x103 cells/g liver, HSD 40x103 cells/g liver). After MCD treatment percentage ratio and cell 
count increases significantly to an average of 9.5% and 781x103 cells/g liver. Batf3-KO mice 




the NC group compared to the WT control (means batf3-KO: NC 1.5%, 24x103 cells/g liver). 
Changes in the HSD or MCD group compared to the NC fed control group match those of the 
WT and there are no significant differences between batf3-KO and WT (means batf3-KO: HSD 
2.5%, 45x103 cells/g liver, MCD 7.1%, 456x103 cells/g liver).  
 
Figure 15 changes of monocyte and macrophage populations in WT C57Bl/6 mice compared to batf3-KO mice after 




leukocytes by selecting all CD45+cells. B) representative contour blots of CD45+ cells showing Ly6C signal (APC 
1:1000) plotted against F4-80 signal (A488 1:200) to gate on Ly6Chi/int F4-80- cells (light blue gate), Ly6Chi/int F4-
80low cells (red gate) and Ly6Clow/neg F4-80+ KCs (green gate) C) Isotype controls for Ly6C (APC 1:1000) and F4-
80 (A488 1:200) D) bar-graphs show comparison of percentage ratio within CD45+ cells (upper graph) and total cell 
amount per gram digested liver (lower graph) of Ly6Clow/neg F4-80+ KCs E) bar-graphs show comparison of 
percentage ratio within CD45+ cells (upper graph) and total cell amount per gram digested liver (lower graph) of 
Ly6Chi/int F4-80neg cells F) bar-graphs show comparison of percentage ratio within CD45+ cells (upper graph) and 
total cell amount per gram digested liver (lower graph) of Ly6Chi/int F4-80low cells (right graph). nNC= 5/group, nHSD= 
5/group, nMCD= 5/group.  
Data (A-F) for HSD and MCD is representative of multiple independent experiments: repetitionsHSD = 5 (n=4-
5/group), repetitionsMCD = 3 (n=4-5/group). NC experiment was performed one time. Significance is indicated 
through *p<0.05, ** p<0.005, ***p<0.0001. Asterisks on top of the bar show statistical significance compared to the 
respective NC group of WT or batf3-KO, underlined asterisks show statistical significance of WT compared to batf3-
KO. 
 
Figure 16 changes of neutrophils in WT C57Bl/6 mice compared to batf3-KO mice after 5 weeks of HSD, MCD or 
NC feeding A) basic gating strategy: debris, doublet and dead cell exclusion. Gating on leukocytes by selecting all 
CD45+cells. B) representative contour blots of CD45+ cells showing Ly6C signal (APC 1:1000) plotted against Ly6G 
signal (FITC 1:200) to gate on Ly6C+ Ly6G+ cells C) Isotype controls for Ly6C (APC 1:1000) and Ly6G (FITC 1:200) 
D) bar-graphs show comparison of percentage ratio within CD45+ cells (right graph) and total cell amount per gram 




Data (A-D) for HSD and MCD is representative of multiple independent experiments: repetitionsHSD = 4 (n=4-
5/group), repetitionsMCD = 4 (n=4-5/group). NC experiment was performed one time. Bar-graphs depict mean + 
SEM. Significance is indicated through *p<0.05, ** p<0.005, ***p<0.0001. Asterisks on top of the bar show statistical 
significance compared to the respective NC group of WT or batf3-KO, underlined asterisks show statistical 
significance of WT compared to batf3-KO 
Summary chapter 3.5.2: 
• HSD induced steatosis in WT animals does not affect KCs, inflammatory 
monocytes, neutrophils or Ly6Chi/intF4-80neg cells.  
• During MCD induced NASH it is possible to observe an influx of all these myeloid 
populations in the liver. 
• The lack of cDCs 1 results in an elevated abundance of inflammatory monocytes 
and Ly6Chi/intF4-80- cells, but does not affect neutrophils or KCs during HSD 
treatment. 
• The lack of cDCs 1 does not affect the myeloid cell populations of the liver during 
NC or MCD treatment. 
3.5.3 Lymphoid cell populations 
To determine whether cDCs 1 also have an impact on lymphoid cell infiltrate a FACS-
analysis was performed using a staining mix containing the lymphoid markers CD3ε, CD19, 
NK1.1 as well as CD45 and F4-80 for pre-gating. The basic gating strategy for the analysis of 
lymphoid cell population includes an additional gating step on F4-80 negative cells. This is 
performed to facilitate the distinction of different lymphoid cell populations by excluding 





Figure 17 discriminating lymphoid cell populations with and without pre-gating on F4-80- cells A) basic gating 
strategy: debris, doublet and dead cell exclusion. Gating on leukocytes by selecting all CD45+cells. B) pre-gating 
on F4-80- cells by plotting F4-80 signal of CD45+ cells against an empty channel to gate on negative cells. C) 
representative contour blots of all CD45+ cells showing CD19 signal (PE-Cy7 1:100) plotted against CD3ε (A488 
1:100) to distinguish lymphoid cell populations D) representative contour blots of F4-80- CD45+ cells showing CD19 
signal (PE-Cy7 1:100) plotted against CD3ε (A488 1:100) to distinguish lymphoid cell populations 
 B cells 
Figure 18 depicts the analysis of B cells in 5 weeks NC, HSD and MCD treated WT and 
batf3-KO animals. Figure 18.A shows the basic gating strategy with debris, doublet and dead 
cell exclusion and gating on CD45+ cells. The CD45+ F4-80- cells are then subsequently plotted 
accordingly to their expression of CD3ε and CD19. This separates the cells into three 
populations: CD19+CD3ε-, CD19-CD3ε+ and CD19-CD3ε- (Figure 18.C). CD19 is a marker for 
B cells, therefore CD19+CD3ε- cells (yellow gate) are identified as such. Figure 18.B shows the 
respective isotype control. 
Figure 18.D depicts changes of percentage ratio and total cell count per gram liver in 
the B cell population of NC, HSD and MCD treated animals. HSD causes a slight, significant 
decrease of percentage ratio in WT animals (means WT: NC 33%, HSD 26%), which can also 
be observed in absolute cell count (means WT: NC 670x103 cells/g liver, HSD 318x103 cells/g 
liver). In MCD treated animals the decrease of B cells to an average 11% seems to be a shift 
in percentage ratio due to influx of other cell populations as the count per gram liver slightly, 
but not significantly increases to 791x103 cells/g liver. Batf3-KO animals show similar 
tendencies in their numbers with no significant difference to the WT control: HSD feeding 
causes a slight, albeit not significant decrease of percentage ratio (means batf3-KO: NC 32%, 
HSD 24%) as well as total cell count (means batf3-KO: NC 651x103 cells/g liver, HSD 439x103 




the total cell count contrarily shows a slight, but insignificant increase (means batf3-KO: MCD 
12%, 820x103 cells/g liver). Concluding B cells represent a large population within immune 
cells of the liver, but are not recruited during NASH or steatosis, which leads to a relative 
decrease of the population within CD45+ cells. cDCs1 do not influence the B cell population 
during steady state or NASH. 
 
Figure 18 changes of B cells in WT C57Bl/6 mice compared to batf3-KO mice after 5 weeks of HSD, MCD or NC 
feeding A) basic gating strategy: debris, doublet and dead cell exclusion. Gating on leukocytes by selecting all 
CD45+cells. Plotting F4-80 signal of CD45+ cells against an empty channel and gating on all F4-80- cells. B) Isotype 
control for CD19 (PE Cy-7 1:100) and CD3ε (A488 1:100) C) representative contour blots of F4-80- cells showing 
CD19 signal (PE-Cy7 1:100) plotted against CD3ε (A488 1:100) to gate on CD19+ CD3ε- cells (yellow gate) D) bar-
graphs show comparison of percentage ratio within CD45+ cells (upper graph) and total cell amount per gram 
digested liver (lower graph) of CD19+ CD3ε- cells. nNC= 5/group, nHSD= 5/group, nMCD= 5/group.  
Data (A-D) for HSD and MCD is representative of multiple independent experiments: repetitionsHSD = 5 (n=4-
5/group), repetition MCD = 3 (n=4-5/group). NC experiment was performed one time. Bar-graphs depict mean + SEM. 
Significance is indicated through *p<0.05, ** p<0.005, ***p<0.0001. Asterisks on top of the bar show statistical 
significance compared to the respective NC group of WT or batf3-KO, underlined asterisks show statistical 
significance of WT compared to batf3-KO. 
 T cells 
Figure 19 depicts the analysis of T cells in WT and batf3-KO mice after 5 weeks feeding 
of NC, HSD or MCD. Figure 19.A shows the basic gating strategy as described in chapter 
3.5.3.1 with gating on living, single CD45+F4-80- cells and the subsequent plotting of CD3ε 
signal against CD19. To investigate T cells the CD19-CD3ε+ population (magenta gate, isotype 
control is depicted in Figure 18.C) is selected, as CD3ε is a universal T cell marker. In a 
following step, these cells are divided based on their expression of NK1.1. to exclude the 
NK1.1. positive T cells, which are analyzed separately (compare chapter 3.5.3.3). As Figure 




two major T cell subtypes CD4+ T-cells and CD8+ T-cells. The FMO-staining control for NK1.1 
is shown in Figure 19.B.   
Changes of percentage ratio and total cell count per gram liver is depicted in Figure 
19.D: Interestingly a significant baseline difference in percentage ratio of T cells can be 
observed in batf3-KO animals compared to the WT (means NC: WT 12.6%, batf3-KO 10.5%). 
This discrepancy is even larger in HSD treated animals with 12.2% in the WT and 8.2% in 
batf3-KO. In batf3-KO animals the percentage ratio of T cells decreases significantly compared 
to the respective NC control whereas percentage ratio in WT animals remains unchanged. A 
slight gap in percentage ratio can still be observed in the MCD treated animals however this is 
not significant (means MCD: WT 10.6%, batf3-KO 8.0%). This can be explained by the fact, 
that the percentage ratio in WT animals slightly, but not significantly, decreases compared to 
the NC and HSD group. In MCD treated batf3-KO animals the percentage ratio does not further 
decrease compared to the HSD group, but is significantly lower compared to the NC group.  
Subsequently absolute cell count per gram liver is determined to see whether these 
differences are real or merely due to shifts in percentage ratio as result of cell infiltrate or lack 
of the cDC 1 population. Interestingly the significant changes between NC and HSD treated 
WT and batf3-KO animals seem to be percentage shifts, as in absolute numbers there are no 
significant difference between the two groups (means NC: WT 212x103 cells/g liver, batf3-KO 
149x103 cells/g liver; means HSD: WT 151x103 cells/g liver, batf3-KO 173x103 cells/g liver). 
Meanwhile in MCD treated animals both WT and batf3-KO show a significant influx of T cells, 
which interestingly is significantly higher in the WT than in the batf3-KO (means MCD: WT 
759x103 cells/g liver, batf3-KO 517x103 cells/g liver).  In conclusion, the lack of batf3-
dependent cDCs 1 does not affect the absolute count of T cells in NC or HSD, but reduces the 
amount of T cell infiltrate in MCD treatment. Nevertheless, it does cause a significant change 
in percentage ratio on a baseline level as well as in HSD treated animals, which might result 
in a relative mismatch of T cells towards other immune cells. 
Since the investigated population includes both the CD8+ and the CD4+ subtype a pilot 
experiment was conducted to see whether the lack of cDCs 1 affects CD4+ T cells in particular. 
Figure 20.A shows the basic gating strategy to gate on CD3ε+CD19-NK1.1- T cells by gating 
on single, living CD45+ cells. Since CD4 was added to the staining mix, F4-80 could not be 
used in these experiments, as the number of antibodies per staining mix is restricted. Therefore 
CD45+ cells are directly separated based on the CD3ε and CD19 expression and T cells are 
further gated on as described above. Figure 20.C shows the CD4 signal of T cells, where CD4+ 
cells separate nicely from the remaining events (forest green gate). The corresponding isotype 




between WT and batf3-KO mice, neither in the HSD, nor the MCD group. However, in HSD 
treated animals a tendency towards lower numbers in batf3-KO animals can be observed 
(means HSD: WT 6.4%, batf3-KO 3.9%). Interestingly the percentage ratio of CD4+ T cells 
decreases in MCD treated animals and the in the HSD group observed gap between WT and 
batf3-KO also diminishes after MCD feeding (means MCD: WT 2.8%, batf3-KO 2.1%). 
Absolute numbers were only calculated for the HSD group. Here the total cell count per gram 
liver is significantly lower in batf3-KO animals (means HSD: WT 128x103 cells/g liver, batf3-
KO 62x103 cell/g liver), a phenomenon which cannot be observed when looking at the 
complete T cell population (compare Figure 19.D).  
 
Figure 19 changes of all T cells in WT C57Bl/6 mice compared to batf3-KO mice after 5 weeks of HSD, MCD or NC 
feeding A) basic gating strategy: debris, doublet and dead cell exclusion. Gating on leukocytes by selecting all 
CD45+cells. Plotting F4-80 signal of CD45+ cells against an empty channel and gating on all F4-80- cells. Then 
plotting CD19 against CD3ε and gating on CD19- CD3ε+ cells (magenta gate) B) representative contour blots of 
CD19- CD3ε+ cells showing NK1.1 signal (primary AB: biotin 1:100, secondary AB: A405 1:400) plotted against 
forwards scatter to gate on NK1.1- cells (orange gate) C) FMO control for NK1.1 (secondary AB: A405 1:400) D) 
bar-graphs show comparison of percentage ratio within CD45+ cells (left graph) and total cell amount per gram 
digested liver (right graph) of CD19- CD3ε+ NK1.1- cells. nNC= 5/group, nHSD= 5/group, nMCD= 5/group.  
Data (A-D) for HSD and MCD is representative of multiple independent experiments: repetitionsHSD = 5 (n=4-
5/group), repetitionsMCD = 3 (n=4-5/group). NC experiment was performed one time. Bar-graphs depict mean + 
SEM. Significance is indicated through *p<0.05, ** p<0.005, ***p<0.0001. Asterisks on top of the bar show statistical 
significance compared to the respective NC group of WT or batf3-KO, underlined asterisks show statistical 





Figure 20 changes of CD4+ T cells in WT C57Bl/6 mice compared to batf3-KO mice after 5 weeks of HSD, MCD or 
NC feeding A) basic gating strategy: debris, doublet and dead cell exclusion. Gating on leukocytes by selecting all 
CD45+cells. Plotting CD19 against CD3ε and gating on CD19- CD3ε+ cells (magenta gate). Then plotting NK1.1 
signal against forwards scatter to gate on NK1.1- cells (orange gate) B) isotype control for CD4 (APC 1:100) C) 
representative contour blots showing CD4 signal (APC 1:100) plotted against forwards scatter of CD19-
CD3ε+NK1.1- cells to gate on CD4+ cells (forest green gate) D) bar-graphs show comparison of percentage ratio 
within CD45+ cells (left graph) and total cell amount per gram digested liver (right graph) of CD19- CD3ε+ NK1.1- 
CD4+ cells. nHSD WT=4, nHSD KO=3, nMCD WT=5, nMCD KO=4.  
Data (A-D) for MCD is representative of two independent experiments (n=4-5/group). HSD experiment was 
performed one time. Bar-graphs depict mean + SEM. Significance is indicated through *p<0.05, ** p<0.005, 
***p<0.0001. Asterisks on top of the bar show statistical significance compared to the respective NC group of WT 
or batf3-KO, underlined asterisks show statistical significance of WT compared to batf3-KO 
 NKT cells 
A further lymphoid population investigated are NKT cells, as depicted in Figure 21. 
Basic gating strategy on T cells is performed as described in chapter 3.5.3.2. Subsequently 
the events are plotted accordingly to their NK1.1 expression and the NK1.1+ cells are selected 
accordingly to the isotype control (Figure 21.B and C). Figure 21.D depicts changes of the 
percentage ratio as well as the absolute cell count per gram liver. The NKT cell population 
represents a quite small fraction of liver immune cells with less than one percent during steady 
state (means NC: WT 0.84%, batf3-KO 0.64%). Neither HSD nor MCD treatment significantly 
changes the percentage ratio, although there is a slight tendency towards higher numbers after 
MCD treatment (means WT: HSD 0.58%, MCD 1.15%; means batf3-KO: HSD 0.69%, MCD 
1.42%). Importantly there is no difference between WT and batf3-KO. Baseline absolute 
numbers in NC treated animals are an average 18x103 cell/g liver in WTs and 13x103 cells/g 
liver in batf3-KOs. HSD treatment does not change the cell count significantly compared to the 
NC control (means HSD: WT 10x103 cells/g liver, batf3-KO 19x103 cells/g liver). Interestingly 




liver and in batf3-KO to 93x103 cells/g liver. Concluding NKT cells are a quite small population 
within the immune cells of the liver, but increase in numbers during NASH. cDCs1 do not 
influence the NKT cell population during steady state, bland steatosis or NASH. 
 
Figure 21 changes of NKT cells in WT C57Bl/6 mice compared to batf3-KO mice after 5 weeks of HSD, MCD or 
NC feeding A) basic gating strategy: debris, doublet and dead cell exclusion. Gating on leukocytes by selecting all 
CD45+cells. Plotting F4-80 signal of CD45+ cells against an empty channel and gating on all F4-80- cells. Then 
plotting CD19 against CD3ε and gating on CD19- CD3ε+ cells (magenta gate) B) representative contour blots of 
CD19- CD3ε+ cells showing NK1.1 signal (primary AB: biotin 1:100, secondary AB: A405 1:400) plotted against 
forwards scatter to gate on NK1.1+ cells (rosé gate) C) FMO control for NK1.1 (secondary AB: A405 1:400) D) bar-
graphs show comparison of percentage ratio within CD45+ cells (right graph) and total cell amount per gram 
digested liver (left graph) of CD19- CD3ε+ NK1.1+ cells. nNC= 5/group, nHSD= 5/group, nMCD= 5/group.  
Data (A-D) for HSD and MCD is representative of multiple independent experiments: repetitionsHSD = 5 (n=4-
5/group), repetitionsMCD = 3 (n=4-5/ group). NC experiment was performed one time. Bar-graphs depict mean + 
SEM. Significance is indicated through *p<0.05, ** p<0.005, ***p<0.0001. Asterisks on top of the bar show statistical 
significance compared to the respective NC group of WT or batf3-KO, underlined asterisks show statistical 
significance of WT compared to batf3-KO 
 NK cells 
Figure 22 depicts dynamics of the NK cells in WT and batf3-KO mice after 5 weeks NC, 
HSD or MCD treatment. As described in chapter 3.5.3.1 living, single CD45+F4-80- cells are 
plotted according to their CD19 and CD3ε expression. As NK-cells express neither of the latter 
surface markers the double negative population (dark blue gate) is selected (Figure 22.A). 
Subsequently the NK1.1 signal is plotted against forward scatter and the positive NK cells (light 
blue gate) separate nicely from the remaining NK1.1- events (Figure 22.C , FMO control in 
Figure 22.B). Changes in percentage ratio as well as absolute cell count per gram liver are 
depicted in Figure 22.D: HSD treated animals show no significant difference in percentage 
ratio, neither compared to the respective healthy control nor between WT and batf3-KO within 




batf3-KO 5.3%). Parallel to this, no significant changes or tendencies in absolute cell count per 
gram liver can be observed in these groups (means NC: WT 93x103 cells/g liver, batf3-KO 
94x103 cells/g liver; means HSD: WT 55x103 cells/g liver, batf3-KO 136x103 cells/g liver). In 
MCD treated animals, percentage ratio of NK cells does not increase significantly in the WT 
whereas the percental mean in batf3-KO animals shows a significant increase (means MCD: 
WT 5.5%, batf3-KO 7.1%). When looking at the absolute cell count, however, this difference 
is relativized as the mean cell count is not significantly increased in the batf3-KO compared to 
the WT. Importantly both animal groups show a significant increase in cell count compared to 
the respective NC control group (means MCD: WT 411x103 cells/g liver, batf3-KO 465x103 
cells/g liver). In conclusion steatosis does not cause an influx of NK cells in the liver, whereas 
established NASH is accompanied by increased abundance of these cells. Further a lack of 
cDCs 1 does not significantly alter the presence of NK cells in the liver or influence their 
recruitment. 
 
Figure 22 changes of NK cells in WT C57Bl/6 mice compared to batf3-KO mice after 5 weeks of HSD, MCD or NC 
feeding A) basic gating strategy: debris, doublet and dead cell exclusion. Gating on leukocytes by selecting all 
CD45+cells. Plotting F4-80 signal of CD45+ cells against an empty channel and gating on all F4-80- cells. Then 
plotting CD19 against CD3ε and gating on CD19- CD3ε- double negative cells (dark blue gate) B) representative 
contour blots of CD19- CD3ε- cells showing NK1.1 signal (primary AB: biotin 1:100, secondary AB: A405 1:400) 
plotted against forwards scatter to gate on NK1.1+ cells (light blue gate) C) FMO control for NK1.1 (secondary AB: 
A405 1:400) D) bar-graphs show comparison of percentage ratio within CD45+ cells (left graph) and total cell amount 
per gram digested liver (right graph) of CD19- CD3ε- NK1.1+ cells. nNC= 5/group, nHSD= 4/group, nMCD= 5/group.  
Data (A-D) for HSD and MCD is representative of multiple independent experiments: repetitionsHSD = 5 (n=4-
5/group), repetitionsMCD = 3 (n=4-5/group). NC experiment was performed one time. Bar-graphs depict mean + 
SEM. Significance is indicated through *p<0.05, ** p<0.005, ***p<0.0001. Asterisks on top of the bar show statistical 
significance compared to the respective NC group of WT or batf3-KO, underlined asterisks show statistical 





Summary chapter 3.5.3: 
• B cells do not increase in numbers during NASH, which leads to a relative diminution 
of the population within liver immune cells due to an influx of other CD45+ cells. The 
lack of cDCs 1 does not affect the B cell population. 
• The number of T cells is increased during MCD induced NASH, but not in bland 
steatosis. The lack of cDCs 1 does not affect absolute numbers in the healthy control 
or steatosis model, but causes a relative diminution of the T cell population within all 
CD45+ cells and absolute reduction of T cells during MCD induced NASH. 
• The relative amount of CD4+ T cells is decreased after MCD treatment compared to 
the HSD group in WT animals. The lack of cDCs 1 does not affect the relative amount 
of CD4+ cells in MCD, but causes a decrease of CD4+ T cells during HSD. 
• NKT cells increase in number during NASH but not during bland steatosis. No relevant 
differences can be observed in the batf3-KO compared to the WT. 
• NK cells increase in number during NASH, but not during bland steatosis. No relevant 
differences can be observed in the batf3-KO compared to the WT. 
3.5.4 Cytokine production of liver NPC 
Compared to the WT control batf3-KO mice show a progression of steatosis towards 
steatohepatitis and exhibit alterations in the cellular infiltrate of the liver. Additional experiments 
were performed to investigate whether the lack of cDCs 1 also influences the hepatic cell 
infiltrate on a functional level, in particular concerning cytokine production of liver 
nonparenchymal cells. The analysis was performed using a cytokine array to have a general 
overview of cytokine production within the liver single cell suspension. Further individual 
cytokines were selected for intracellular staining to gather information on a cellular level.  
 Cytokine array 
To get a broad overview of cytokines produced within the liver of HSD and MCD treated 
animals, a cytokine array was performed using cell culture supernatant of LPS stimulated liver 
homogenate. Figure 23.A depicts the assay membranes of the HSD groups together with the 
mean grey values of cytokines, that differ between batf3-KO and WT. The major differences 
can be found in Serpin E1, IL-1ra, CCL22, CCL2, CXCL1 and CCL5, which show higher signals 
in batf3-KO mice. Interestingly the production of resistin is higher in WT animals. In MCD 




CXCL1 and CCL5 as depicted in Figure 23.B. Further they also show higher values of CXCL5, 
Osteopontin, CXCL1 and CXCL2. 
 
Figure 23 cytokine production of liver cell suspension after 18 hours of stimulation with 250 ng/ml LPS A) cytokine 
array of cell culture supernatant from liver single cells of 5 weeks HSD treated animals. Bar-graph shows mean 
grey values of the signals of boxed signals. B) cytokine array of cell culture supernatant from liver single cells of 5 
weeks MCD treated animals. Bar-graph shows mean grey values of boxed signals. 
 TNFα production 
Chapter 3.3.4 characterizes TNFα-production of DC subtypes and ultimately shows that 
CD11c+ and F4-80+ cells are the major populations that increase TNFα-production in the 




TNFα-production of these cells an intracellular staining was performed. Figure 24.A shows the 
gating strategy to select CD11c+ and F4-80+ cells as described in chapter 3.3.4. Cells are then 
plotted accordingly to their TNFα-signal and the positive events are selected (Figure 24.B and 
D). As depicted in Figure 24.C, TNFα-production in CD11c+ cells does not show a significant 
difference one a baseline level (means NC: WT 5.0%, batff3-KO 6.7%). Equally to WT animals, 
in batf3-KO animals TNFα-production increases significantly after MCD diet (means MCD: WT 
12.6%, batf3-KO 15.1%). Interestingly HSD treated batf3-KO animals show a significant 
increase in TNFα-production compared to the NC control, contrary to the WT animals which 
have values similar to their respective control NC group (means HSD: WT 5.6%, batf3-KO 
10.5%). This effect can also be observed in the F4-80+ cell population. On baseline WT and 
batf3-KO animals do not differ significantly in their TNFα production and it increases in equal 
proportions after MCD treatment (means NC: WT 4.3%, batf3-KO 6.0%; means MCD: WT 
21.5%, batf3-KO 23.0%). In the HSD group, however, TNFα production increases significantly 
batf3-KO animals, while WTs show no significant change compared to the respective NC 
control (means HSD: WT 3.6%, KO 11.5%). In conclusion, the lack of cDCs 1 does not 
influence TNFα-production of CD11c+ and F4-80+ cells during steady state or MCD treatment, 





Figure 24 TNFα production of different cell populations stimulated with 250ng/ml LPS for 5 hours in WT C57Bl/6 
mice compared to batf3-KO mice after 5 weeks of HSD, MCD or NC feeding A) basic gating strategy with debris 
and doublet cell exclusion. Gating on leukocytes by selecting all CD45+cells, then gating on either CD11c+ cells 
(red gate) or F4-80+ cells (orange gate) B) representative contour-blots of the TNFα signal (APC 1:200) plotted 
against forwards scatter within CD11c+ cells. Gated on TNFα+ cells C) bar-graph shows comparison of percentage 
ratio of TNFα+ cells within CD11c+ cells. nNC=4/group, nHSD=4/group, nMCD=4/group D) representative contour-blots 
of the TNFα signal (APC 1:200) plotted against forwards scatter within F4-80+ cells. Gated on TNFα+ cells C) bar-
graph shows comparison of percentage ratio of TNFα+ cells within F4-80+ cells. nNC=4/group, nHSD=4/group, nMCD 
=4/group 
Data (A-E) shown for CD11c+ cells is representative of multiple independent experiments for HSD and MCD: 
repetitionsHSD= 4 (n=4/group), repetitionsMCD = 3 (n=4/group). Experiment for NC was performed one time. Data (A-
E) shown for F4-80+ cells is representative multiple independent experiments of HSD: repetitionsHSD = 3 
(n=4/group). Experiments for MCD and NC were performed one time. Bar-graphs depict mean + SEM. Significance 
is indicated through *p<0.05, ** p<0.005, ***p<0.0001. Asterisks on top of the bar show statistical significance 
compared to the respective NC group of WT or batf3-KO, underlined asterisks show statistical significance of WT 
compared to batf3-KO 
 Production of chemokines 
As the cytokine arrays of both HSD and MCD treated animals show differences in 
cytokine production an intracellular staining was performed to investigate the production on a 
cellular level. Three cytokines were selected, namely CXCL-1, CXCL-2 and CCL-5, and the 




described in chapter 3.3.4. Cells are then plotted accordingly to their APC signal (FMO control 
is depicted in Figure 25.B) and the positive signals are selected.  
The production of CXCL-1, as depicted in Figure 25.D, shows a baseline difference in 
the healthy control, where the percentage of CXCL-1 producing CD11c+ cells is significantly 
higher in batf3-KO animals than in the WT (means NC: WT 1.3%, batf3-KO 3.1%). The 
production then increases significantly in HSD treated batf3-KO animals, whereas HSD treated 
WT animals show no significant difference with respects to the healthy control (means HSD: 
WT 2.2%, batf3-KO 5.2%). Only after MCD treatment do also WT animals show an increase 
in CXCL-1 production of CD11c+ cells and batf3-KO animals shows an even further increase 
to an average (means MCD: WT 5.4%, batf3-KO 8.1%).  
 Figure 25.F shows the percentage ratio of CCL-5 producing cells within the CD11c+ 
population. The baseline production of CCL-5 in CD11c+ cells shows no significant difference 
between WT and batf3-KO (means NC: WT 2.5, batf3-KO 2.5%). Parallel to observations made 
for TNFα and CXCL-1, the production of CCL-5 increases significantly in HSD treated batf3-
KO mice, while the values of WT animals remain similar as the baseline level (means HSD: 
WT 1.5%, batf3-KO 12.2%). MCD treatment causes an increase in cytokine production in WT 





Figure 25 Cytokine production of different cell populations stimulated with 250ng/ml LPS for 5 hours in WT C57Bl/6 
mice compared to batf3-KO mice after 5 weeks of HSD, MCD or NC feeding. A) basic gating strategy with debris 
and doublet cell exclusion. Gating on leukocytes by selecting all CD45+cells, then gating on CD11c+ cells (red gate) 
B) FMO control of an intracellular staining without the primary antibody (SA A647 1:800) C) representative contour-
blots of the CXCL-1 signal (primary AB unlabeled goat 1:500, secondary AB A647 1:800) plotted against forward 
scatter within CD11c+ cells. Gated on CXCL-1+ cells D) bar-graph shows comparison of percentage ratio of CXCL-
1+ cells within CD11c+ cells. nNC=4/group, nHSD=4/group, nMCD=4/group. Data (C, B) is representative of two 
independent experiments for HSD and MCD (n=4/group). NC experiment was performed one time. E) 
representative contour-blots of CCL-5 signal (primary AB unlabeled goat 1:500, secondary AB A647 1:800) plotted 
against forward scatter within CD11c+ cells. Gated on CCL-5+ cells F) bar-graph shows comparison of percentage 
ratio of CCL-5+ cells within CD11c+ cells. nNC=4/group, nHSD=3/group, nMCD=3/group. Experiment for data (E, F) 
was performed one time per group. Data was created using the digest protocol I.  
Significance is indicated through *p<0.05, ** p<0.005, ***p<0.0001. Asterisks on top of the bar show statistical 
significance compared to the respective NC group of WT or batf3-KO, underlined asterisks show statistical 
significance of WT compared to batf3-KO 
Summary chapter 3.5.4: 
• The lack of cDCs 1 increases the pro-inflammatory cytokine production within a liver 
homogenate cell culture in both during HSD and MCD treatment 
• The lack of cDCs 1 increases TNFα production by CD11c+ and F4-80+ cells during HSD 
• The lack of cDCs 1 increases CXCL-1 production by CD11c+ cells on a baseline level 
as well as during HSD and MCD treatment 
• The lack of cDCs 1 increases CCL-5 production by CD11c+ cells during HSD and MCD, 




3.6 The influence of batf3-dependent cDCs 1 on incipient NASH 
The most striking effects of batf3-dependent cDCs 1 can be observed in the HSD 
steatosis model: after 5 weeks of HSD batf3-KO mice experience worse liver damage and 
exhibit clear tendencies towards a higher inflammatory milieu than the WT control. In the 5 
weeks MCD induced NASH model the lack of cDCs 1 has a lower impact and shows only little 
differences between WT and batf3-KO animals. To see whether cDCs 1 influence incipient 
NASH, a pilot experiment was conducted in which animals were treated with MCD for two 
weeks instead of five. The hematopoietic infiltrate during the onset of steatohepatitis was then 
investigated using the same multicolored flow cytometric analysis as in previous experiments.  
3.6.1 Dendritic cell subtypes 
To investigate changes of individual DC subpopulations the cells were gated as 
described in chapter 3.3. Figure 26.A and B depicts changes in the cDC 1 population after 2 
weeks of MCD diet: in WT animals this treatment causes an increase in percentage ratio of 
1.7-fold to an average 3.8% within all CD45+ cells and a 3.0-fold increase in total cell count to 
an average 110x103 cells/g liver. In comparison after 5 weeks of diet they increase an average 
2.4-fold and 8.2-fold respectively. 
The CD11b+ DC population of WT animals, as depicted in Figure 26. C and D, also 
increases significantly in the 2 weeks MCD group compared to respective control animals. 
Percental ratio increases an average 3.5-fold to 7.7% and total cell count an average 5.1-fold 
to 227x103 cells/g liver. Here the 5 weeks MCD diet leads to an increase of 3.6-fold in 
percentage ratio and 13-fold in total cell count. When separating the CD11b+ DCs accordingly 
to their origin both the cDCs 2 and moDC subtype increase after 2 weeks of MCD feeding 
(Figure 26.E, F, G). CD64- cDCs 2 show an average 4.6-fold increase in percentage ratio 
(means WT: NC 1.4%, 2 wks MCD 6.0%) and 6.2-fold increase in total cell count (means WT: 
NC 28x103 cells/g liver, 2 wks MCD 178x103 cells/g liver). moDCs on the other hand show an 
average 6.4-fold increase in percentage ratio (means WT: NC 0.3%, 2 wks MCD 1.68%) and 
8.9-fold increase in total cell count (means WT: NC 5x103 cells/ g liver, 2 wks MCD 49x103 
cells/g liver). In batf3-KO animals CD11b+ DCs increase significantly in percentage ratio 
(means batf3-KO: NC 3.9%, 2 wks MCD 11.5%) as well as in total cell count (means batf3-
KO: NC 59x103 cells/g liver, 2 wks MCD 354x103 cells/g liver). The significantly higher 
percentage ratio compared to the WT, which would suggest a higher increase of CD11b+ in 
the batf3-KO, turns out to be not significant in absolute numbers, although a tendency towards 




significantly in percentage ratio (means batf3-KO cDCs 2: NC 3.0%, 2wks MCD 7.4%; means 
batf3-KO moDCs: NC 0.3%, 2 wks MCD 3.9%) as well as total cell count (means batf3-KO 
cDCs 2: NC 46x103 cells/g liver, 2 wks MCD 225x103 cells/g liver; means batf3-KO moDCs: 
NC 5x103 cells/g liver, 2 wks MCD 123x103 cells/g liver). Importantly in moDCs a significant 
difference in percentage ratio towards the WT can be observed in batf3-KO animals and 
although this is not significant in numbers a clear tendency towards higher values in the batf3-
KO is detectable.  
The pDC population of WT animals shows no significant change in percentage ratio 
(means WT: NC 3.0%, 2 weeks MCD 3.0%), but a slight increase in total cell count (means 
WT: NC 9x103 cells/106 living cells, 2 wks MCD 16x103 cells/106 living cells). Showing no 
significant difference towards the WT, pDCs in batf3-KO animals equally are not changed in 
percentage ratio (means batf3-KO: NC 3.0%, 2 wks MCD 2.7%), but are slightly increased in 
total cell count (means batf3-KO: NC 9x103 cells/106 living cells, 2 wks MCD 15x103 cells/106 
living cells).  
Concluding individual DC subpopulations of WT animals show similar tendencies to 
increase after 2 weeks of MCD diet as they do after 5 weeks, however in a lower augmentation. 
Importantly pDC changes can only be detected in total cell count, but not in percentage ratio. 
The recruitment of CD11b+ DCs includes both cDCs 2 and moDCs, with cDCs 2 forming the 
larger fraction of cells, but moDCs showing an overall higher increase. In batf3-KO animals 
DC subtypes change similarly as they do in the WT, although a significant difference can be 
detected in percentage ratio of CD11b+ DCs, in particular CD64+ moDCs. Importantly, unlike 
in the HSD treated animals, this difference, although slightly reflected through a tendency 





Figure 26 changes of DC subtypes in WT C57Bl/6 mice compared to batf3-KO mice after 2 weeks of MCD and NC 
feeding A) representative contour blots of CD11chi cells showing CD11b signal (PE-Cy7 1:2000) plotted against 
CD103 signal (PE 1:200) to gate on CD103+ cells (black gate) B) bar-graphs show comparison of percentage ratio 
within CD45+ cells (left graph) and total cell amount per gram digested liver (right graph) of CD11chiCD11b-CD103+ 
cells (violet gate) C) representative contour blots of CD11chiMHC-IIhi cells showing CD11b signal (PE-Cy7 1:2000) 
plotted against forward scatter to gate on CD11b+ cells. D) bar-graphs show comparison of percentage ratio within 
CD45+ cells (left graph) and total cell amount per gram digested liver (right graph) of CD11chiMHCIIhiCD11b+ cells 




plotted against CD11b (PE-Cy7 1:2000) to gate on CD64+ cells (dark red gate) and CD64- cells (dark green gate). 
F) bar-graphs show comparison of percentage ratio within CD45+ cells (upper graph) and total cell amount per gram 
digested liver (lower graph) of CD11chiMHCIIhiCD11b+CD64- cells G) bar-graphs show comparison of percentage 
ratio within CD45+ cells (upper graph) and total cell amount per gram digested liver (lower graph) of 
CD11chiMHCIIhiCD11b+CD64+ cells H) representative contour blots of CD11c+ cells showing CD11b signal (PE-
Cy7 1:2000) plotted against PDCA-1 signal (PE 1:200) to gate on CD11b-PDCA-1+ cells (light green gate) I) bar-
graphs show comparison of percentage ratio within CD45+ cells (left graph) and total cell amount per 106 living cells 
(right graph) of CD11c+CD11b-PDCA-1+ cells. nNC= 5/group, n2wks MCD= 3/group  
Data (A-I) for NC is representative of multiple independent experiments: repetitionsNC= 2 (n=3-5/group). 2wks MCD 
experiment was performed one time. Bar-graphs depict mean + SEM. Significance is indicated through *p<0.05, ** 
p<0.005, ***p<0.0001. Asterisks on top of the bar show statistical significance compared to the respective NC group 
of WT or batf3-KO, underlined asterisks show statistical significance of WT compared to batf3-KO 
Summary chapter 3.6.1: 
• Similar as after 5 weeks, 2 weeks feeding of MCD causes an influx of all DC subtypes 
into the liver, however with lower fold changes than observed in the 5 weeks treatment. 
• The influx of CD11b+ DCs consists of both cDCs 2 as well as moDCs with cDCs 2 
making up the majority of cells, but moDCs showing an overall higher increase 
• The lack of cDCs 1 results in a significant increase in percentage ratio of CD11b+ DCs, 
particularly moDCs 
3.6.2 Myeloid cells 
Figure 27 depicts changes within the myeloid cell populations after 2 weeks of MCD 
treatment in WT and batf3-KO animals compared to the NC control. Surface staining and cell 
gating was performed as described in chapter 3.5.2.  
Figure 27.B shows that the percentage ratio of KCs in both WT and batf3-KO animals 
decreases similarly as after 5 weeks of MCD diet (means NC: WT 18,2%, batf3-KO 16.7%; 
means 2 wks MCD: WT 11,3%, batf3-KO 13,1%). Contrary to 5 weeks treated animals, 
however, total cell count does not change significantly compared to the NC control (means 
NC: WT 517x103 cells/g liver, batf3-KO 482x103 cells/g liver. Means 2 wks MCD: WT 436x103 
cells/g liver, batf3-KO 509x103 cells/g liver). This indicates that the decrease in percentage 
ratio is due to an increase of other CD45+ cells rather than an actual decrease of KCs. 
Considering the increased cell count after 5 weeks of MCD treatment, it also suggests that the 
observed increase of KCs in steatohepatitis happens during later stages of disease 
development.  
Looking at Ly6Chi/intF4-80- cells in Figure 27.C they show an increase of percentage 
ratio both in WT and batf3-KO after 2 weeks of MCD diet, with batf3-KO showing significantly 
higher values (means NC: WT 16,9%, batf3-KO 17,2%. Means 2 wks MCD: WT 24,7%, batf3-
KO 32,6%). Total cell counts also show an increase in Ly6Chi/intF4-80- cells in 2 weeks MCD 




wks MCD: WT 953x103 cells/g liver, batf3-KO 129x104 cells/g liver). Importantly the total cell 
count after 2 weeks of MCD treatment ends up being lower than after 5 weeks MCD diet, but 
higher than after the HSD treatment. Similar as in HSD treated animals the absolute cell count 
is higher in batf3-KO than in WT animals, albeit this remains not significant. 
Lastly Figure 27.D shows changes of the Ly6Chi/intF4-80low population. These cells also 
show an increase of percentage ratio after 2 weeks of MCD diet in both groups, but with 
significantly higher values in batf3-KO animals compared to the WT (means NC: WT 0.8%, 
batf3-KO 0.8%. means 2 wks MCD: WT 4.9%, batf3-KO 11.8%). Such tendency towards 
higher values in batf3-KO animals can also be observed in absolute numbers, where batf3-KO 
animals exhibit a significant increase compared to the NC control, and numbers in the WT are 
merely slightly increased compared to their respective NC control (means NC: WT 27x103 
cells/g liver, batf3-KO 33x103 cells/g liver. Means 2wks MCD: WT 191x103 cells/g liver, batf3-
KO 472x103 cells/g liver).  
 
Figure 27 changes of monocyte and macrophage populations in WT C57Bl/6 mice compared to batf3-KO mice after 
2 weeks of MCD compared to NC feeding A) representative contour blots of CD45+ cells showing Ly6C signal (APC 
1:1000) plotted against F4-80 signal (A488 1:200) to gate on Ly6Chi/int F4-80- cells (blue gate), Ly6Chi/int F4-80low 
cells (red gate) and Ly6Clow/neg F4-80+ KCs (green gate) B) bar-graphs show comparison of percentage ratio within 
CD45+ cells (upper graph) and total cell amount per gram digested liver (lower graph) of Ly6Clow/neg F4-80+ KCs C) 
bar-graphs show comparison of percentage ratio within CD45+ cells (upper graph) and total cell amount per gram 
digested liver (lower graph) Ly6Chi/intF4-80neg cells D) bar-graphs show comparison of percentage ratio within CD45+ 
cells (upper graph) and total cell amount per gram digested liver (lower graph) Ly6Chi/int F4-80low cells. nNC= 5/group, 
n2wks MCD= 3/group.  
Data (A-D) for NC is representative of multiple independent experiments: repetitionsNC= 2 (n=3-5/group). 2wks MCD 
experiment was performed one time. Bar-graphs depict mean + SEM. Significance is indicated through *p<0.05, ** 
p<0.005, ***p<0.0001. Asterisks on top of the bar show statistical significance compared to the respective NC group 





Summary chapter 3.6.2: 
• The KC population is not increased during incipient NASH after 2 weeks treatment with 
MCD  
• Both Ly6Chi/intF4-80- and Ly6Chi/intF4-80low cells increase after 2 weeks of MCD and, 
similar as in the HSD experiments, the lack of cDCs 1 results in a higher increase of 
these cell populations after 2 weeks of MCD. 
• Differences between WT and batf3-KO after 2 weeks of MCD diet are not as explicit as 
after HSD diet. 
3.6.3 Lymphoid cells 
The analysis of lymphoid cell infiltrate was performed as described in chapter 3.5.3. 
Figure 28.A and B show percentage ratio and absolute cell count of B cells. Similar as the 5 
weeks MCD treated group a decrease in percentage ratio can be observed (means NC: WT 
33%, batf3-KO 26%; means 2 wks MCD: WT 24%, batf3-KO 15%). Again, this decrease is not 
paralleled by a decrease of absolute numbers, which indicates that it is due to increase of other 
CD45+ cells rather than an actual diminution of the B cell population (means NC: WT 670x103 
cells/g liver, batf3-KO 651x103 cells/g liver; means 2 wks MCD: WT 766x103 cells/g liver, batf3-
KO 411x103 cells/g liver). The decrease in percentage ratio of B cells is significantly higher in 
batf3-KO animals than in the WT control. In absolute cell count this difference cannot be 
objectified. 
Figure 28.C and D depicts changes within the NK cell population after 2 weeks of MCD 
diet: NK cells show no significant increase in percentage ratio after the treatment (means NC: 
WT 4.4%, batf3-KO 4.6%; means 2 wks MCD: WT 5.5%, batf3-KO 5.0%). In both WT and 
batf3-KO animals the absolute cell count increases compared to the NC control (means NC: 
WT 93x103 cells/g liver, batf3-KO 94x103 cells/g liver; means 2wks MCD: WT 172x103 cells/g 
liver, batf3-KO 158x103 cells/g liver). Compared to 5 weeks treatment the cell count of NK cells 
is markedly lower after 2 weeks of MCD, suggesting that they continuously increase with 
progression of the disease. The lack of batf3-dependent cDCs 1 does not alter NK cell infiltrate. 
Changes of the NKT cells are depicted in Figure 28.E and F: NKT cells do not increase 
significantly after 2 weeks of MCD treatment compared to the NC control neither in percentage 
ratio (means NC: WT 0.8%, batf3-KO 0.6%. means 2 wks MCD: WT 1.0%, batf3-KO 0.7%) 
nor in absolute cell count (means NC: WT 18x103 cells/g liver, batf3-KO 13x103 cells/g liver. 




however, the percentage ratio as well as the absolute cell count of batf3-KO animals is 
significantly lower in the 2 weeks MCD treatment group than the WT control.  
Figure 28.E and G show changes of all T cells after 2 weeks of MCD feeding. While 
this treatment does not affect the T cell population in WT animals, it results in significant 
decrease of the percentage ratio in batf3-KO animals (means NC: WT 12.6%, batf3-KO 10.5%. 
means 2 wks MCD: WT 11.1%, batf3-KO 6.2%). Again, the absolute cell count does not 
change, therefore this can be accounted by an increase of other CD45+ cells (means NC: WT 
212x103 cells/g liver, batf3-KO 149x103 cells/g liver. Means 2 wks MCD: WT 354x103 cells/g 
liver, batf3-KO 164x103 cells/g liver). Interestingly, albeit not significant, absolute cell count of 
T cells seems to slightly increase in WT animals after 2 weeks of MCD. This tendency cannot 
be observed in the batf3-KO animals. This fits to the observations made in HSD and 5 weeks 
MCD treatment, where batf3-KO animals show a relative decrease of T cells during NC and 
HSD, while the absolute cell count does not change. 5 weeks MCD treatment causes an 
increase in T cells in both groups, however numbers in WT animals are significantly higher. In 
Figure 28. H and I CD4+ T cells are specifically investigated. As observed after HSD, batf3-KO 
animals show a significantly lower percentage ratio of CD4+ T cells (means 2 wks MCD: WT 
5.1%, batf3-KO 2.6%) and also exhibit lower absolute numbers (means 2wks MCD: WT 
163x103 cells/g liver, batf3-KO 69x103 cells/g liver). 
Summary chapter 3.6.3: 
• After 2 weeks of MCD diet B cells show a relative reduction within the CD45+ liver cells, 
which is higher in WT animals than in batf3-KO animals, but show no significant 
changes in absolute cell count. 
• NK cells increase after 2 weeks of MCD diet and cDCs 1 have no effect on the dynamics 
of this population 
• NKT cells do not increase after 2 weeks of MCD diet. In the absence of cDCs 1 this 
population is diminished. 
• The number of T cells slightly increases after 2 weeks of MCD feeding. Batf3-KO 
animals consistently show lower T cell numbers than the WT, which includes 





Figure 28 changes of lymphocyte cell populations in WT C57Bl/6 mice compared to batf3-KO mice after 2 weeks 
of MCD compared to NC feeding A) representative contour blots of CD45+F4-80- cells showing CD19 signal (PE-
Cy7 1:100) plotted against CD3ε (A488 1:100) to gate on CD19+ CD3ε- cells (yellow gate) B) bar-graphs show 
comparison of percentage ratio within CD45+ cells (left graph) and total cell amount per gram digested liver (right 




(primary AB: biotin 1:100, secondary AB: A405 1:400) plotted against forwards scatter to gate on NK1.1+ cells (light 
blue gate) D) bar-graphs show comparison of percentage ratio within CD45+ cells (left graph) and total cell amount 
per gram digested liver (right graph) of CD19- CD3ε- NK1.1+ cells. E) representative contour blots of CD45+F4-80-
CD19- CD3ε+ cells showing NK1.1 signal (primary AB: biotin 1:100, secondary AB: A405 1:400) plotted against 
forwards scatter to gate on NK1.1+ T cells (rosé gate) and NK1.1- T Cells (orange gate) F) bar-graphs show 
comparison of percentage ratio within CD45+ cells (right graph) and total cell amount per gram digested liver (left 
graph) of CD19- CD3ε+ NK1.1+ cells. G) bar-graphs show comparison of percentage ratio within CD45+ cells (right 
graph) and total cell amount per gram digested liver (left graph) of CD19- CD3ε+ NK1.1- cells H) representative 
contour blots showing CD4 signal (APC 1:100) plotted against forwards scatter of CD19-CD3ε+NK1.1- cells to gate 
on CD4+ cells (forest green gate) I) bar-graphs show comparison of percentage ratio within CD45+ cells (left graph) 
and total cell count per gram digested liver (right graph) of CD19- CD3ε+ NK1.1- CD4+ cells. nNC= 5/group, n2wks MCD= 
3/group  
Data (A-I) for NC is representative of multiple independent experiments: repetitionsNC= 2 (n=3-5/group). 2 wks MCD 
experiment was performed one time. Bar-graphs depict mean + SEM. Significance is indicated through *p<0.05, ** 
p<0.005, ***p<0.0001. Asterisks on top of the bar show statistical significance compared to the respective NC group 
of WT or batf3-KO, underlined asterisks show statistical significance of WT compared to batf3-KO 
3.7 The influence of batf3-dependent cDCs 1 on the systemic metabolism 
Previous results primarily concern the effects the lack of batf3-dependent cDCs 1 has 
on the liver. NAFLD/NASH is closely connected to the metabolic syndrome, which is 
accompanied by augmented systemic inflammatory response, insulin resistance and modified 
lipid metabolism. To see whether the increased inflammation observed in the liver was a local 
effect or part of increased systemic inflammation as an effect of the batf3-KO genotype, 
analyses were performed to investigate the impact of batf3-dependent cDCs 1 on the systemic 
fat and glucose metabolism.  
3.7.1 Fat metabolism 
What first intrigued during the experiments and thus led to further investigations of fat 
metabolism are the significant differences in weight gain during NC and HSD treatment 
between WT and batf3-KO animals as depicted in Figure 29.A: During NC treatment, the 
weight gain in relation to the animals starting weight is significantly higher in batf3-KO animals 
than in the WT animals (means NC: WT 11%, batf3-KO 22%). HSD feeding causes 
significantly higher weight gain compared to the NC group and here, too, batf3-KO animals 
gain more weight than the WT controls (means HSD: WT 26%, batf3-KO 33%). As expected 
during MCD treatment the animals lose weight, importantly there is no difference between WT 
and batf3-KOs (means MCD: WT -20%, batf3-KO -23%). Following these observations, the 
serum leptin was measured as well as the amount of retroperitoneal fat in relation to total body 
weight. As depicted in Figure 29.B the amount of retroperitoneal fat is significantly higher in 
NC-fed batf3-KO animals compared to the WT control (means NC: WT 0,13%, batf3-KO 
0,34%). Although in both groups the retroperitoneal fat increases with HSD feeding, in batf3-
KO animals the increase is relatively lower than in the WT, as the baseline difference vanishes 




such a significant weight loss there is no retroperitoneal fat to be measured. Interestingly, as 
depicted in Figure 29.C, serum leptin levels mirror the dynamics of the retroperitoneal fat. On 
baseline batf3-KO animals exhibit significantly higher serum leptin values than the WT control 
(means NC: WT 4,0 ng/ml, batf3-KO 9,6 ng/ml). During the HSD treatment, the serum values 
increase in both groups, but do not show a significant difference between them (means HSD: 
WT 14,8 ng/ml, batf3-KO 19,0 ng/ml). MCD treatment causes a significant decrease of leptin 
levels, in some cases below the detection limit, in both WT and batf3-KO (means MCD: WT 
0,6 ng/ml, batf3-KO 1,0 ng/ml).  
 
Figure 29 clinical parameters of the fat metabolism in WT C57Bl/6 mice compared to batf3-KO mice after 5 weeks 
of NC, HSD or MCD treatment A) bar-graphs show weight gain or loss in percentage of body weight at the beginning 
of the treatment nNC=5/group, nHSD=5/group, nMCD=5/group. Graphs are representative for four independent 
experiments n=3-5/group B) bar-graphs show serum leptin levels nNC=5/group, nHSD=5/group, nMCD WT=4, nMCD KO=6. 
Data was created using samples of two independent experiments per group C) bar-graphs show the retroperitoneal 
fat in percentage of total body weight nNC=12/group, nHSD=13/group. Bar-graphs depict mean +SEM. Significance 
is indicated through *p<0.05, ** p<0.005, ***p<0.0001. Asterisks on top of the bar show statistical significance 
compared to the respective NC group of WT or batf3-KO, underlined asterisks show statistical significance of WT 
compared to batf3-KO 
In batf3-KO mice HSD treatment leads to a significant increase of inflammatory 
responses within the liver compared to the WT animals. Keeping this in mind and with the 
above described differences in fat metabolism the next step was to see whether the lack of 
batf3-dependent cDCs 1 also affects inflammatory and immune mechanisms in the fat tissue. 
Figure 30. shows the flow cytometric analysis of fat tissue in NC and HSD treated batf3-KO 
and WT mice as well as qPCR analysis of retroperitoneal fat tissues of HSD treated mice. As 
depicted in Figure 30.A the basic gating strategy on leukocytes by selecting only single, living, 
CD45+ cells is kept for retroperitoneal fat tissue. Figure 30.B and C shows the analysis of F4-
80+ cells, this includes macrophages and inflammatory monocytes, in retroperitoneal fat tissue. 
Interestingly WT animals show a significant increase of F4-80+ cells after HSD treatment, 




but have an increased baseline frequency that corresponds to the WT HSD values (means 
NC: WT 45.0%, batf3-KO 77.4%. means HSD: WT 72.0%, batf3-KO 76.0%). CD11b+ DCs are 
investigated by gating on F4-80- cells (magenta gate) and then gating on all CD11c+ MHC-II+ 
cells (green gate) as depicted in Figure 30.A. The pre-gating on F4-80- cells excludes all 
macrophages and inflammatory monocytes, which might otherwise shift into the CD11c and 
MHC-II expressing population. Following this the CD11b signal is plotted against CD103 signal 
and only the CD11b expressing cells are selected (blue gate, Figure 30.D). Importantly, 
changes of the CD11b+ population as observed in the liver do not pertain in retroperitoneal fat 
tissue. There is no increase of CD11b+ DCs as observed in the liver after HSD treatment, nor 
does the frequency of CD11b+ DCs show a significant difference between WT and batf3-KO 
neither in NC (means NC: WT 4.7%, batf3-KO 4.8%) nor in HSD treated animals (means HSD: 
WT 6.8%, batf3-KO 6.5%) (Figure 30.E). Ultimately it was investigated whether the lack of 
batf3-dependet cDCs 1 influences the expression of inflammatory cytokines in retroperitoneal 
fat tissue during HSD. Figure 30.G shows the fold change for TNFα, CXCL-10, CCL2 and IL-
6, none of which is significantly altered in batf3-KO animals. 
 
Figure 30 Flow cytometric and qPCR analysis of retroperitoneal fat tissue in WT C57Bl/6 mice compared to batf3-
KO mice after 5 weeks of HSD or NC feeding. A) basic gating strategy with debris and doublet cell exclusion. Gating 
on leukocytes by selecting all CD45+cells, plotting the F4-80 (primary AB biotin 1:20, secondary AB VioBlue 1:400) 
against an empty channel to gate on F4-80- (magenta gate) cells, then plotting MHC-II (FITC 1:4000) against CD11c 
(APC 1:400) to gate on CD11c+MHC-II+ cells. B) representative dot blots of the F4-80 signal (primary AB biotin 




(orange gate) C) bar-graphs shows comparison of percentage ratio of F4-80+ cells within CD45+ cells D) 
representative dot blots of the CD11b signal (PE-Cy7 1:2000) plotted against CD103 signal (PE 1:200) within F4-
80-CD11c+MHC-II+ cells to gate on CD11b+CD103- cells (blue gate). E) bar-graphs show comparison of percentage 
ratio of CD11c+MHC-II+CD11b+ cells within CD45+ cells. Experiment for Data (A-E) was performed one time with 
nNC=3/group, nHSD=5/group G) bar-graphs show fold changes in gene expression of retroperitoneal fat tissue 
between HSD treated WT and batf3-KO animal. Beta-actin was used as a housekeeping gene. n=4/group. Bar-
graphs depict mean +SEM. Significance is indicated through *p<0.05, ** p<0.005, ***p<0.0001. Asterisks on top of 
the bar show statistical significance compared to the respective NC group of WT or KO, underlined asterisks show 
statistical significance of WT compared to KO 
Summary chapter 3.7.1: 
• The lack of cDCs 1 results in higher weight gain, higher amounts of retroperitoneal fat with 
a higher frequency of F4-80+ cells and higher serum leptin levels in liver-healthy, NC fed 
animals.  
• The lack of cDCs 1 results in higher weight gain in HSD fed animals, but a relatively lower 
increase of retroperitoneal fat, F4-80+ cells and serum leptin compared to the respective 
WT control. It does not influence the expression of inflammatory cytokines in the 
retroperitoneal fat tissue. 
• Unlike in the liver the lack of cDCs 1 does not affect the frequency of CD11b+ DCs in 
retroperitoneal fat tissue, neither does HSD treatment increase their frequency. 
3.7.2 Glucose metabolism 
To see whether HSD treatment alters the glucose metabolism an intraperitoneal 
glucose tolerance test was performed with WT and batf3-KO animals prior to and after HSD 
diet (Figure 31.B). When fed with NC both WT and batf3-KO show an increase in blood sugar 
levels that peaks at 30 minutes post injection and then decreases in the following two hours. 
HSD treatment causes in both WT and batf3-KO animals elevated fasting glucose levels over 
200 mg/dl and with peaks over 450mg/dl 30 minutes post injection, suggesting impaired 
glucose tolerance. Interestingly, the decrease of blood glucose in the three hours following the 
injection is shallower in HSD treated WT animals than in batf3-KO animals. Moreover, WT 
control animals consistently show higher glucose values than the batf3-KO animals. The 
analysis of glycated hemoglobin is not significantly altered between WT and batf3-KO (means 
HSD: WT 12.5 mmol/mol, batf3-KO 14.3 mmol/mol), nor are the serum insulin levels (compare 





Figure 31 clinical parameters of glucose metabolism in WT C57Bl/6 mice compared to batf3-KO mice after 5 weeks 
of NC or HSD treatment A) Graph curves depict blood glucose values of WT and KO animals during the 
intraperitoneal glucose tolerance test (IPGTT) before (lower curves) and after (upper curves) 5 weeks HSD 
treatment. nWT=4, nKO=3. B) bar-graphs depict the concentrations of glycated hemoglobin (HbA1c) in 5 wks HSD 
treated WT and KO animals nWT=4, nKO=3 C) bar graphs depict concentration of fasting serum insulin in 5 wks HSD 
treated WT and KO animals. nWT=4, nKO=3. Significance is indicated through *p<0.05, ** p<0.005, ***p<0.0001  
Summary chapter 3.7.2: 
• After HSD feeding both WT and batf3-KO animals show elevated glucose levels during 
the IGPTT compared to the NC control, but batf3-KO animals showed no significant 
difference in glucose metabolism compared to the respective WT control 
• The lack cDCs 1 does not affect serum insulin levels, nor does it affect HbA1c ratio, 






The incidence of the metabolic syndrome and its associated conditions has increased 
considerably worldwide. NASH is considered as the hepatic consequence of the metabolic 
syndrome and is suggested to become the first cause for liver transplant over the next years 
(2). Although it has been in the focus of intense research over the past decades the complex 
mechanisms involved in the pathophysiology of NASH are still incompletely understood. DCs 
are powerful mediators of adaptive and innate immune responses and have been suggested 
to play an important role in the development of NASH. In 2012 Henning et al. showed that the 
depletion of CD11c+ cells in the MCD model of NASH exacerbates hepatic inflammation, 
apoptosis and fibrosis (109). Importantly the depletion of CD11c+ cells is not limited to DCs, 
but can also include macrophages, monocytes or NK cells, therefore the observed effects 
cannot be accredited solely to DCs (101). Further the DC population consists of different 
subtypes which hold different functions within the liver and each subtype needs to be 
individually addressed when trying to figure out their role in the complex pathogenesis of NASH 
(43). In this study, we mapped different DC subtypes in the liver using dietary models of 
steatosis and NASH to gather more information on the dynamics of each subset during disease 
progression. Then we used the batf3 knockout model, which constitutively lacks CD8+ DCs in 
lymphoid tissue and CD103+ DCs in non-lymphoid tissue, to specify the role these cells play 
in the prevention or progression of NASH (77). 
4.1 A 5-week HSD in WT C57Bl/6 mice results in steatosis, a 5-week MCD 
results in NASH 
NAFLD includes a wide spectrum of liver pathologies that reaches from mild, 
uncomplicated steatosis to steatohepatitis with inflammation and hepatocyte damage. The 
histological assessment of mice liver after 5 weeks of MCD reveals micro- and macrovesicular 
steatosis as well as inflammatory infiltrate and hepatocellular damage. These results concur 
with the elevated values of liver triglyceride content, CD45+ cell infiltrate and ALT serum levels. 
Taken together and considering the lack of any other cause for secondary steatosis these 
findings comply with the diagnosis of NASH (128). MCD is an established dietary model to 
induce NASH in mice and this confirms the method used to investigate the NASH phenotype 
(35).  
The HSD used in this study was originally provided by the manufacturer as a control diet 




acids. In HSD and MCD 20% of calorie intake is provided by fat and 40% by sucrose. 
Importantly, animals treated with HSD develop increased liver triglyceride content within the 
liver and show histological signs of mild hepatic steatosis without major inflammatory reaction. 
This fits to data published by Tetri et al. in 2008 in which animals were treated with “Western 
diet”, a diet developed to mimic the human dietary situation leading to NAFLD, which, too, 
contains high amounts of fat and sucrose. Treatment with western diet causes macrovesicular 
steatosis after 4 weeks and hepatic steatosis with necroinflammatory changes similar to 
human NASH after 16 weeks of treatment (129). Taking this into account it becomes evident 
that HSD for 5 weeks should not be used as a healthy control group for MCD treatment in this 
study, since the high amounts of fat and sucrose by themselves affect the liver. Nevertheless, 
the HSD for 5 weeks shows to be a suitable model to investigate liver steatosis without 
developing necroinflammation.  
In conclusion, a 5-weeks treatment of WT C57Bl/6 mice with HSD can be used as a 
model to investigate bland liver steatosis, while the 5-weeks treatment with MCD is useful to 
investigate NASH. 
4.2 NASH is associated with increased abundance of all DC subtypes  
Liver DCs consists of CD11chiMHC-IIhiCD103+ cDCs 1, CD11chiMHC-IIhiCD11b+ cDCs 2 
(CD64-) and moDCs (CD64+) as well as CD11cintPDCA-1+ pDCs (62,87–89,101). Previous 
studies to clarify the role of DCs in liver injury have shown that CD11c+ cells increase in number 
and exhibit a pro-inflammatory phenotype in various models of liver damage (105,107,108). 
However, said studies did not take into account the promiscuity of the CD11c surface marker 
nor the heterogeneity of the DC population, therefore remains the need to clarify the role of 
individual DC subtypes in liver disease (101).  
This study shows an increase of CD11b+ DCs as well as cDCs 1 and pDCs after 5 
weeks of MCD treatment. Previously published results describe an increase of CD11c+ cells 
in murine models of both acute and chronic liver injury, e.g. acute acetaminophen 
hepatotoxicity or MCD induced NASH (105,107). In the NASH model, Henning et al. observed 
an influx of CD11c+MHC-II+ cells after 6 weeks of diet,  of which the CD11b+ DC subtype shows 
the highest increase(109). This is in line with our results where CD11b+ DCs exhibit the overall 
highest fold change of all DC subtypes. Henning’s study also details the dynamics of other 
fractional DC subsets, particularly B220+ cells, which the authors identified as pDCs, and CD8+ 
cells, which they identified as cDCs 1(109). In these two DC populations, the authors noticed 
a decrease after 6 weeks of MCD treatment, which would be contradictory to our results. 




CD8 as a marker to identify cDCs 1 is valid when investigating this subtype in lymphoid organs, 
but CD8 is not a suitable marker in non-lymphoid organs, where CD103 should be used instead 
(60,62). Thus, the observations made for CD8+ cells might not truly represent changes of the 
cDC 1 subtype. Second, the observed decrease of pDCs and CD8 “cDCs 1” is based on the 
percentage ratio within all DCs and does not consider changes in absolute numbers. 
Considering that the CD11b+ subtype shows the highest overall fold change the fractional 
decrease of the other two populations is a mathematical consequence, but does not 
necessarily reflect the overall expansion of the DC compartment in the liver. Our study shows 
an increase of all three DC subtypes as a fraction of all hematopoietic cells as well as in 
absolute cell count within the liver. Importantly other research groups report similar dynamics, 
e.g. in the TAA fibrosis models the percentage ratio of the pDC population decreases amongst 
all liver DCs, while the absolute number is actually augmented compared to the healthy control 
(107). Therefore, observations made in the 6 weeks MCD study by Henning et al. do not 
contradict our results, rather they represent a different aspects of DC dynamics during NASH, 
which would be the relation of DC subtypes amongst each other. Taken together all three DC 
subsets increase during NASH suggesting they are all involved in the pathomechanism of the 
disease.  
 During steady state liver DCs have been described to exhibit mostly tolerogenic 
properties, while, as presented by Henning et al., during MCD-induced NASH they switch 
towards a pro-inflammatory phenotype manifesting in increased production of pro-
inflammatory cytokines and increased ability to induce CD4+ T-Cell stimulation (100,109). 
Importantly, until now no studies have been conducted to investigate if and how simple 
steatosis without inflammatory aspects affects the different liver DC subtypes. In the HSD 
steatosis model DC subpopulations are not altered compared to the healthy control and the 
influx of DCs to the liver does not occur until inflammation is present. Liver injury has been 
associated with DCs evolving towards an immunogenic phenotype, which is associated with 
increased intracellular lipid content and upregulation of co-stimulatory surface 
markers(105,107). It remains to be determined whether DCs during simple steatosis retain 
their tolerogenic function or whether they are altered towards an immunogenic phenotype. 
Future studies might include more detailed analysis of DCs from steatotic livers on a functional 
level, such as in vitro experiments to determine cytokine production or their capacity to induce 




4.3 cDCs are not the major TNFα producing CD11c+ cell population in the liver 
TNFα is a potent pro-inflammatory cytokine and has been identified as an essential 
molecule in the pathophysiology of NASH (130). Functional analyzes of liver immune cells 
have shown that CD11c+ cells increase their TNFα production during liver injury (105,107,109). 
This led to the assumption that liver DCs modulate the inflammatory environment through 
increased TNFα production (105,107). To identify the exact source of increased TNFα levels 
within the CD11c+ population during NASH, CD11b, CD103 and F4-80 are added as additional 
surface markers in flow cytometric analyses. Similar as in previously published data, CD11c+ 
cells show a significant increase of TNFα production after 5 weeks of MCD. Importantly neither 
the cDC 1 subtype nor CD11b+ DCs exhibit a significant change in TNFα production compared 
to the healthy control. This suggests that other CD11c expressing cells must be the major 
source of TNFα during inflammation. Importantly when analyzing TNFα-production by F4-80+ 
cells they display a similar increase as observed in CD11c+ cells. F4-80+ is a surface marker 
of KCs and some monocyte populations (101,131). KCs and inflammatory monocytes have 
previously been identified as a major source of TNFα as part of the innate immune response 
during NASH (132,133). Considering that KCs and monocytes also express CD11c this 
suggests that the increase of TNFα production Henning et al. observed in CD11c+ cells from 
NASH liver most likely stems from KCs and DCs are not the major TNFα producing populations 
during NASH (101).  
Nevertheless CD11b+ DCs show some positive signals for TNFα, which suggests that, 
although not upregulated during inflammation, these cells have a baseline production of TNFα. 
The cDC 1 gate shows only few TNFα positive signals compared, suggesting that this cell type 
is no important source of TNFα in the liver. 
4.4 cDCs 1 protect from progression of steatosis towards steatohepatitis 
Liver steatosis affects around 20 to 30% of the western population (2). While in most 
cases this does not affect long term prognosis, 10-20% develop the more severe NASH which 
is accompanied to increased risk for end stage liver disease (13,14). Especially for developing 
prevention measures and treatment strategies for NASH understanding the exact mechanisms 
behind this progression is of major importance. As elaborated in the introduction the role of 
DCs in hepatic injury has been described as of a dichotomous character: on the one hand they 
hold a protective role as they help to maintain allograft survival after liver transplantation, 
protect from liver injury through elevated IL-10 production in the ischemia-reperfusion model 




CD11c+ cells exacerbates liver pathology (100,101,110,134). On the other hand liver DCs 
exhibit pro-inflammatory characteristics including increased TNFα-production, high lipid 
content and T-Cell stimulation as described in models of chronic liver injury such as MCD-
induced NASH or TAA-induced fibrosis (101,135). Importantly most of this research is based 
on the study of CD11c-DTR mice and therefore little is known about the role of individual DC 
subtypes. The first part of this study shows that NASH is associated with increased abundance 
of all DC subtypes in the liver, which suggests that all of them are included in the pathogenesis 
of NASH. To gain more profound insight on how the cDC 1 subtype influences disease 
development batf3-KO mice were subjected to either NC, HSD or MCD treatment.  
Henning et al. showed that in the MCD model of NASH ablation of CD11c+ cells 
significantly aggravates the disease. CD11c-DTR mice exhibit a larger CD45+ cell infiltrate, 
increased prevalence of apoptosis and accelerated hepatic fibrosis (109). As opposite to this 
the isolated absence of cDCs 1 has only little effect on the severity of the disease in MCD 
induced NASH, as evident in the histopathological scoring which indicates an advanced NASH 
phenotype, but with no difference to that of WT animals. In contrast to the MCD model the 
absence of cDC 1 has quite striking effects in the HSD model. While in WT animals 5 weeks 
of HSD feeding results in elevated liver triglyceride content without overt inflammation, batf3-
KO animals undergoing this treatment exhibit clear signs of an exacerbated disease. They 
develop profound macrovesicular steatosis with markedly elevated liver triglyceride content 
and histopathological scoring of liver sections indicates severe necroinflammation, which is 
also reflected in the significant influx of CD45+ hematopoietic cells in the liver. These are typical 
features of NASH indicating a progression of steatosis towards steatohepatitis in HSD treated 
mice lacking the cDCs 1 subtype. 
Thus, the lack of cDCs 1 has tremendous consequence during liver steatosis, whilst 
having only little effect on the NASH model. Having said this, both during HSD and MCD 
treatment batf3-KO animals develop higher liver triglyceride contents than the WT controls. 
Accumulation of lipotoxic metabolites of free fatty acids and the resulting oxidative stress on 
hepatocytes has in recent years been identified as a key mechanism in liver injury and 
inflammation (29). The increase of liver triglycerides indicates that animals lacking cDCs 1 
respond differently to the high amounts of sucrose and fat in HSD and MCD. A detailed 
analysis of the genes involved in lipid metabolism is presented by Anna Meier in her master 
thesis, where she shows that batf3-KO animals show a different expression profile of genes 
for fatty acid beta-oxygenation and transport (136). This suggests altered lipid metabolism as 




Henning et al. postulated that DCs protect from hepatic damage through different 
mechanisms that limit inflammation, such as being involved in clearance of apoptotic cells and 
necrotic debris (109). MCD diet causes a significant increase of serum ALT-values in batf3-
KO mice, indicating hepatocellular damage, whereas animals treated with HSD show no 
significant difference to the healthy control. Importantly, compared to WT animals the absence 
of cDCs 1 does not result in significantly elevated ALT serum values during either diet. Further 
the expression of apoptotic genes in batf3-KO animals, as presented in detail by Anna Meier 
in her master thesis, is also not different to the WT animals’ (136). This suggests that cDCs 1 
have no effect on hepatocellular damage during NASH and that the increased cellular death 
observed by Henning et al. in CD11c depleted animals under MCD treatment is not due to the 
lack of cDCs 1, but other CD11c expressing cells. This might include macrophages, which are 
potent phagocytic cells and thus are more likely to be the population responsible for clearance 
of dead cells and debris (43). Apart from that, the lack of a significant increase in serum-ALT 
levels in HSD treated batf3-KO mice does not stand in contrast to the histopathological scoring. 
In fact this is consistent with observations made in human disease, which indicate that ALT 
levels do not necessarily correlate with histological findings and NASH can be present also in 
subjects with normal ALT values (7–9). 
Lastly, connective tissue staining shows no significant fibrosis development after HSD 
or MCD treatment neither in WT nor in batf3-KO animals. This indicates that the lack of cDCs 
1 does not result in accelerated fibrogenesis. Nevertheless, one should keep in mind that HSD 
usually does not cause fibrosis development and that under MCD treatment fibrosis does not 
occurs only until 8 to 10 weeks of treatment (34,35,129,137). Therefore, a longer MCD 
treatment might be necessary to determine the exact role of cDCs 1 in fibrosis progression. 
4.5 The lack of cDCs 1 increases the inflammatory infiltrate during the 
development of NASH 
Increased inflammatory infiltrate is one of the hallmarks of NASH. At some point during disease 
progression the delicate homeostasis between immunity and tolerance in the liver is skewed 
towards an inflammatory response. During HSD, the lack of cDCs 1 results in an influx of 
CD45+ cells to the liver. DCs are powerful regulators of immune response and communicate 
closely with cells of the innate and adaptive immune system. To understand how cDCs 1 shape 
the hematopoietic infiltrate during the progression of NASH the CD45+ cell compartment needs 




 Ly6C+F4-80low cells are inflammatory monocytes circulating the blood stream and are 
rapidly recruited to inflammatory sites where they act as “first responders” to inflammatory 
signals or differentiate into monocyte-derived macrophages or moDCs (138). Importantly, 
several studies have shown that inflammatory monocytes contribute to liver inflammation and 
fibrosis, as for example impaired monocyte recruitment in CCR-2-KO mice results in reduced 
HSC activation and diminished liver fibrosis (138). In WT animals, HSD treatment does not 
cause increase of the inflammatory monocyte infiltrate compared to the healthy control. In the 
absence of cDCs 1 on the other hand inflammatory monocytes significantly expand, which is 
a clear indicator of an ongoing inflammatory response. Not only inflammatory monocytes, but 
also other cells of the innate immune system are recruited when feeding HSD to bat3-KO 
animals. This is evident in the increase of Ly6Chi/intF4-80- cells, which are a mixture of myeloid 
cells including neutrophils, eosinophils and myeloid-derived suppressor cells (117). Importantly 
during MCD treatment numbers of inflammatory monocytes as well as Ly6Chi/intF4-80- myeloid 
cells are significantly higher in both WT and batf3-KO animals than in the batf3-KO HSD group, 
thus indicating even more advanced inflammation and further progressed steatohepatitis. 
Since neutrophil accumulation is a prominent feature of inflammation in NASH, we specifically 
analyzed Ly6G+i cells, to see whether the lack of cDCs 1 induces neutrophil recruitment (139). 
As can be expected MCD treated animals exhibit hepatic neutrophil recruitment as part of the 
inflammatory response. Interestingly HSD treated mice also show a slight tendency towards 
higher neutrophil numbers indicating a mild immune response even during steatosis. However, 
despite the elevated recruitment of Ly6ChiF4-80- cells, Ly6G+ neutrophils are not significantly 
increased in batf3-KO animals during HSD diet. This is even more surprising as functional 
analyzes of chemokine production within the liver reveal differences in cytokine production 
involved in neutrophil recruitment (compare chapter 4.6.2). It remains to be elucidated whether 
histological analyses would underline similar presence of Ly6G+ cells within the parenchyma 
of WT and batf3-KO HSD- and MCD-treated animals. It is still a likely possibility that batf3-KO 
animals have higher tissue neutrophil counts and these cells display increased susceptibility 
to apoptosis upon isolation. 
Hepatic macrophages play a key role during liver injury and fibrogenesis in perpetuating 
inflammation through the release of proinflammatory cytokines and activation of HSCs 
(138,140). During steady state KCs, the liver resident macrophages, are self-renewing, while 
during inflammation the liver macrophage population is greatly augmented by monocyte-
derived macrophages (138). This explains why the F4-80+Ly6Clow population, which represents 
KCs, increases relatively little during MCD treatment compared to other myeloid cells. 




elevated abundance of KCs indicating that cDCs 1 have no direct effect on KC expansion. 
Nevertheless, their absence might still augment the intrahepatic macrophage population 
through the observed recruitment of inflammatory monocytes. Importantly, previously 
published results show, that the frequency of KCs does not change during early stages of 
NASH, but they acquire an proinflammatory phenotype (133). Our results show that the lack 
of cDCs 1 causes increased production of inflammatory cytokines of F4-80+ and CD11c+ cells, 
indicating that cDCs 1 may limit the inflammatory response of KCs. These results are 
discussed in detail in chapter 4.6.1. 
Another cell population that expands in mice lacking cDCs 1 during HSD are CD11b+ 
DCs. In lymphoid organs CD11b+ DCs are capable of inducing CD4+ T-cell immunity, but in 
the liver the specific role of CD11b+ DCs remains unclear (117,141). A big challenge in 
assigning specific functions to these cells remains the heterogeneity of this population as it 
comprises cells from both the classical DC lineage as well as monocyte derived DCs (61,117). 
Studies of moDCs, which were formed in the presence of pathogens in various tissues, have 
shown that they participate in the activation of the innate and adaptive immune system (142). 
With the abundance of inflammatory monocytes in batf3-KO animals we hypothesized that the 
increase of CD11b+ DCs results from an increase of moDCs. Indeed, preliminary results 
indicate that the increase of CD11b+ DCs in batf3-KO animals during HSD stems primarily from 
an increase of CD64+ moDCs, thus representing another potentially pro-inflammatory cell 
population that expands in the absence of cDCs 1. During MCD diet, the lack of cDCs 1 has 
no effect on the total CD11b+ DC population. Regrettably CD64 expression was not analyzed. 
These are promising results and further studies might be useful to determine the individual 
dynamics of moDCs and cDCs 2 during NASH and whether this is influenced by cDCs 1. 
Moreover, experiments to clarify the role of CD11b+ DCs in NASH could also involve IRF4-/- 
mice, which lack a transcription factor that controls cDC 2 development (61,117,143). Since 
moDCs develop independently from IRF4 this could help to differentiate functions of moDCs 
from cDCs 2 (43). Importantly the pDC population remained unchanged in batf3-KO animals, 
suggesting that their recruitment occurs independently from cDCs 1. 
T cells are important effector cells of the adaptive immune response. In WT animals, the 
T cell population remains stable during HSD induced bland steatosis and expands during MCD 
indicating involvement of the adaptive immune system. This is consistent with previously 
published results, where animals treated with high fat diet (HFD) to induce steatosis exhibit no 
increase in intrahepatic T cells, but animals with NASH under choline deficient HFD do (144). 
Interestingly, the absence of cDCs 1 does not lead to an expansion of the T cell population 




Increased CD4+ T cell death has been described in MCD treated animals (145). Importantly 
this was accredited to their increased sensitivity towards certain metabolic intermediates, 
namely linoleic acid, a FFA which accumulates during MCD treatment (145). Considering the 
changes of lipid metabolism observed in the absence of cDCs 1 (compare chapter 4.4), a 
selective loss of CD4+ T cells due to metabolic disturbances could possibly explain the limited 
expansion of T cells in batf3-KO mice. Regrettably CD4+ T cells were not investigated in the 5 
weeks MCD model, but the fact that in both the HSD model and 2 weeks MCD model CD4+ T 
cells are significantly lower in batf3-KO animals strongly supports this assumption. Moreover, 
cDCs 1 are important for the induction of CD4+CD25+FoxP3+ Tregs (60,84). Another possible 
explanation for the lack of CD4+ T cells in batf3-KO animals could be impaired induction of 
regulatory T cells. Importantly, Tregs help control inflammation during steatosis, as they reduce 
inflammatory signaling and protect from LPS-induced hepatotoxicity (146). Impaired induction 
of Tregs in the absence of cDCs 1 could therefore contribute to disease progression. To clarify 
this, future experiments should include a detailed functional analysis of individual T cell 
subsets, particularly CD4+ T cells, during steatosis and NASH and to determine the influence 
of cDCs 1 on constitution and dynamics of individual T cell subtypes. Characterizing the 
composition of hepatic FFAs in WT and batf3-KO animals during HSD and MCD could also 
help to assess whether the influence of cDCs 1 on the hepatic lipid metabolism is connected 
to the lack of hepatic CD4+ T cells. 
Besides T cells, B cells represent the second large lymphocyte population of the adaptive 
immune system. Their prototypical feature is the production of antibodies which contribute to 
the humoral immune response, but other functions include T cell modulation, cytokine 
production and antigen presentation (147). Studies show that B cells are involved in the 
pathogenesis of NASH through the production of antibodies: in MCD treated mice the 
development of liver injury and inflammation is paralleled by the occurrence of antibodies 
against lipid peroxidation products (148). Importantly, neither HSD- nor MCD treatment alters 
the amount of intrahepatic B cells, which is consistent with previously published results of a 
murine NASH model treated with choline-deficient HFD (144). Correspondingly, the lack of 
cDCs 1 and the associated progression of disease during HSD treatment also does not affect 
this cell population. Importantly, as discussed in chapter 4.4, the lack of cDCs 1 alters hepatic 
lipid metabolism, which might trigger the formation of antibodies against lipid peroxidation 
products (136,148). Therefore, an interesting aspect might be investigating B cells in the 
hepatic draining lymph nodes, since their differentiation and clonal expansion typically occurs 
in the germinal centers of secondary lymphoid organs with the help of CD4+ TH2 Cells (96). 




is involved in the induction of CD4+ T cell immunity (61). Besides antibody production, B cells 
have also been indirectly linked to the pathogenesis of NASH through their contribution to 
insulin resistance and adipose tissue inflammation (147,149). Importantly neither glucose 
metabolism nor adipose tissue inflammation is significantly worsened in batf3-KO animals 
during HSD (compare chapter 4.8), suggesting that this, too, is a mechanism independent from 
cDCs 1.  
NK cells are important innate effector cells that arrive very early at the site of 
inflammation, where they lyse their target cells and mediate inflammation through production 
of cytokines (97). Their role in liver injury has been studied extensively during viral hepatitis 
and in fibrosis models. Here NK cells play a critical role in controlling liver fibrogenesis through 
lysis of HSCs and also hold important anti-viral and anti-tumor functions by killing stressed 
hepatocytes and tumor cells (150–152). Their contribution in development and progression of 
NAFLD is less defined (150). Analysis of human liver biopsies reveal that, compared to healthy 
controls, the number of intrahepatic NK cells in NASH patients is markedly elevated as is the 
expression of NK cell associated cytotoxic mediators indicating an activated phenotype of 
these cells (153). Consistent with this, NK cell numbers also increase in MCD treated mice, 
pointing towards the involvement of NK cells in the pathogenesis of NASH. Interestingly, 
although several studies have demonstrated intense crosstalk between NK cells and DCs, the 
progression of disease in batf3-KO animals under HSD treatment is not associated with 
alterations of the intrahepatic NK cell population, suggesting that here cDCs 1 are not directly 
involved in the recruitment of NK cells (41,70,74). Likewise, the lack of cDCs 1 also has no 
effect on NK cells during MCD treatment. Although the lack of cDCs 1 does not affect the 
intrahepatic NK cells, analyzing the NK cell population in the hepatic draining lymph nodes 
might reveal more details on dynamics and the relationship between cDCs 1 and NK cells 
during NAFLD. 
NKT cells express surface markers of both T cells and NK cells (97). Current research 
indicates that they play an important role in the regulation of metabolic disorders mainly 
through their interaction with CD1d, a MHC-I-like glycolipid antigen presenting molecule 
(54,154). Their role during NAFLD has been widely analyzed in both murine models as well as 
human disease (155). Several studies suggest a protective role of NKT cells during mild liver 
steatosis: CD1d deficient mice, which lack NKT cells, exhibit increased susceptibility to fatty 
liver during high fat diet (156). Further, reduced numbers of hepatic NKT cells are associated 
with increased TH1 cytokine production in WT mice during high fat diet and the adoptive 
transfer of NKT cells has been shown to reduce steatosis in ob/ob mice (154,157,158). In 




increase during choline deficient HFD induced NASH, promote NASH development and 
contribute to the transition towards hepatocellular carcinoma (144). Another study 
demonstrated that NKT cells accumulate in livers with NASH induced fibrosis and drive fibrosis 
progression through simulating myofibroblastic activities of HSCs, while CD1d deficient mice 
are protected from fibrosis development (159). Tajiri et al. reported that in human NAFLD the 
number of intrahepatic NKT cells increases as the disease progresses and the expression of 
CD1d is upregulated (160). This fits to our results, where the number of intrahepatic NKT cells 
increases during NASH, but is not altered in the steatosis model. Tajiri et. al postulated that 
during steatohepatitis disease progression is promoted by increased presentation of lipid 
antigens through elevated expression of CD1d on liver APCs, which then results in activation 
of NKT cells (160). Although DCs are potent APCs the lack of cDCs 1 has no effect on the 
intrahepatic NKT cell population, suggesting that the mechanisms by which NKT cells influence 
hepatic disease progression is independently from cDCs 1.  
4.6 The lack of cDCs 1 shifts the balance towards a pro-inflammatory milieu 
During inflammatory reactions a variety of cytokines, which are specialized messenger 
molecules, are involved in mediating inflammation. To obtain information regarding the 
influence of cDCs 1 on intrahepatic cytokine production in the liver a cytokine array was used. 
This provides a general overview of the current immunologic milieu within the liver. The lack 
of cDCs 1 results in differences in the production of several cytokines associated with NASH 
pathogenesis or liver injury, indicating an augmented inflammatory response in batf3-KO 
animals. Importantly the proinflammatory shift in the hepatic milieu is not only evident in HSD 
treated animals, but also in MCD treated animals, suggesting that to some extend cDCs 1 
obtain their anti-inflammatory function even during advanced stages of the disease. 
Batf3-KO animals exhibit in increased levels of Serpin E1, a molecule that has been 
associated with hepatic injury. Serpin E1, also known as plasminogen activator inhibitor-1, is 
a key regulator of fibrinolysis by plasmin (161). It belongs to acute phase proteins and is 
induced in models of hepatic fibrosis (162–164). Mice lacking serpin E1 develop less injury in 
response to acetaminophen application and are protected from cholestatic-induced liver 
damage and fibrosis after bile duct ligation (163,165). Osteopontin (OPN) is synthesized by 
both immune and non-immune cells and is associated with a variety of pathological processes 
including cell-adhesion, chemoattraction and immunomodulation (166,167). OPN has been 
linked to the pathogenesis in MCD induced NASH, where it is upregulated from the early 
stages of the disease, and OPN-deficient mice develop significantly less liver injury and fibrosis 




of the MCD group, not during HSD, which indicates that cDCs 1 are also involved during later 
stages of disease development. IL-1 is a potent pro-inflammatory cytokine, which is released 
by activated KCs during liver inflammation (117). IL-1ra is a natural occurring antagonist for IL-
1-type cytokines and plays a protective role during liver injury as shown in IL-1ra deficient mice, 
which develop severe inflammatory infiltrate and portal fibrosis under high fat diet (168). During 
HSD batf3-KO animals produce higher amounts of IL-1ra than the WT control and this 
difference increases during MCD diet. The upregulation of IL-1ra might represent a 
compensatory reaction to counterbalance the increased inflammatory response in batf3-KO 
animals. This fits to data of human disease, where researchers have linked elevated serum 
levels of IL-1ra and increased hepatic mRNA expression to the degree of inflammation and 
presence of NASH (169). Interestingly, during HSD WT animals exhibit higher values of 
resistin, a pro-inflammatory molecule that promotes inflammation and insulin resistance 
(170,171). In rodents, resistin is primarily produced by adipocytes and serum levels increase 
during obesity (170). A previously published study shows that injection of mice with resistin 
exacerbates inflammatory cell recruitment and necrosis caused by LPS in the liver (172). In 
mice an intrahepatic production of resistin has not yet been described, but in humans hepatic 
resistin expression increases during NASH and other chronic inflammatory liver diseases 
(170,173,174). Importantly, TNFα downregulates resistin expression of adipocytes in vitro 
(175). If this is also true for resistin expression in other tissues, the observed increase of TNFα 
production observed in batf3-KO animals (compare chapter 4.7) would explain the lowered 
resistin levels. Future studies should include hepatic qPCR analysis to investigate the 
expression of resistin in mice during NAFLD and in vitro experiments to specify the production 
of resistin dependent on the presence of TNFα.  
 
Chemokines are a specialized group of cytokines which are involved in recruitment and 
regulation of immune cells. Changes of chemokine production in the liver is of special interest, 
as it can provide more insight on how the lack of cDCs 1 alters the immune cell recruitment. 
The array shows increases in the production of CXCL-1 in batf3-KO animals. Analysis of 
hepatic gene expression patterns have shown that CXCL-1 is upregulated in both humans and 
mice with NASH (176,177). In the context of hepatic inflammation CXCL-1 has been primarily 
connected to the recruitment of neutrophils, e.g. forced expression of CXCL-1 in rat liver 
causes liver injury and neutrophil infiltration (177,178). CXCL-2 and CXCL-5 production is also 
increased in batf3-KO animals. An upregulation of CXCL-2 expression has been described in 
the liver of NASH patients, whereas increased CXCL-5 expression has been associated with 




superfamily as CXCL-1 and are, too, involved in neutrophil recruitment (180,181). Despite the 
differences in chemokine production the neutrophil infiltrate is not altered during neither 
steatosis nor steatohepatitis compared to the WT control (compare chapter 1.6). As discussed 
above, using alternative methods to determine neutrophil infiltration, such as histological 
staining, could help to gain better understanding of the dynamics of the neutrophil population 
in batf3-KO animals. Importantly, CXCL-1, -2 and -5 execute their function through CXCR-2, 
which is also expressed on other immune cells, including immature DCs and monocytes (181). 
Whether the increased recruitment of monocytes and CD11b+ DCs in batf3-KO animals is 
linked to increased CXC-chemokine production needs to be further investigated.  
Besides CXC-chemokines, the lack of cDCs 1 also increases the production of CCL-2 
and CCL-5. These two chemokines hold an important function during hepatic inflammation and 
the pathogenesis of NASH. CCL-2 is released by activated KCs as well as damaged 
hepatocytes and activated HSC and is critically involved in the recruitment of inflammatory 
monocytes during liver injury (182,183). Pharmacologic inhibition of CCL-2 during MCD 
treatment reduces macrophage infiltration und ameliorates steatohepatitis (184). The 
upregulation of CCL-2 in batf3-KO mice could thus point to the mechanism involved in the 
influx of inflammatory monocytes during HSD. CCL-5 promotes hepatic inflammation and 
fibrosis development by activating macrophages and HSCs through the receptors CCR-1 and 
CCR-5 (180,183,185). Treatment with CCR-5 antagonists or CCL-5 antagonists significantly 
lowers inflammation and histological scoring of dietary induced NASH and limits fibrosis 
development in murine fibrosis models (186,187). Moreover, CCL-5 is also involved in DC T 
cell crosstalk as well as the recruitment of T cells, eosinophils and basophils (188). Hence, all 
measured chemokines are involved in the recruitment of inflammatory cells and could therefore 
contribute to the exacerbation of inflammation observed in batf3-KO animals. Interestingly, 
batf3-KO animals also exhibit higher values of CCL-22, a chemokine responsible for TH2 and 
Treg cell migration (181). In viral hepatitis CCL-22 is involved in the recruitment of regulatory T 
cells (183,189). Whether the increase of CCL-22 is linked to the decrease of CD4 T-Cells, for 
example as a compensatory mechanism, will need further investigation.  
The shift towards a proinflammatory milieu evident in the cytokine array can also be 
measured on a cellular level in mice that lack cDCs 1. Henning et al. showed that the lack of 
CD11c+ cells during MCD diet leads to increased TNFα production by F4-80+ cells (109). As 
opposite to this, the isolated absence of cDCs 1 does not lead to significantly changed TNFα 
production of neither CD11c+ nor F4-80+ cells in the 5 weeks MCD NASH model. During HSD 
feeding, however, the lack of cDCs 1 results in elevated TNFα production by said cells. KCs 




onset of steatohepatitis (133). As discussed in chapter 4.3., the TNFα producing CD11c+ cells 
observed during NASH are most likely CD11c+ expressing F4-80+ cells, such as KCs and 
monocytes. This suggests that cDCs 1 protect from progression of steatosis towards 
steatohepatitis by regulating the inflammatory response of KCs and inflammatory monocytes. 
Besides TNFα, CD11c+ cells also show elevated production of CXCL-1 and CCL-5 in the 
absence of cDCs 1. As discussed above both CXCL-1 and CCL-5 are involved in NASH 
pathogenesis. This indicates an activated phenotype of CD11c+ cells, but as mentioned this is 
a heterogeneous population and therefore it is not possible to pinpoint the increased 
chemokine production to one specific cell type. Having said this, as the production of TNFα is 
elevated in KCs and monocytes, it is likely that they also contribute to the increased chemokine 
production. Moreover, activated KCs are known to produce CXCL-1 and CCL-5 during liver 
injury (183). Regrettably, whether KCs are responsible for increased CXCL-1 and CCL-5 
production cannot be confirmed, as F4-80+ expression was not analyzed in this experiment 
and a more detailed characterization of the CD11c+ cells is necessary. Nevertheless, these 
results hint that cDCs 1 modulate KC activation. In vitro experiments on isolated KCs from WT 
and batf3-KO animals under HSD and MCD diet could be useful to determine how cDCs 1 
influence inflammatory response of KCs. This could include characterizing the cytokines 
produced by KCs or starting a KC cDC 1 co-culture to identify molecules involved in the 
communication of cDCs 1 and KCs. 
4.7 The impact of cDCs 1 on disease progression lessens in advanced stages 
of disease 
In this study, the 5 weeks HSD model and the 5 weeks MCD model have been studied 
extensively to evaluate the effects of the cDC 1 subtype on liver steatosis and NASH. 
Importantly, results indicate that cDCs 1 inhibit progression of inflammation during hepatic 
steatosis, but have only limited effect on the ultimate severity of the disease. Regarding their 
effects in the NASH model, it is possible that after 5 weeks MCD treatment steatohepatitis is 
already too advanced to reveal the influence cDCs 1 have on the inflammatory response. 
Therefore, to confirm the effects cDCs 1 have on disease progression, their impact was also 
investigated after 2 weeks of MCD treatment. Studies have shown that during this timepoint of 
the diet hepatic steatosis is already significant and the inflammation is starting to occur (34). 
Therefore, 2 weeks MCD treatment is a fine model to investigate the effects of cDCs 1 on the 
onset of steatohepatitis and to see whether they concur with the observations made in the 




immune cells in WT animals is changed in a manner that corresponds with a state of early 
inflammation. All DC subtypes increase in the liver after 2 weeks of MCD treatment, although 
in a lower fold change than after 5 weeks treatment, suggesting that they are all involved in 
the inflammatory reaction from an early stage on. Inflammatory monocytes (Ly6Chi/intF4-80low) 
and Ly6Chi/intF4-80- myeloid cells are, too, infiltrating the liver, but again in a lower fold change 
than after 5 weeks treatment. Concerning lymphoid cell populations, NK cells start to 
accumulate in the liver after 2 weeks MCD diet, whereas the NKT cells and T cells seem to be 
recruited during later phases of the inflammatory reaction. B cells as during steatosis or 
established steatohepatitis are not affected at all.  
Like in the HSD model the inflammatory infiltrate changes in batf3-KO animals. Here, 
too, the lack of cDCs 1 does not affect the pDC population, but causes tendentially higher 
recruitment of CD11b+ DCs, especially moDCs. Likewise, inflammatory monocytes 
(Ly6Chi/intF4-80low) and Ly6Chi/intF4-80- myeloid cells are tendentially higher in batf3-KO 
animals. Further, the number of intrahepatic T cells, especially CD4+ T cells is decreased, 
consistent with the observations made in the HSD and 5 weeks MCD model. Notably, batf3-
KO animals have lower NKT cells than the WT animals after 2 weeks of MCD diet, which has 
not been observed in any of the other experiments. Further experiments are necessary to 
analyze the observations in the 2 weeks treated animals. The remaining cell types, including 
pDCs, KCs, B cells and NK cells are not altered by the lack of cDCs 1 just as in the HSD 
experiment. 
 This data suggests that cDCs 1 do not only protect from the progression of steatosis 
towards steatohepatitis, but also moderate the inflammatory reaction during the onset and 
early phases of steatohepatitis itself. Indeed, such anti-inflammatory function of CD103+ DCs 
have also been described in other organs, such as the gut, where CD103+ DCs protect against 
experimentally induced colitis, or the lung, where depletion of CD103+ cDCs 1 in batf3-KO mice 
exacerbates airway inflammation (84,190). The regulatory and tolerogenic properties of cDCs 
1 are most potent during earlier timepoints in the pathogenesis of NASH and prevent that an 
inflammatory response occurs in the first place. On this aspect, it would also be interesting to 
see whether cDCs 1 have a protective effect in other chronic inflammatory liver conditions, 




4.8 Progression of NASH in the absence of cDCs 1 is not associated with 
increased adipose tissue inflammation 
 Excess energy uptake results in augmented fat accumulation and obesity, which is 
linked to increased risk of IR/ DM-II, NAFLD, hypertension, dyslipidemia and atherosclerosis 
(191). Importantly development of obesity is multifactorial and depends on life style, appetite 
control as well as genetic and environmental factors (191). Batf3-KO animals exhibit 
significantly higher weight gain during both control diet and HSD, suggesting that this strain is 
more susceptible for developing obesity. One important factor that drives obesity is the 
organism’s sensitivity towards leptin. Under physiologic circumstances leptin is secreted by 
adipocytes and serves as a negative feedback mechanism to reduce food intake and moderate 
glucose and fat metabolism (192,193). Obesity in both humans and rodents is associated with 
hyperleptinemia and the development of a leptin resistant state despite the relative abundance 
of the hormone (194). Correlating with the increased weight gain batf3-KO animals have 
significantly higher leptin levels at baseline compared to the WT and exhibit an equal tendency 
during HSD feeding. Thus, the excessive weight gain could be due to leptin resistance in batf3-
KO animals.  
Importantly, research suggests that leptin holds an important function in prevention of 
lipotoxicity through limiting lipid accumulation in non-adipose tissue (195). Furthermore, leptin 
resistance has been associated with the development of hepatic steatosis (193). In fact both 
leptin-deficient and leptin-resistant mice are established research models for NAFLD as they 
develop hepatic steatosis during both normal and high-calorie diets (196). In humans, serum 
leptin levels correlate directly with the degree of steatosis during NASH (193). Importantly, 
leptin-deficient and leptin-resistant animals do not spontaneously progress to steatohepatitis, 
but need a “second hit” to develop steatohepatitis (197). Hence, a predisposition to leptin 
resistance in batf3-KO mice could account for the elevated liver triglyceride content during 
HSD, but does not explain the progression towards steatohepatitis. 
Not only the total weight gain differs from the WT control, but batf3-KO animals also put 
on relatively higher amounts of retroperitoneal fat tissue. Interestingly, this is especially 
significant in animals treated with normal chow, but mice in the HSD group also tend to have 
relatively higher amounts of retroperitoneal fat. A chronic, low-grade inflammatory state due to 
adipose tissue dysfunction during obesity has been identified as one of the key factors that 
drive the metabolic syndrome and its associated conditions (191,198). Such dysfunctional 
state of the adipose tissue is associated with the infiltration of F4-80+ macrophages as well as 




of TNFα, IL-6 or chemoattractant molecules like CCL-2 (191,199). This is especially relevant 
for ectopic fat tissue, which includes visceral, retroperitoneal, omental and organ fat deposits, 
while subcutaneous fat is comparatively inert and has little influence on metabolic and 
inflammatory parameters (191,200). Considering the increased retroperitoneal fat and 
increased hepatic triglyceride content, fat distribution in batf3-KO animals seems to be favored 
towards ectopic fat accumulation. Therefore, it is reasonable to ask whether the lack of cDCs 
1 not only changes distribution of fat tissue, but also drives adipose tissue inflammation, which 
could accelerate the progression of steatohepatitis. Importantly, the characterization of 
inflammatory cells in adipose tissue shows that HSD treatment in batf3-KO animals is not 
associated with an increased abundance of F4-80+ macrophages. Likewise, CD11b+ DCs, 
which are markedly elevated in the liver of batf3-KO animals on HSD, show no significant 
difference to WT animals. Fittingly qPCR analysis of retroperitoneal fat tissue also shows no 
change in the expression of the chemokines CCL-2 or CXCL-10 nor of the cytokines TNFα or 
IL-6. Hence there is no aggravated adipose tissue inflammation in batf3-KO animals on HSD, 
suggesting that adipose tissue dysfunction is not involved in the progression towards 
steatohepatitis in the absence of cDCs 1. Notably, analysis of retroperitoneal fat tissue in batf3-
KO animals on normal chow shows an increased frequency of F4-80+ macrophages, which is 
possibly due to the excess weight gain in these animals. Nevertheless, the role of DCs in 
adipose tissue inflammation is still poorly understood and will need further clarification (201). 
4.9 Progression of NASH in the absence of cDCs 1 is not associated with 
altered glucose metabolism 
IR is the common feature of the metabolic syndrome and its associated conditions and 
strongly correlates with the development of NAFLD/NASH (202). In adipose tissue it leads to 
increased lipolysis with increased release of FFA, while hepatic IR promotes hepatic 
lipogenesis and contributes to hyperglycemia through impaired glycogenesis and increased 
glycogenolysis and gluconeogenesis (29). 
As HSD is known to cause IR in mice, it is important to clarify, whether IR is more 
severe in batf3-KO mice, which could then contribute to the development of steatohepatitis 
(38). In the IPGTT mice treated with HSD show markedly higher blood glucose levels than the 
healthy control, but no difference between WT and batf3-KO mice. This indicates that the HSD 
causes pathologic glucose tolerance in treated animals, but the lack of cDCs 1 does not further 
pejorate the insulin response. Concurring with the IPGTT, there are also no significant 




all, this shows that impaired glucose metabolism and worsened IR does not contribute to the 
progression of steatohepatitis in batf3-KO animals. 
4.10 Conclusion and perspective 
This study shows that during NASH all hepatic DC subtypes are recruited to the liver, 
suggesting that they are all involved in the pathogenesis of the disease. It highlights the role 
of cDCs 1 during steatosis and shows that they hold an important protective function in 
preventing progression towards steatohepatitis by regulating the composition of hepatic 
immune cells, the influx of inflammatory cells and the production of cytokines. Through the 
MCD model this study also demonstrates that the protective influence of cDCs 1 on disease 
progression is lessened during more advanced stages of the disease. Importantly, this study 
also demonstrates, that the progression of the disease during HSD in the absence of cDCs 1 
is a local effect and is not due to aggravated adipose tissue inflammation or insulin resistance. 
cDCs 1 hold a powerful protective function in the development of NASH. This is especially 
relevant, as further studies have shown that adoptive transfer of cDCs 1 can reverse the 
changes observed in the steatosis model of batf3-KO mice and even mitigate the outcome of 
MCD diet in WT animals, which indicates a potential therapeutic relevance of the cDC 1 subset 
(136,203). Additionally, studies of human transplant liver have shown that the number of 
hepatic CD141+ DCs, which have been identified as the human equivalent of the murine 
CD8/CD103+ cDCs 1 subtype, decreases in liver pathologies associated with inflammation, 
suggesting that, in human disease too, cDCs 1 hold a protective role in liver injury (204,205). 
A next step could be to investigate the role of cDCs 1 in human NASH and to clarify the 
molecular mechanisms through which cDCs 1 exert their protective actions. A better 
understanding of this could help to identify possible therapeutic targets for NASH. It will also 
be interesting to see, whether cDCs 1 can also protect from other chronic liver diseases with 
an inflammatory component, such as alcoholic steatohepatitis or chronic viral hepatitis. 
Moreover, it is an exciting question what role the other liver DC subtypes play during NAFLD. 
This could be done by using knock out strains, such as the IRF4-/- or IRF2-/- mouse, which 
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